

Cancer Incidence and Mortality in Visakhapatnam District

Andhra Pradesh State, India: 2017 - 2018

Population-Based Cancer Registry (PBCR) Report



Homi Bhabha Cancer Hospital & Research Centre (HBCR&RC)

Visakhapatnam District, Andhra Pradesh State, India

Centre for Cancer Epidemiology (CCE), Mumbai, India

Tata Memorial Centre (TMC), Mumbai, India

Cancer Registry Principal Investigator, Co-Principal Investigators and Co-Investigators

Tata Memorial Centre (TMC), Mumbai

Name	Role	Designation
Dr. Sudeep Gupta	Principal Investigator	Director (w.e.f. Dec.01, 2023)
Dr. R A Badwe	Ex-Principal Investigator	Ex-Director (until Nov. 30,2023)
Dr. Umesh Mahantshetty	Co- Principal Investigator	Director, HBCH&RC, Visakhapatnam
Dr. Pankaj Chaturvedi	Co-Investigator	Director, ACTREC
Dr. Rajesh Dikshit	Co-Investigator	Director, CCE
Dr. Atul Budukh	Co-Principal Investigator	Professor Epidemiology
Ms. Sushama Saoba	Focal Person	Scientific Assistant 'E'

Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam

Name	Designation
Dr. Dolorosa Fernandes	Assistant Professor
Dr. Rohit Vadgaonkar	Associate Professor

Population-Based Cancer Registry, Visakhapatnam Staff

Name	Designation
Mr. Kumar VVSSS	Senior Supervisor (until Feb. 2024)
Mr. Adarsh Kumar Ponnada	Project Co-ordinator
Mrs. V. Vara Lakshmi	Field Investigator
Mr. Lokesh Nimma	Ex. Data Manager
Mrs. G. Venkata Lakshmi	Field Investigator
Mr. U. Rajeshwara Rao	Field Investigator
Mrs. P. Jyothi	Field Investigator
Mr. K. Krishnam Raju	Field Investigator
Mr. K. Anil Kumar	Field Investigator
Mr. K. Mukesh Kumar	Ex. Field Investigator
Mr. P. Srihari	Ex. Field Investigator
Mr. P. Gowtam Buddha	Data Entry Operator

Citation: Saoba S, Fernandes D, Budukh A M, Chaturvedi P, Dikshit R A, Mahantshetty U, Badwe R, Gupta S. Cancer Incidence and Mortality in Visakhapatnam District, Andhra Pradesh State, India: 2017 – 2018. Tata Memorial Centre (TMC), Mumbai, India

Office Address

**Population-Based Cancer Registry, Visakhapatnam District
Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam
Agnampudi
Andhra Pradesh State, India**

Mobile Number: 9920863064

Email: atul.budukh@gmail.com / budukham@tmc.gov.in

Contents

Sr. No.	Topic	Page No.
	Executive Summary	1
1	Andhra Pradesh State Profile	7
2	Visakhapatnam District Profile	9
3	Administrative Order by the State Government for the Cancer Registration Process	15
4	Population Covered by the Cancer Registry	19
5	Cancer Registration Method	21
6	Community Involvement in the Cancer Registration Process	27
7	Quality Control	33
8	Cancer Cases Registered by Source of Registration - First Source of Information	35
9	Cancer Incidence and Mortality – All Sites	37
10	Leading Cancer Sites by Sex	39
11	Cancer Pattern in Urban and Rural Areas	49
12	Childhood Cancer Pattern	55
13	Tobacco-related Cancers	59
14	Cancer burden ass per anatomical system	63
15	Sociodemographic Information	67
16	Comparison of Cancer Incidence Rate with Other Indian registries	69

Sr. No.	Topic	Page No.
17	Abstracts Selected in IACR conferences	77
18	The COVID-19 pandemic effect	83
	Hurdles in Cancer Registration	85
19	Under Reporting of Cancer Cases in Visakhapatnam Cancer Registry	87
20	Continuing Medical Education (CME) in Visakhapatnam District of Andhra Pradesh State	93
21	Description of Statistical Terms Used	95
22	Standard Registry Tables	97
23	Standard Registry Tables for Visakhapatnam Urban	109
24	Standard Registry Tables for Visakhapatnam Rural	119
25	Standard Registry Tables for Visakhapatnam Tribal	129
26	Paediatric Cancer Incidence Tables as per ICC-3	139
27	References	143
28	Acknowledgment	145
29	Annexure	149





Visakhapatnam District Mandal-wise Map (Undivided)

The Inauguration of Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, 2014



The Cancer Congress 2022



Morning Marathon at Beach



World No Tobacco Day at Visakhapatnam



Executive Summary

Background

Tata Memorial Centre, Mumbai (TMC), an autonomous institute under the Department of Atomic Energy, Government of India, has started a population-based cancer registry in Visakhapatnam district on June 2, 2014.

The registry was initially located in the King George Hospital, Visakhapatnam. However, with the establishment of the Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, the registry office was relocated to the Agnampudi.

The objective of the cancer registry is to measure the burden of cancer in terms of incidence and mortality and to know the patterns of cancer in the district. The cancer registry data will be useful in planning cancer control activities and to strengthen cancer care services in this area.

Population Covered

The cancer registry covers the forty-three health blocks/ mandals of the district covering a population of 4.5 million. The registry covers urban areas (145 wards) as well as 3072 villages of the district. More than 52.5% of the population of the district is rural.

Registration Method

Field investigators, trained in cancer registration methodology at the Centre for Cancer Epidemiology, Mumbai, collect the cancer patient data from various data sources like hospitals, primary health centres (PHC), nursing homes, pathology laboratories, radiodiagnosis centres and vital statistics department. The registry staff interacts with the village panchayat sarpanch, Accredited Social Health Activist (ASHA) workers, Auxiliary Nurse Midwife (ANM), PHC staff to get the information of the cancer cases in the village. With the help of the ASHA workers, detailed information is sought from the patient/patients' relative regarding the type cancer and details of diagnosis.

In the urban areas, information is obtained from the Greater Visakhapatnam Municipal Corporation office as well as the various Government and Private hospitals and nursing homes, pathology laboratories and radiodiagnosis centres.

The patients, whose information is received, are visited by the field staff and the detailed information is sought i.e., information on the number of years of the residence in Visakhapatnam and details on the diagnosis date etc. as per the core proforma of the Cancer Registry.

A number of patients from the adjoining areas of Visakhapatnam as well as Odisha state come to Visakhapatnam for disease management. The data for these patients is classified as '*Non-Residents*'. The non-resident data is not entered in the database.

The information brought by the field staff is entered in *CanReg5*, a software tool by the IARC for Cancer Registry record-keeping, quality control and analysis, and duplicity checking is done using the 'Exact Search' option in *CanReg5*. This helps elimination of duplicates in the database.

Tata Memorial Centre (TMC), Mumbai started Homi Bhabha Cancer Hospital and Research Centre (HBCH&RC) in Agnampudi, Visakhapatnam. The cancer centre provides patient care and treatment services in Visakhapatnam. All incidence cases of 2017 - 2018 registered with the HBCH&RC, Visakhapatnam have been shared with the Population Based Cancer Registry.

Results

This report is based on the Cancer Registry data for incidence and mortality in the year 2017 - 2018. The PBCR has recorded 5414 incident cancer cases in Visakhapatnam district of which 2210 (40.8%) were males and 3204 (59.2%) were females. The age-adjusted incidence rate for males is 49.6 per 100,000 population and for females, it is 66.0 per 100,000 population. The cumulative risk for the age group 0-74 in males is 5.4% (1 in 18 men is at risk of developing cancer) and in females, it is 7.0% (1 in 14 females is at risk of developing cancer).

During the year 2017 - 2018, the PBCR team has recorded 2768 cancer deaths, of which 1320 (47.7%) were males and 1448 (52.3%) were females. The age-adjusted mortality rate for males was 30.5 per 100,000 population and for females, it is 30.1 per 100,000 population. The cumulative risk of death due to cancer in the age group 0-74 in males is 3.4% and for females, it is 3.3% (1 in 30 males and 1 in 30 females is at risk of death due to cancer).

Cancer rates by anatomy

Anatomically, in the male population, the cancer incidence was found to high in Head and Neck Cancers (AAR: 13.8 per 100,000 population) with a leading subsite of Oral Cavity (AAR: 7.9 per 100,000) whereas among the female population, Genito Urinary cancers were high (AAR: 23.3 per 100,000) with Cervical cancers as the leading subsite of cancer (AAR: 15.1 per 100,000) among these cancers.

Table I: Highest Rates of Cancer Anatomically in 2017 - 2018

System	Male					Female				
	Nos.	%	CR	AAR	TR	Nos.	%	CR	AAR	TR
Head & Neck	641	29.0	14.1	13.8	27.9	355	11.1	7.7	7.4	16.2
<i>Oral Cavity</i>	383	17.3	8.4	7.9	17.7	199	6.2	4.3	4.2	8.8
<i>Oropharynx</i>	37	1.7	0.8	0.8	1.9	11	0.3	0.2	0.2	0.6
<i>Nasopharynx</i>	11	0.5	0.2	0.3	0.4	6	0.2	0.1	0.1	0.3
<i>Hypopharynx</i>	118	5.3	2.6	2.7	4.2	118	3.7	2.6	2.4	5.7
<i>Larynx</i>	72	3.3	1.6	1.7	2.8	8	0.2	0.2	0.2	0.3
<i>Para Nasal Sinus</i>	6	0.3	0.1	0.1	0.3	7	0.2	0.2	0.1	0.3
<i>Salivary Gland (Major)</i>	14	0.6	0.3	0.3	0.5	6	0.2	0.1	0.1	0.1
Genito Urinary Organs	232	10.5	5.1	5.4	7.8	1128	35.2	24.5	23.3	56.0
<i>Cervix</i>	-	-	-	-	-	738	23.0	16.0	15.1	38.3
<i>Corpus Uteri</i>	-	-	-	-	-	100	3.1	2.2	2.1	4.4
<i>Other Uterus, part unspecified</i>	-	-	-	-	-	0	0.0	0.0	0.0	0.0
<i>Ovary</i>	-	-	-	-	-	199	6.2	4.3	4.0	9.8
<i>Vagina</i>	-	-	-	-	-	23	0.7	0.5	0.5	0.9
<i>Vulva</i>	-	-	-	-	-	38	1.2	0.8	0.8	1.8
<i>Other Female Genital Organs</i>	-	-	-	-	-	2	0.1	0.0	0.0	0.1
<i>Penis</i>	48	2.2	1.1	1.1	2.2	-	-	-	-	-
<i>Prostate</i>	84	3.8	1.8	2.2	2.0	-	-	-	-	-
<i>Testis</i>	23	1.0	0.5	0.4	0.7	-	-	-	-	-
<i>Other Male Genital Organs</i>	1	0.0	0.0	0.0	0.0	-	-	-	-	-
<i>Kidney</i>	44	2.0	1.0	1.0	2.1	19	0.6	0.4	0.5	0.4
<i>Urinary Bladder</i>	31	1.4	0.7	0.7	0.8	8	0.2	0.2	0.2	0.3
<i>Ureter</i>	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
<i>Unspecified Urinary Organs</i>	1	0.0	0.0	0.0	0.1	1	0.0	0.0	0.0	0.0

Leading cancer sites

It was observed that the leading site of cancer among men was Lung followed by Mouth, Stomach, Tongue, and NHL; whereas among women, the leading site of cancer was Breast followed by Cervix, Ovary, Mouth and Stomach.

The leading sites among men and women are mentioned in the table I and II respectively:

Table II: Leading Sites of Cancer among Males in 2017 - 2018

Rank	ICD-10	Site	Nos	%	CR	ASR	TR
1	C33-C34	Lung	219	9.9	4.8	5.2	8.2
2	C03-C06	Mouth	191	8.6	4.2	4.0	8.5
3	C16	Stomach	189	8.6	4.2	4.3	8.3
4	C01-C02	Tongue	187	8.5	4.1	3.8	9.2
5	C82-C85 & C96	NHL	90	4.1	2.0	2.0	3.2
	C00-C95	All Sites	2210	100.0	48.6	49.6	86.7

CR: Crude Incidence Rate per 100,000, AAR: Age-Adjusted Rate per 100,000, TR: Truncated Incidence Rate per 100,000 Population

Table III: Leading Sites of Cancer among Females in 2017 - 2018

Rank	ICD-10	Site	Nos	%	CR	ASR	TR
1	C50	Breast	804	25.1	17.5	16.4	40.5
2	C53	Cervix	738	23.0	16.0	15.1	38.3
3	C56	Ovary	199	6.2	4.3	4.0	9.8
4	C03-C06	Mouth	141	4.4	3.1	3.0	6.5
5	C16	Stomach	106	3.3	2.3	2.2	4.5
	C00-C95	All Sites	3204	100.0	69.7	66.0	150.6


CR: Crude Incidence Rate per 100,000, AAR: Age-Adjusted Rate per 100,000, TR: Truncated Incidence Rate per 100,000 Population

Primary unknown (C80) cases

There was an improvement in the cancer case registration as the percentage of Unknown Primary Origin cancers decrease for males from 4.9% to 3.4% as compared to the previous i.e., 2015-2016 report; however, slight increase was observed in the case of females from 2.5% to 2.1%

Comparison of cancer registry rate with other registries in India

In Visakhapatnam, there is an under-reporting of cancer cases. The rates observed in Visakhapatnam are much lower than those observed in the other Indian Cancer Registries ^[13, 23]. The comparison below is with leading cancer registries covering urban areas except Varanasi Cancer Registries which is semi-urban and similar to Visakhapatnam which is also semi-urban registry also covering tribal population.

Figure A. Comparison of cancer incidence rates in various Indian cancer registries

Cancer patterns in urban, rural and tribal areas

The Visakhapatnam cancer registry covers urban (23,38,672), rural (15,79,366) and tribal (6,53,711) population. The cancer incidence rate in urban, rural and tribal areas for males is 58.4, 52.5 and 10.7 per 100,000 population respectively. For females, the cancer incidence rate in urban, rural and tribal areas is 72.6, 77.8 and 14.0 per 100,000 population. The urban area cancer incidence rates are higher compared to the rural area while considering the male population; however, the rural incidence rates amongst female is higher than the urban.

The leading site of cancer among male population in urban, rural and tribal areas was lung, mouth and tongue with an age-adjusted incidence rate of 6.7, 5.5 and 2.0 per 100,000 population respectively.

Among the females, breast, cervix uteri and ovary are the top three leading cancer sites. Breast cancer is the leading cancer site among females in urban areas whereas in rural and tribal areas, cervix cancer was observed to be the leading cancer. Among urban, rural and tribal females, cervix cancer with an age-adjusted incidence rate 12.3, 23.1 and 3.3 per 100,000 population respectively whereas breast cancer rates were 21.4, 15.0 and 2.5 per 100,000 population respectively.

Due to COVID-19 pandemic we have limited access to the rural and tribal area hospital. The registry may have missed the cases from the rural and tribal areas and due to a low community interaction,

chance of under reporting is high especially in rural and tribal area; also, there may be under diagnosis in these areas.

Paediatric cancer registry

Visakhapatnam population-based cancer registry maintains the data for the childhood cancers and reports them as per the International Childhood Cancer Classification-3 (ICCC-3) standard. The cancer incidence rate among boys was 55.0 per million for the 0-14 yrs. age group; the same for girls was observed to be 36.5 per million.

Recommendations for cancer control activities in Visakhapatnam


The data reported by the cancer registry in Visakhapatnam, estimates a 5.4% risk of development of cancer among males and 7.0% risk among females. The majority cancer burden is due to breast, cervix uteri, mouth, lung and stomach. These cancers are preventable cancers as most of these are tobacco related cancers. 41.1% of the cancers observed among males and 15.8% of the cancer observed among females are tobacco-related cancers.

Stomach cancer, which is one of the top-five leading cancers among both, men and women, in Visakhapatnam, is a diet related cancer and has risk factors such as consumption of large amounts of foods preserved by salting, such as salted fish and meat and pickled vegetables. Eating processed, grilled, or charcoaled meat regularly appears to increase risk of non-cardia stomach cancers. Alcohol consumption and smoking also increases the risk for stomach cancers.

Awareness programs in the community are required to educate the people regarding the risk factors of cancer as well hazards of tobacco-use. With the presentation of this report, we would also like to recommend the initiation of such community activities in schools, colleges, work places and community. The primary health centre workers, and government medical officers should also be involved in such activities.

It is also recommended that there should be ease of access to diagnosis of symptomatic/ likely cases and the confirmed cancer cases should be provided timely and affordable care at the cancer centres.

The public health department of the Andhra Pradesh state should implement these activities with technical support from the HBCH & RC, Visakhapatnam. The population-based cancer registry in the Visakhapatnam district will be used to monitor cancer trends and to evaluate the effects of prevention and treatment modalities. The cancer registry will act as a foundation for epidemiological studies of common cancers in Visakhapatnam district.



1. Andhra Pradesh state profile

Andhra Pradesh is a state in the south-eastern coastal region of India. It shares its borders with Telangana, Chhattisgarh, Odisha, Tamil Nadu and Karnataka states. The state is bordered by the Bay of Bengal on the east. Andhra State was the first state to be formed on a linguistic basis in India on 1 October 1953^[1]. On 1 November 1956, Andhra State was merged with the Telugu-speaking areas (ten districts) of the Hyderabad State to form United Andhra Pradesh^[2]. In 2014, these merged areas of Hyderabad State are bifurcated from United Andhra Pradesh to form new state Telangana^{[2] [3] [4] [5]}.

Andhra Pradesh had a total area of 275045 sq. km. in 2011 of which 162975 sq. kms. forms Andhra Pradesh after the bi-furcation^{[6] [7]}.

Table 1: Andhra Pradesh state population, literacy and area

Sr. No.	Characteristics	Year: 2011	Year: 2014
1.	Area (km ²)	275,045	162975
	(i) Rural (km ²)	267190.5	1,56,085.73
	(ii) Urban (km ²)	7854.5	4,119.27
2.	Total population ^[6]	84,580,777	49,386,799
	(i) Rural	56,361,702	34,776,389
	(ii) Urban	28,219,075	14,610,410
3.	Districts	23	26
4.	Density (/km ²)	308	308
5.	Female per 1000 male	993	996
6.	Literacy rate	67.02%	67.41%

2. Visakhapatnam district profile

Old Visakhapatnam has been the smallest district in the state of Andhra Pradesh. Visakhapatnam (formerly known as Vizagapatam district also known locally as Vizag) is one of the six districts in the Uttarandhra region of the Indian state of Andhra Pradesh, headquartered at Visakhapatnam. Earlier one of thirteen, is now one of twenty-six districts in Andhra Pradesh state. The district shares borders with Vizianagaram district in the north, and Anakapalli district in south-west and Bay of Bengal in east ^[8].

In 2022, old Visakhapatnam district was divided into three districts: Visakhapatnam, Anakapalli, and Alluri Sitharama Raju ^{[9][10]}. However, the Visakhapatnam Cancer Registry collects the data from the undivided Visakhapatnam as earlier. The location of the Visakhapatnam district is presented in figure 1. Visakhapatnam district health blocks and the number of villages are presented in table 2.

Figure 1: Location of Undivided Visakhapatnam district, Andhra Pradesh



Table 2: Blocks under Old Visakhapatnam district

Sr. No.	Mandal (CD Block)	Area (km ²)	Villages	Wards
1	Anakapalle	170	31	21
2	Anandapuram	177	32	0
3	Ananthagiri	858	278	0
4	Araku Valley	264	163	1
5	Atchutapuram	111	33	0
6	Bheemunipatnam	96	18	31
7	Butchayyapeta	177	38	0
8	Cheedikada	117	30	0
9	Chintapalle	698	244	1
10	Chodavaram	119	30	1
11	Devarapalle	228	40	0
12	Dumbriguda	303	87	0
13	G Madugula	645	292	0
14	Gajuwaka	139	0	16
15	Golugonda	232	34	0
16	Gudem Kotha Veedhi	736	170	1
17	Hukumpeta	412	168	0
18	K Kotapadu	141	32	0
19	Kasimkota	158	26	0
20	Kotauratla	233	20	0
21	Koyyuru	1,051	136	0
22	Madugula	211	49	0
23	Makavarapalem	195	25	0

Sr. No.	Mandal (CD Block)	Area (km ²)	Villages	Wards
24	Munagapaka	80	26	0
25	Munchingi Puttu	490	303	0
26	Nakkapalle	204	30	1
27	Narsipatnam	103	11	2
28	Nathavaram	273	35	0
29	Paderu	328	199	1
30	Padmanabham	150	24	0
31	Paravada	130	14	3
32	Payakaraopeta	130	18	1
33	Peda Bayalu	503	268	0
34	Pedagantyada	53	0	6
35	Pendurthi	119	15	5
36	Rambilli	135	30	0
37	Ravikamatham	188	33	0
38	Rolugunta	123	28	0
39	S Rayavaram	147	22	0
40	Sabbavaram	186	27	0
41	Visakhapatnam Rural	127	0	0
42	Visakhapatnam Urban	112	0	55
43	Yelamanchili	129	13	1
	Total	11181	3072	147

Health infrastructure of Visakhapatnam district


The district of Visakhapatnam has five central government hospitals, four district hospitals and four sub-district hospitals with basic diagnostic and surgical facilities. The district has 89 primary health centres, 13 community health centres, and 584 sub-centres^[8]. Primary health care is offered at these hospitals. Detailed information about the hospital and PHC is presented in Table 3.

Table 3: Major Health Facilities in Visakhapatnam district

Sr. No	Institute	Number
1	Central Government Hospitals	5
2	District Hospitals (DH)	4
3	Sub District Hospitals	4
4	Community Health Centre	13
5	Primary Health Centre	89
6	Sub Centre	584
7	Maternity welfare centre	1
8	Maternity welfare sub-centre	3
9	Rural Hospitals	
	(a) Allopathic	-
	(b) Ayurvedic	8
	(c) Homeopathic	5
	(d) Unani	9
	(e) TB Centre	2

Tata Memorial Centre, Mumbai – an autonomous unit of the Department of Atomic Energy, Government of India has started the Homi Bhabha Cancer Hospital and Research Centre (HBCH&RC) in Visakhapatnam. The HBCH&RC have surgical, radiotherapy and medical oncology facilities. From 2014, more than 29,000 cancer patients have been registered. The hospital is listed in the various government-sponsored schemes for cancer treatment. The patient from Visakhapatnam district travel to Hyderabad, Kochi, Chennai and Mumbai for cancer treatment. The distance from Visakhapatnam to different cancer treatment centres is presented in figure 2.

Figure 2: The distance from Visakhapatnam to different cancer treatment centres



3. Administrative Orders

The Chief Medical Officer (CMO), District Public Health Department of the Visakhapatnam district has issued an administrative order to all the government and private hospitals to provide data of all cancer patients to the population-based cancer registry. The Director, HBCH&RC, Visakhapatnam and Director, TMC, Mumbai issued the letter to all the hospitals to support the cancer registry staff in cancer cases data collection. Due to administrative support from the government sector, we have very good co-operation from the government institutes.



HOMI BHABHA CANCER HOSPITAL & RESEARCH CENTRE
 A CENTRE FOR TREATMENT, RESEARCH & EDUCATION IN CANCER
 A Unit of Tata Cancer Hospital, Mumbai
 (A Grants-in-Aid Institution, Department of Atomic Energy, Government of India)

Prof. D. Raghunadharao, MD, DM
 Director

31 October 2017

To
 Dr. Kamineni Srinivas garu
 Honourable Minister for Health & Medical Education
 Government of Andhra Pradesh

Respected Sir,

The Homi Bhabha Cancer Hospital & Research Centre is established as an institute of excellence, under the Department of Atomic Energy, Government of India, at the invitation of the Government of Andhra Pradesh.

One of our mandates is to organise a District Cancer Registry for Visakhapatnam. We have been gathering information on a core data format, without any loss of privacy to the treating physician, hospital or patient or any health care provider, since 2 June 2014.

We have well trained field staff to visit all municipal corporations, municipalities, panchayats, diagnostic centres, pathological labs, nursing homes and hospitals – private and public.


We have obtained the requisite permissions from the District Collector and the District Medical & Health Officer.

The analysed data would be made available as a periodic report to the Government of Andhra Pradesh and all stake holders, for evaluation of patterns of presentation, utilisation of health care resources, cost, quality of life, survival and outcomes. This will help formulate a clear policy for the State, namely, decisions to tailor its cancer services – preventive, curative and palliative care.

In this regard, I request you to issue orders permitting the collection of data from all the hospitals, dispensaries and health centres - government as well as private, as well as from the Arogyasree data of the District of Visakhapatnam and to perform outcome follow up on standardised formats.

I shall be glad to clear any aspect of the data collection to you at any time. Please feel free to contact me regarding any queries.

With regards,

Yours sincerely,

 D Raghunadharao
 Director




Aganampudi (V), Gajuwaka (M), Visakhapatnam - 530 053, Andhra Pradesh
 Phone : 0891-2871561 e-mail : directorviza@tmc.gov.in

10-Emb
 10/11
 3/11

**Dr.NTR Vaidya Seva Trust
Government of Andhra Pradesh**

From
Dr.A.Ravi Shankar, IPS.,
Chief Executive Officer,
Dr.NTR Vaidya Seva Trust,
Govt. of A.P.,
Chuttugunta, Guntur

To
Prof. D.Raghunadharao, M.D.,D.M.,
Director,
Homi Bhaha Cancer Hospital & Research Centre,
Vishakapatnam.

Lr.No.Dr.NTRVST/ 1562/PBCR /Emp/2017, Dt.4.11.2017

Sir,

The Government of Andhra Pradesh has been implementing Dr.NTR Vaidya Seva from 01.4.2007 with the objective of assisting poor families by providing cashless treatment in the empanelled Government and Private hospitals, thus protecting them from catastrophic health expenditures. The financial coverage is Rs 2.50 lakhs, per family, per year on floater basis. Including treatment for various Cancers the scheme covers 1044 secondary and tertiary procedures

We understand that Population Based Cancer Registries (PBCRs) have always remained the corner stone of National Cancer Registry Program and that Interesting geographical variation in patterns of cancer within the same country calls for a region-specific research and planning of control programmes.

As Investigation into various possible risk factors particular to the areas of high incidence is imperative Dr.NTRVaidya Seva Trust is planning to establish a Population Based Cancer Registry. Dr.NTRVaidya Seva Trust maintains a huge electronic database of cancer patients in the state of Andhra Pradesh since 01.4.2007 and we have field staff in each mandal and town who can also be utilised for the data collection.

In this regard, we would like to invite you to Dr.NTRVaidya Seva Trust, Chuttugunta, Guntur, to guide us on process of establishing the Population Based Cancer Registry (PBCRs) for the State of Andhra Pradesh using data available with Dr.NTRVaidya Seva Trust.

Yours Faithfully

Haw
4/11

Chief Executive Officer



Rc.No. 181/D/2014, dt. 24-7-2014

District Rural Development Agency,
Visakhapatnam.

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Tata Memorial Hospital, Aganampudi, Visakhapatnam, has deployed their team to study cancer in community, incidence, prevalence, trends, overall survival in the community apart from to provide background for overall clinical research and other purposes. Therefore, the team has approached the District Collector, Visakhapatnam to accord permission to take up their study and to visit all hospitals and clinical labs in the district.

Therefore, the team is hereby permitted to visit all hospitals, clinical labs etc., to take up the above study. Hence, all the hospitals and clinical labs in Visakhapatnam District are hereby requested to extend cooperation to the above team to obtain any details if they so desire.


PROJECT DIRECTOR
DRDA., VISAKHAPATNAM

TATA MEMORIAL HOSPITAL CANCER REGISTRY PROGRAMME
Visakhapatnam Cancer Registry

DATE :

To,

11/7/17
 the Project Director
 DISTRICT WOMEN and Child Dev Agency
 VISAKHAPATNAM.

Dear Sir/Madam,

Tata Memorial Center, Mumbai has started a **Population based Cancer Registry** in Visakhapatnam district of Andhra Pradesh.

1. The primary concern is to study Cancer in Community, Incidence, Prevalence, trends, overall survival in community.
2. Provide background for overall Clinical Research.
3. Research-Epidemiological Descriptive/Analytic studies.
4. Provides indicators for Cancer Control activity.
5. Helps to assess effectiveness of preventive measures.
6. Helps to plan cancer services for geographical area.

Our team will be visiting different sources from the district such as Hospitals, Clinics, Radiology labs, Radiology centers etc. We request your good self to provide us information about all types of Cancer cases from your hospital which are coming from these districts. The cases will be collected by our Social Investigators and added in our Cancer registry. Our field investigators will visit your hospital/clinic/labs etc to collect the cases. So kindly permit them to abstract information during office hours (10.00am to 5.00pm) and do the needful.

Looking forward for your best cooperation.

Thanking you.

Yours Sincerely,

[Signature]

Dr. Ganesh B
 Prof. & Head,
 Department of Medical Records, Biostatistics & Epidemiology
 Tata Memorial Hospital, Mumbai.

4. Population covered by the cancer registry

Visakhapatnam district is divided into 43 mandals/blocks. As per the 2011 census, the total population of Visakhapatnam district is 42,90,589 ^[6]. Of the total population, 52.5% i.e. 22,54,667 is rural whereas 47.5% (20,35,922) is urban. The male population is 49.9% and 50.1% is female population. The distribution of as per the 2011 census is given in table 4 below.

Table 4: Visakhapatnam district population as per census 2011

Area	Male Population	Female Population	Total Population
Rural	11,13,234	11,41,433	22,54,667 (52.5%)
Urban	10,25,676	10,10,246	20,35,922 (47.5%)
Total	21,38,910 (49.9%)	21,51,679 (50.1%)	42,90,589 (100.0%)


Estimated population of Visakhapatnam district: 2017 - 2018

The registry population for 2017 - 2018 was estimated by the ratio method by using the 2001 to 2011 census population^[6]. As a result, average population of year 2017 - 2018 is 45,71,750 in which 22,71,835 males (49.7%) and 22,99,915 females (50.3%). The estimated average population for 2017 - 2018 is presented in table 5. The population pyramid of the Visakhapatnam district is shown in figure 3.

Table 5: Estimated average population of Visakhapatnam district: 2017 – 2018

Age Groups	Male		Female		Total	
	Number	%	Number	%	Number	%
00-04	156239	6.9	147727	6.4	303967	6.6
05-09	156582	6.9	145558	6.3	302140	6.6
10-14	198873	8.8	192924	8.4	391798	8.6
15-19	200937	8.8	195921	8.5	396858	8.7
20-24	218206	9.6	230086	10.0	448292	9.8
25-29	217354	9.6	222436	9.7	439791	9.6
30-34	189490	8.3	194990	8.5	384480	8.4
35-39	185805	8.2	199867	8.7	385671	8.4
40-44	176325	7.8	170042	7.4	346367	7.6
45-49	149313	6.6	139211	6.1	288524	6.3
50-54	110101	4.8	106436	4.6	216538	4.7
55-59	86434	3.8	96947	4.2	183381	4.0
60-64	91422	4.0	106038	4.6	197460	4.3
65-69	68598	3.0	74200	3.2	142798	3.1
70-74	36894	1.6	40067	1.7	76961	1.7
75+	29261	1.3	37463	1.6	66724	1.5
Total	2271835	100.0	2299915	100.0	4571750	100.0

Figure 3: Population pyramid of Visakhapatnam district 2017 - 2018



5. Cancer registration method

Staff selection and training

The field investigators, field supervisors, and data entry operators were selected from the district and they were provided training in cancer registry operation at the Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai. Periodically training programs were conducted by the Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai either in person or virtual.

Cancer incidence cases

The trained field staff visit the various sources like hospitals, nursing homes, pathology laboratories, radio-diagnosis centres for collection of cancers cases. The information is also obtained by interacting with the village Sarpanch, Auxiliary Nurse Midwives (ANMs), Anganwadi workers, Accredited Social Health Activist (ASHA) workers and medical officers of primary healthcare centres. Information regarding the diagnosis of cancer and cancer death is noted at the same time. The social worker takes the detailed information of the cancer case and visits the patient's house, along with the ASHA workers.

The field investigator interacts with the patient/patient's relative and obtains answers to the questions like: when the patient was diagnosed, where was the diagnosis established, any casenumber assigned then, whether any reports or discharge summary cards / radiation therapy cards are available.

The field investigator notes all the information gained from the patient / patients' relatives in a pre-designed proforma. The field investigator later traces the cases back from the source. In case of non-availability or un-accessibility of the medical records of the patient, staff registers the case based on the information provided by the patient/patient's relatives.

The field investigator visits the sources as well as the villages periodically to collect the vital status of the existing known patients at the same time to collect any new cancer cases diagnosed or cancer deaths after the previous visits.

Cancer death cases

During the village visit, the field investigator inquiries about cancer deaths that may have occurred in the village. The death case information is also collected from the village panchayat death register as well as Birth and Death Registrar's office (Vital Statistics Department). The field investigator interacts with the patient's relative and collects information regarding cancer death in a manner similar to that while collection

of the incidence cases. Based on the information provided by the relatives and cross verifying the information with the medical records available in the cancer registry, the cancer death is registered.

Cancer prevalence cases

The field investigator come across the few cases that were diagnosed before 2017 - 2018 and were not registered in the cancer registry database. In this situations, the field investigator collects detailed information on the cancer case from the patient's relative and maintains the data in the registry office. During the subsequent visits, field investigator update the status of these cancer cases. If there is any death of the prevalent case in the current year of data collection, then the cancer death is registered as a mortality case after cross verifying the registry database.

Data checking and quality control

All the cases collected by field investigator from the villages, wards, diagnostic centres as well as from the cancer treating hospitals are scrutinized by the senior staff members. After residence confirmation, the cancer case information is documented in a prescribed format. The primary site and histology are coded based on the International Classification of Diseases for Oncology – Third Edition, Geneva, 2000 (ICD-O3) ^[11]. The preventive oncology consultant checks all the data and ICD coding as well the difficult cases were discussed with the clinician/pathologist. CCE-TMC team regularly visits the project office for quality control.

Data entry

The data entry is carried out in CanReg5 software developed by the International Agency for Research on Cancer (IARC), Lyon, France ^[12]. After duplicate checking and other quality measures, the cancer incidence and death cases are registered. The cancer registration process of the registry is presented in figure 4.


Cancer cases data collection from different hospitals

The registry staff regularly visits the following centres to collect information on the cancer cases and death cases in Visakhapatnam district. The different sources of data collection are mentioned in table 6.

Table 6: Different sources of data collection

Sr. No.	Source Name
1	Homi bhabha Cancer Hospital & Research Centre
2	Tata Memorial Hospital, Mumbai (TMH)
3	All- Anganwadi Centers, Visakhapatnam
4	All- CHC, ASR
5	All- Greater Visakhapatnam Municipal Corporation, Visakhapatnam
6	All- Panchayth Office, Visakhapatnam
7	All- PHC, CHC, Anakapalle
8	All- Sachivalayams, Visakhapatnam
9	All- UPHC, PHC, CHC, Visakhapatnam
10	Anil Neerukonda Hospital, Visakhapatnam
11	Area Hospital- Aganampudi, Visakhapatnam
12	Area Hospital- Araku, ASR
13	Area Hospital- Narsipatnam, Anakapalle
14	Chaitanya Medical Centre, Visakhapatnam
15	District Hospital- Paderu, ASR
16	District Rural development Agency (DRDA) Office, Visakhapatnam
17	Dolphin Diagnostic Services, Visakhapatnam
18	ESI Hospital, Visakhapatnam
19	Gitam Institute of Medical Science and Research
20	Golden Jubilee Hospital (Port Hospital), Visakhapatnam
21	Government ENT Hospital, Visakhapatnam
22	Government Victoria Hospital (Ghosha Hospital), Visakhapatnam
23	Govt General Hospital, Kakinada
24	King George Hospital (KGH), Visakhapatnam
25	NTR Hospital, Anakapalle
26	Steel Plant General Hospital, Visakhapatnam
27	Vijaya Diagnostic Centre, Visakhapatnam
28	Visakha Institute of Medical Sciences (VIMS), Visakhapatnam

Figure 4: Cancer registration method



6. Community involvement in the cancer registration process

The cancer patients from the Visakhapatnam district travel to different cities for cancer treatment. It is practically difficult for the registry staff to visit these centres regularly. Few hospitals and private laboratories are reluctant in providing cancer patient's data of the district. To overcome this problem, we started community interaction. The primary health centre staff, ASHA workers, and Anganwadi workers cooperated by providing information on newly diagnosed cancer/cancer deaths that occurred in the village. The trained field investigator from the registry continuously interacts with these community members to obtain information regarding cancer cases in the villages. In the urban area, we have interacted with municipal corporators and the local leaders.

The community interaction confirmed the residence information of the cancer cases. Interaction with the patient/ patient's relatives provides demographic information such as education, income, religion, etc. Regular village visits and interaction with the community have enabled the registry to update the status of cancer patients, which will be utilized for cancer survival analysis. Initially, various centres were reluctant to provide data on cancer cases. To tackle this, field visits and interactions with community leaders enabled the registry to acquire information about the cancer cases from the villages after contacting patients / their relatives through these community leaders. In 2017 - 2018, registry staff interacted with **3,823** community leaders which included Sarpanch, Municipal corporator, Medical officer, ANM and ASHA workers. Registry staff interacted with community leaders and primary health centre staff to collect information about diagnosed cancer cases. The detail of the same by blocks is presented in table 7.

Table 7: Community leaders/ primary health centre staff involved in the cancer registration process

Sr. No.	Mandal Name	Total No. of Villages / Wards	Sarpanch Panch/ Parshad (Sabhasad)	SMO	MO	HEO	ANM	Asha Workers	Anganwadi Workers	MPHW	Total
1	Anakapalle (Urban)	5	0	4	3	1	10	32	23	1	74
	Anakapalle Rural	32	32	1	1	1	12	40	12	1	100
2	Anandapuram	32	26	1	1	1	4	22	5	1	61
3	Ananthagiri	315	24	2	6	1	5	14	2	1	55
4	Araku Valley	170	14	3	4	2	5	104	4	2	138
5	Atchutapuram	34	27	1	3	2	4	8	4	2	51
6	Bheemunipatnam (Urban)	5	0	1	1	2	4	10	22	2	42
	Bheemunipatnam (Rural)	18	18	1	1	1	6	16	12	1	56
7	Butchayyapeta	40	32	2	4	1	2	15	5	1	62
8	Cheedikada	24	23	1	3	1	3	12	5	1	49
9	Chintapalle	249	17	4	5	3	8	201	1	3	242
10	Chodavaram	32	32	4	2	2	4	64	12	2	122
11	Devarapalle	43	26	1	2	2	5	57	12	2	107
12	Dumbriguda	87	18	1	2	1	2	5	1	1	31
13	G.Madugula	328	17	0	3	1	4	8	0	1	34
14	Gajuwaka (Urban)	16	0	6	5	7	6	44	14	7	89
15	Golugonda	36	24	1	3	2	9	9	6	2	56
16	Gudem Kotha Veedhi	174	16	2	8	7	5	112	0	7	157

Sr. No.	Mandal Name	Total No. of Villages/ Wards	Sarpanch Panch/ Parshad (Sabhasad)	SMO	MO	HEO	ANM	Asha Workers	Anganwadi Workers	MPHW	Total
17	Hukumpeta	168	33	2	4	2		5	0	2	48
18	K.Kotapadu	32	21	1	3	2	4	14	5	2	52
19	Kasimkota	28	26	1	3	2	6	68	5	2	113
20	Kotauratla	21	21	1		1	5	10	4	1	43
21	Koyyuru	162	32	2	7	5	4	122	1	5	178
22	Madugula	53	28	3	4	3	4	14	8	3	67
23	Makavarapalem	25	25	1	3	2	5	12	8	2	58
24	Munagapaka	28	20	1	1	2	3	14	6	2	49
25	Munchingi Puttu	325	22	1	3	3	5	2	0	3	39
26	Nakkapalle	31	30	0	2	1	5	12	5	1	56
27	Narsipatnam	14	9	14	4	4	5	7	6	4	53
28	Nathavaram	39	27	0	4	2	5	7	5	2	52
29	Paderu	214	26	5	7	2	4	14	3	2	63
30	Padmanabham	25	21	0	1	1	5	53	6	1	88
31	Paravada	23	14	2	4	2	5	33	4	2	66
32	Payakaraopeta	19	18	1	4	3	1	22	12	3	64
33	Peda Bayalu	271	23	1	2	2	1	2	0	2	33
34	Pedagantyada (Urban)	6	0	1	3	2	6	50	11	2	75
35	Pendurthi (Urban)	5	0	6	3	2	3	60	12	2	88
	Pendurthi (Rural)	15	15	0	2	1	3	62	6	1	90
36	Rambilli	31	28	1	2	2	5	8	4	2	52
37	Ravikamatham	35	24		3	2	2	12	3	2	48
38	Rolugunta	30	21	1	4	3	3	11	3	3	49
39	S.Rayavaram	22	22	1	3	2	1	9	3	2	43
40	Sabbavaram	31	24	2	1	2	3	47	9	2	90
41	Visakhapatnam (Rural)	9	0	2	7	5	10	153	14	5	196
42	Visakhapatnam (Urban)	51	0	16	17	17	33	255	32	17	387
43	Yelamanchili	16	16	9	2	2	4	14	8	2	57
	Total	3369	892	111	160	117	238	1865	323	117	3823

Cancer awareness program

While interacting with ANM/ASHA workers, a need of a cancer awareness program for ANM/ASHA and school teachers was observed. In the awareness meetings, emphasis was laid on the awareness of cancer signs and symptoms, risk factors and preventive measures especially on mouth, breast and cervix uteri cancer. Health education program explaining cancer registry activities, role of school teachers/ students and family members in the cancer registry program was also conducted.

Due to the cancer awareness program, the registry received valuable cooperation from ANM/ASHA workers in identifying the cancer cases in the community. The cancer awareness program conducted by the registry staff is mentioned in table 8.

Table 8: Cancer awareness program conducted by the registry staff

Sr. No.	Date	Name of the village	Nature of the camp
1	01.03.2022	Rampuram	Volunteer awareness camp
2	02.03.2022	Rampuram	Volunteer awareness camp
3	07.04.2022	Pharma city	Volunteer awareness camp
4	08.04.2022	Pharma city	Volunteer awareness camp
5	10.10.2022	Eedalapaka	Volunteer awareness camp
6	29.09.2022	Cheedigummala	Volunteer awareness camp
7	03.03.2022	Rampuram	Screening camp
8	09.04.2022	Pharma city	Screening camp
9	01.10.2022	Cheedigummala	Screening camp
10	07.01.2023	Chodavaram	Screening camp
11	11.10.2022	Eedalapaka	Screening camp
12	18.12.2022	Chodavaram	Tobacco awareness camp
13	14.12.2022	Thimmaraju peta	Tobacco awareness camp
14	15.10.2021	Thaalla palem	Asha workers awareness camp
15	02.10.2022	Kasim kota	Asha workers awareness camp
16	25.10.2022	Vadlapudi	Asha workers awareness camp
17	11.10.2022	Pendurthi	Asha workers awareness camp
18	01.11.2022	Pedagantyada	Asha workers awareness camp
19	03.01.2023	Madagada	Asha workers awareness camp
20	03.01.2023	Gennela	Asha workers awareness camp
21	03.01.2023	Koyyuru	Asha workers awareness camp
22	03.01.2023	Lammasingi	Asha workers awareness camp
23	03.01.2023	Thajangi	Asha workers awareness camp
24	03.01.2023	Dumri guda	Asha workers awareness camp

Sr. No.	Date	Name of the village	Nature of the camp
25	06.12.2022	Sabbavaram	Asha workers awareness camp
26	03.01.2023	Hukumpeta	Asha workers awareness camp
27	05.11.2022	Revadi	Asha workers awareness camp
28	19.10.2022	Rolugunta	ANMs awareness camp
29	26.10.2022	KJ Puram	ANMs awareness camp
30	20.10.2022	Ravikamatham	ANMs awareness camp
31	25.10.2022	Kinthala	ANMs awareness camp
32	27.10.2022	Minumuluru	ANMs awareness camp
33	28.10.2022	Downuru	ANMs awareness camp
34	03.10.2022	Gomangi	ANMs awareness camp
35	04.11.2022	Dumriguda	ANMs awareness camp
36	02.11.2022	Lobburu	ANMs awareness camp
37	04.11.2022	Munchangiputtu	ANMs awareness camp
38	06.12.2022	Sabbavaram	ANMs awareness camp
39	02.11.2022	Rudakota	ANMs awareness camp
40	12.07.2022	CME	District doctors

Some photographs



7. Quality Control

Mortality to incidence ratio

The mortality-incidence or MI ratio is an indicator of the completeness and accuracy of cancer registry data. In the years 2017 - 2018, 5192 incident cancer cases (2093 males (40.3%) and 3099 females (59.7%)) have been registered by PBCR Visakhapatnam. For the same period, 2729 cancer deaths have been registered (1296 males (47.5%) and 1433 females (52.5%)). The overall mortality to incidence ratio is 0.53 (males 0.62 and females 0.46). The MI ratio is comparable to other established rural PBCRs in India. (1)

Re-abstraction of the cases

A quality control exercise was carried out for the improvement of the records and to retrain the staff, if required. The CCE-TMC team checked all cancer case data. During the quality control exercise, a need was observed to retrain the registry staff in the abstraction of cases of the primary site unknown, metastatic, and lymphoma leukaemia. Based on the results, the staff was retrained by CCE-TMC, Mumbai. The data was modified and re-entered.

Incidence rates of childhood cancers

In the year 2017 - 2018, PBCR has registered 24 cancer cases in boys and 12 in girls. The age-specific rates reported the paediatric cancer are mentioned in table 9.

Table 9: Incidence rate of paediatric cancer cases in Visakhapatnam district: 2017 - 2018

Age groups	Boys		Girls		Both Sexes	
	Number	ASR per 1000,000	Number	ASR per 1000,000	Number	ASR per 1000,000
0-4	18	57.6	8	27.1	26	42.8
5-9	19	60.7	14	48.1	33	54.6
10-14	18	45.3	14	36.3	32	39.6
Age Adjusted Rate per 1,000,000 (AAR per million)	55.0		36.5		45.7	

The age-adjusted incidence rate for the paediatric age group (0-14) was 55.0 per million for boys and 36.5 per million for girls. As per the International Incidence of Childhood Cancer volume III, the incidence rate for boys and girls is less than 60 per million (10). There is under-reporting of the paediatric cancer cases diagnosed in the district. **The underreporting is more in girls as compared to boys. We need to**

undertake studies to find out the reason for the under-reporting of paediatric cancer cases. Of the total cases registered, 1.68% of them belong to paediatric cancer.

The microscopic confirmation was 100.0% in both boys and girls.

Microscopic verification of the cases

In 2017 - 2018, the microscopic verification was found to be 98% among males as well as females. That indicates the cases that were diagnosed on clinical basis were missed in this data. Of the 5414 cancer cases reported, 5258 were diagnosed microscopically; with 7.6% cytology confirmation and 89.5% biopsy confirmation of diagnosis.

Death Certificate Only (DCO) Cases

None of the cases were diagnosed on the basis of Death Certificate Only as the death certificate does not have the documentation on the underlying cause of death.

Per source case registration

The number of sources per incidence case registered was noted. The cases were counted as per source notification. In Visakhapatnam, the average number of sources per case registered is 1.5. This may be due to low community interaction.

Table 10: Confirmation of cancer cases by sources

Source	Number of Cases Confirmed
Source 1	5414
Source 2	1189
Source 3	1095
Source 4	157
Source 5	53
Source 6	10
Total Sources	7918 / 5414
Per Source of Registration	1.5

8. Cancer cases registered by source of registration: First source of information

HBCH & RC, Visakhapatnam served as a one of the primary source of information for identifying newly diagnosed cancer cases whereas village visits and the Vital Statistics department serves as a major source for information on cancer death registration.

Table 11: Cancer cases information by the first source of cancer registration


Sr. No.	Source Name	Male		Female		Total	
		Nos.	%	Nos.	%	Nos.	%
1	Chaitanya Medical Center	484	21.9	590	18.4	1074	19.8
2	Homi bhabha Cancer Hospital & Research Centre	447	20.2	475	14.8	922	17.0
3	KGH Hospital	188	8.5	393	12.3	581	10.7
4	Vijaya Medical Centre	81	3.7	256	8.0	337	6.2
5	HCG Pinnacle Hospital	79	3.6	143	4.5	222	4.1
6	Queens NRI Hospital	45	2.0	112	3.5	157	2.9
7	NCDIR, ICMR	61	2.8	51	1.6	112	2.1
8	Access Path Labs Pvt Limited (Path Care Labs)	47	2.1	62	1.9	109	2.0
9	ESI Hospital	39	1.8	47	1.5	86	1.6
10	Vijaya Diagnostic Center	21	1.0	44	1.4	65	1.2
11	Likhitha Diagnostics and Specilaity Labs -LDSL LAB	9	0.4	38	1.2	47	0.9
12	Gayatri Vidya Parishad Institute of Healthcare & Medical Technology	12	0.5	22	0.7	34	0.6
13	Rangaraya Medical College	12	0.5	21	0.7	33	0.6
14	CARE Hospital	15	0.7	17	0.5	32	0.6
15	Surya Global Hospital - Kakinada	8	0.4	24	0.7	32	0.6
16	GITAM Institute of Medical Science and Research	15	0.7	14	0.4	29	0.5
17	Apollo Hospital	14	0.6	15	0.5	29	0.5
18	Basavatarakam Indo American Cancer Hospital-Hyd	10	0.5	19	0.6	29	0.5
19	Anil Neerukonda Hospital	14	0.6	13	0.4	27	0.5
20	M.N.J Institute of Oncology & Regional Cancer Centre	15	0.7	10	0.3	25	0.5
21	Medall Diagnostic Centre	9	0.4	16	0.5	25	0.5
22	SRL Diagnostic centre	10	0.5	13	0.4	23	0.4
23	Strand Life Sciences PVT.LTD	6	0.3	17	0.5	23	0.4
24	Adarsh Diagnostics Centre	5	0.2	18	0.6	23	0.4
25	Prasad Medical Centre	10	0.5	11	0.3	21	0.4
26	Laxmi Diagnostic Center	4	0.2	13	0.4	17	0.3
27	Hope International Hospital Kakinada	6	0.3	10	0.3	16	0.3
28	Indus Hospital	10	0.5	5	0.2	15	0.3

Sr. No.	Source Name	Male		Female		Total	
		Nos.	%	Nos.			Nos.
29	Dolphin Diagnostic Services	3	0.1	11	0.3	14	0.3
30	Nizam's Institute of Medical Sciences - Hyd	6	0.3	7	0.2	13	0.2
31	GSL General Hospital	5	0.2	6	0.2	11	0.2
32	Seven Hills Hospital	5	0.2	5	0.2	10	0.2
33	AmPath Laboratory	5	0.2	5	0.2	10	0.2
34	KIMS- ICON Hospital	4	0.2	5	0.2	9	0.2
35	MyCure Hospital	4	0.2	5	0.2	9	0.2
36	Life Scan & Life Line Diagnostics	1	0.0	8	0.2	9	0.2
37	VIMS Hospital	0	0.0	9	0.3	9	0.2
38	Christian Medical College - CMC Vellore	6	0.3	2	0.1	8	0.1
39	Omni RK Super Speciality Hospital	6	0.3	2	0.1	8	0.1
40	NTR Govt Hospital - Anakapalli	3	0.1	5	0.2	8	0.1
41	Steel Plant General Hospital	2	0.1	6	0.2	8	0.1
42	Maharajahs Institute	3	0.1	4	0.1	7	0.1
43	Tata Memorial Hospital, Mumbai (TMH)	2	0.1	4	0.1	6	0.1
44	Omega Hospitals	2	0.1	4	0.1	6	0.1
45	Dr. Lal path labs	4	0.2	1	0.0	5	0.1
46	Yashoda Hospital	2	0.1	3	0.1	5	0.1
47	Swathi Imaging & Diagnostic Centre	2	0.1	3	0.1	5	0.1
48	INHS Kalyani Hospital	1	0.0	4	0.1	5	0.1
49	Padmaja Hospital	1	0.0	4	0.1	5	0.1
50	Prime Path Labs	2	0.1	2	0.1	4	0.1
51	Doctors Diagnostic Centre	1	0.0	2	0.1	3	0.1
52	Government General Hospital Kakinada	0	0.0	3	0.1	3	0.1
53	Lions cancer Hospital	1	0.0	1	0.0	2	0.0
54	Asian Institute of Gastroenterology	1	0.0	1	0.0	2	0.0
55	Sri Venkateswara Institute of Medical Sciences	1	0.0	1	0.0	2	0.0
56	Port Hospital (Golden Jubilee)	0	0.0	2	0.1	2	0.0
57	PHC	1	0.0	0	0.0	1	0.0
58	Ghosha Hospital mother & child hospital	1	0.0	0	0.0	1	0.0
59	Anuhya Diagnostics	1	0.0	0	0.0	1	0.0
60	Sowmya Multispeciality Hospital	1	0.0	0	0.0	1	0.0
61	Pragnaa Diagnostics & Research Centre	1	0.0	0	0.0	1	0.0
62	Medicover Hospital	1	0.0	0	0.0	1	0.0
63	Govt. T. B. Hospital	0	0.0	1	0.0	1	0.0
64	Manipal Hospitals	0	0.0	1	0.0	1	0.0
65	Pragathi Medical Centre	0	0.0	1	0.0	1	0.0
66	Others	455	20.6	617	19.3	1072	19.8
	Grand Total	2210	100.0	3204	100.0	5414	100.0

9. Cancer incidence and mortality

In the year 2017 - 2018, the Visakhapatnam cancer registry registered 5,414 cancer case; of which 2210 were males and 3204 were females. The age-adjusted incidence rate for males was 49.6 per 100,000 population and for females, it was 66.0 per 100,000 population. In the year 2017 - 2018, the cancer registry registered 2768 cancer deaths of which 1320 were male (47.7%) deaths and 1448 were female (52.3%) deaths. The age-adjusted mortality rate for males was 29.9 per 100,000 population and for females, it was 29.8 per 100,000 population. The cancer incidence and mortality rates for all sites for males and females are presented in figure 5.

Figure 5: All sites cancer incidence and mortality rate by sex: 2017-2018 (Visakhapatnam district)



The age specific incidence and mortality rates for all sites for males and females are given in the figure 6 and figure 7 respectively.

Figure 6: Age specific incidence and mortality rates – male – all sites





Figure 7: Age specific incidence and mortality rates – female – all sites



There is an under-reporting of the cancer cases in this report and this is due to the various challenges faced by the cancer registry team. Some of them are listed below:

- Geographical area of Visakhapatnam district is vast (11,161 sq kms.). The district has hilly terrain covered by the Eastern Ghats, plains as well as coastal areas.
- The field staff conducts house-visits to all the patients for collection of the demographic, diagnostic and treatment information. Commutation is challenging due to the inaccessibility of the interiors and unavailability of public transportation in some areas.
- Some of private hospitals give reasons such as patient privacy or at times feel a potential threat of business competition.
- In India, Cancer is not a reportable or notifiable disease. Some states have made 'Cancer as a Notifiable Disease'.
- Also, the cause of death is not recorded on the Death Certificates. This information is incompletely obtained from the Vital Statistics Departments.
- Some of pathology laboratories and radiology centres refuse to share the information or share partial data, i.e. name of patient, age, gender and diagnosis, as they feel maintaining such data or additional variable like address, phone number etc will be time consuming.
- As per the Census 2011, the tribal population in Visakhapatnam district is 6,18,500. The illiteracy rate amongst this population is high (63.1% among males and 75.9% among females). The tribal population due to illiteracy, do not come forward for diagnosis to the allopathy doctors and prefer to go to local healers or perform 'pooja' for the various ailments in the community. Hence the cancer diagnosis is low or we could say, there is underdiagnosis of 'Cancer' in this community.
- The COVID-19 pandemic has definitely affected the data collection process. Most of the hospitals and the PHC/CHC were busy treating the COVID-19 restricted the field staff from entering their premises and as their own staff was limited during this period, the cancer patient data was not provided by emails either. During this period, the village and house-visits were also restricted and the registry had to limit their work to patient follow-ups using phone-calls to update the survival data.

10. Leading cancer sites by gender

The leading sites of cancer among males are lung, mouth, stomach, tongue, supraglottic larynx, hypopharynx, non-hodgkins' lymphoma, prostate, oesophagus, colon and rectum. The top ten leading cancer sites for males are presented in figure 8. Among females, breast, cervix uteri, ovary, mouth, corpus uterii, hypopharynx, stomach, lung, oesophagus and thyroid were the leading cancer sites. The top ten leading cancer sites for females are presented in figure 9.

Figure 8: Leading cancer sites among males: 2017 – 2018





Figure 9: Leading cancer sites among females: 2017 - 2018



Cancer Lung (C33-C34)

	Male	Female
Number of Cases	219	93
Percentage	9.9	2.9
Crude Incidence Rate per 100,000	4.8	2.0
Age-Adjusted Incidence Rate per 100,000	5.2	2.0
Truncated Incidence Rate per 100,000	8.2	4.6

Figure 10: Age-specific incidence rate of lung cancer: 2017 - 2018 (Visakhapatnam district)





Figure 11: Comparison of lung cancer incidence rate with other Indian registries ^[13]



Cancer of the mouth (C03-C06)

	Male	Female
Number of Cases	191	141
Percentage	8.6	4.4
Crude Incidence Rate per 100,000	4.2	3.1
Age-Adjusted Incidence Rate per 100,000	4.0	3.0
Truncated Incidence Rate per 100,000	8.5	6.5

Figure 12: Age-specific incidence rate of cancer of mouth: 2017 - 2018 (Visakhapatnam district)





Figure 13: Comparison of mouth cancer incidence rate with other Indian registries^[13]



Stomach (C16)

	Male	Female
Number of Cases	189	106
Percentage	8.6	3.3
Crude Incidence Rate per 100,000	4.2	2.3
Age-Adjusted Incidence Rate per 100,000	4.3	2.2
Truncated Incidence Rate per 100,000	8.3	4.5

Figure 14: Age-specific incidence rate of cancer of stomach: 2017 - 2018 (Visakhapatnam district)





Figure 15: Comparison of stomach cancer incidence rate with other Indian registries^[13]



Cancer Tongue (C01-C02)

	Male	Female
Number of Cases	187	60
Percentage	8.5	1.9
Crude Incidence Rate per 100,000	4.1	1.3
Age-Adjusted Incidence Rate per 100,000	3.8	1.3
Truncated Incidence Rate per 100,000	9.2	2.4

Figure 16: Age-specific incidence rate of cancer of tongue: 2017 - 2018 (Visakhapatnam district)





Figure 17: Comparison of tongue cancer incidence rate with other Indian registries^[13]



Cancer of breast (C50)

	Female
Number of Cases	804
Percentage	25.1
Crude Incidence Rate per 100,000	17.5
Age-Adjusted Incidence Rate per 100,000	16.4
Truncated Incidence Rate per 100,000	40.5

Figure 18: Age-specific incidence rate of cancer of breast: 2017 - 2018 (Visakhapatnam district)





Figure 19: Comparison of breast cancer incidence rate with other Indian registries^[13]



Cancer of cervix uteri (C53)

	Female
Number of Cases	738
Percentage	23.0
Crude Incidence Rate per 100,000	16.0
Age-Adjusted Incidence Rate per 100,000	15.1
Truncated Incidence Rate per 100,000	38.3

Figure 20: Age-specific incidence rate of cancer of cervix uteri: 2017 - 2018 (Visakhapatnam district)





Figure 21: Comparison of cervix uteri cancer incidence rate with other Indian registries^[13]



Cancer of Ovary (C56)

	Female
Number of Cases	199
Percentage	6.2
Crude Incidence Rate per 100,000	4.3
Age-Adjusted Incidence Rate per 100,000	4.0
Truncated Incidence Rate per 100,000	9.8

Figure 22: Age-specific incidence rate of cancer of ovary: 2017 - 2018 (Visakhapatnam district)





Figure 23: Comparison of ovarian cancer incidence rate with other Indian registries ^[13]



Other and unspecified Sites

The other and unspecified cancer sites refer to the following cancer types:

C26	Other and Ill-Defined Digestive Organ	C77	Secondary and Unspecified Malignant Neoplasm of Lymph Node
C39	Other and Ill-Defined Sites Within Respiratory Systems and Intra thoracic Organ	C78	Secondary Malignant Neoplasm of Respiratory and Digestive Organs,
C48	Retro Peritoneum and Peritoneum,	C79	Secondary Malignant Neoplasm of Other and Unspecified Sites
C75	Other Endocrine Glands and Related Structures,	C80	Malignant Neoplasm Without Specification of Site
C76	Other and Ill-Defined, Secondary and Unspecified sites	C97	Malignant Neoplasm of Independent (Primary) Multiple sites

In males, out of 2210 cases, 76 (3.4%) cases were of other and unspecified sites. The predominant cases were of C80 – Primary unknown (3.1%), followed by C26 - Malignant neoplasm of other and ill-defined digestive organs (0.2%), and C48 - Malignant neoplasm of retroperitoneum and peritoneum (0.1%). In females, out of 3,204 cases, 68 (2.1%) cases were of other and unspecified sites. The predominant cases were of C80 – primary unknown (1.9%), followed by C48 – Malignant neoplasm of retroperitoneum and peritoneum (0.1%) and C26 - Malignant neoplasm of other and ill-defined digestive organs (0.1%). The details are presented in table 12.

Table 12: Distribution of Cancers of Other and Unspecified sites

Site	Male		Female		Grand Total	
	Number	%	Number	%	Number	%
Other & Unspecified Sites	76	3.4	68	2.1	144	2.7
C26	5	0.2	3	0.1	8	0.1
C48	2	0.1	4	0.1	6	0.1
C80	69	3.1	61	1.9	130	2.4
Total Cancer Cases	2210	100.0	3204	100.0	5414	100.0

Cancer of other and unspecified (C26, C39, C48, C75, C76, C77, C78, C79, C80, C97)

All Sites	Male	Female
Number of Cases	76	68
Percentage	3.4	2.1
Crude Incidence Rate per 100,000	1.7	1.5
Age-Adjusted Incidence Rate per 100,000	1.7	1.4
Truncated Incidence Rate per 100,000	2.8	3.6

Figure 24: Age-specific incidence rate of cancer of other and unspecified: 2017 - 2018 (Visakhapatnam district)





Figure 25: Comparison of other and unspecified cancer incidence rate with other Indian registries ^[13]



11. Cancer pattern in urban, rural and tribal population

The Visakhapatnam cancer registry covers 94.3% of rural areas and 5.7% of urban areas both of which include tribal population; more of the later resides in rural Visakhapatnam. The estimated average population for the year 2017 - 2018 is distributed as urban: 2338673 (male: 1171468; female: 1167205), rural : 1579367 (male: 782499; female: 796868) and tribal : 653711 (male: 317868; female: 335843). We have observed the difference in the cancer incidence rate in urban, rural and tribal population. The urban cancer incidence rate among males was 54.3 per 100,000 population whereas it was 50.6 per 100,000 population in rural and 11.0 per 100,000 in tribals. Among females, the rural cancer incidence rates (76.1 per 100,000) are higher as compared to the urban area (69.2 per 100,000) and tribal population (13.6 per 100,000). The cancer incidence rate by the area and sex is mentioned in figure 30. The all site cancer mortality by area and sex is mentioned in figure 31

Figure 26: All sites cancer incidence rate by area and sex: 2017 - 2018 (Visakhapatnam district)





Figure 27: All site cancer mortality rate by area and sex: 2017 - 2018 (Visakhapatnam district)



Leading cancer sites in urban, rural and tribal area

Among the males, the leading cancers sites differ in the ranks in urban, rural and tribal areas. The lung cancer incidence in the urban area (6.7 per 100,000 population) is higher than that observed in the rural area (4.9 per 100,000 population) (RR 1.39, 95% CI 1.05-1.83) and fourteen times higher if compared to the tribal males (RR 14.55, 95% CI 8.96-23.66).

Stomach which is the second leading site of cancer among urban males (4.9 per 100,000), is same as observed in the rural males (4.5 per 100,000 population) (RR 1.1, 95% CI 0.81-1.48). However, if the incidence rate of stomach cancer in the urban males is compared with the tribal males (1.5 per 100,000 population), it is thrice as high (RR 3.38, 95% CI 2.42-4.72). The incidence of Mouth in urban males (3.9 per 100,000 population) is lower than that observed in rural males (5.5 per 100,000 population) (RR 0.70, 95% CI 0.51-0.95) whereas when it is compared to tribal males (1.3 per 100,000 population), it is two times higher (RR 2.98, 95% CI 2.12-4.20).

Among females, the cervical cancer incidence rate in Visakhapatnam urban population (12.3 per 100,000 population) is half of that observed in the rural population (23.1 per 100,000 population) (RR 0.53, 95% CI 0.45-0.63) but higher than the tribal population (3.3 per 100,000 population) (RR 3.70, 95% CI 3.02-4.54) whereas, the breast cancer incidence rate in Visakhapatnam urban female population (21.4 per 100,000 population) is in comparison to rural population (15.0 per 100,000 population) (RR 1.43, 95% CI 1.23-1.66) and higher than that in tribal females (2.5 per 100,000 population) (RR 8.53, 95% CI 6.90-10.55).

The difference in the cancer burden and patterns in the urban, rural and tribal areas may be due to different lifestyles, food habits, education levels, and access to the diagnostic and treatment facilities. In this period due to COVID-19 pandemic, the cancer registry staff had limited access to medical records in the cancer centres in the district and hence cancer cases may have missed. The rates in tribal areas show the under-diagnosis as well as under reporting of cancer. The leading cancer sites by sex and area are presented in figures 28 to 33.

Figure 28: Leading cancer sites in urban area: male (2017 - 2018)




Figure 29: Leading cancer sites in rural area: male (2017 - 2018)




Figure 30: Leading cancer sites in tribal area: male (2017 - 2018)




Figure 31: Leading cancer sites in urban area: female (2017 - 2018)




Figure 32: Leading cancer sites in rural area: female (2017 - 2018)





Figure 33: Leading cancer sites in tribal area: female (2017 - 2018)



12. Childhood cancer pattern

In the year 2017 - 2018, the Visakhapatnam cancer registry has recorded 91 (1.7%) cancer cases in the pediatric age-group (0-14 years). The age-adjusted incidence observed among boys is 55.0 per million whereas among girls, it is 36.5 per million population.

The leading sites of cancer among boys is lymphoid leukaemia, acute myeloid leukemia, bone tumours, NHL (except Burkitt's lymphoma), Hodgkin's disease, CMD, brain CNS tumour, kidney, osteosarcoma, hepatoblastoma, nasopharynx, brain CNS tumours and soft tissue tumours. Among girls, lymphoid leukemia, kidney tumours, bone tumours, liver, NHL, soft tissue, chronic myeloproliferative disorders and Hodgkin's disease are common. The leading sites of cancer amongst boys and girls are shown in figures 34 and figure 35 respectively.

Figure 34: Leading cancer sites in boys: 2017 - 2018





Figure 35: Leading cancer sites in girls: 2017 - 2018



It is a known fact that the cancer in children is completely different from those in adults as they are not exposed to the risk-factors like life-style, environmental, diet etc. as adults. Hence, they need to be studied and classified separately.

The classification of childhood cancer is based on tumor morphology and primary site with an emphasis on morphology rather than the emphasis on primary site for adults. The International Classification of Childhood Cancer, 3rd edition (ICCC-3) has mentioned separate coding to know the cancer burden in children according to appropriate diagnostic groups.^[14] ICCC-3 having 12 main groups and further these are divided into subgroups and division of selected subgroups.

The age-adjusted incidence rate as per subgroups in boys and girls per million population is mentioned in Table 13. The paediatric cancer burden as per ICCC-3 standard is mentioned separately in Table 69 and 70. (International Classification of Childhood Cancer Volume III: International Agency for Research on Cancer (IARC), World Health Organization (WHO) ^[15].

Figure 36: Proportion of paediatric cancer cases by age-group: Both sex (Visakhapatnam district)




Table 13: Number of cancer case, percentage and age-adjusted incidence rate per million population:
Visakhapatnam district (2017 - 2018)

ICCC Code	Site	Boys			Girls		
		Nos.	% All	AAR (0-14)	Nos.	% All	AAR (0-14)
1a.	Lymphoid	20	36.4	21.1	11	30.6	11.7
1b.	Acute myeloid	5	9.1	5.1	1	2.8	1.1
1c.	CMD	3	5.5	3.0	1	2.8	0.8
1e.	Unspecified	0	0.0	0.0	2	5.6	1.9
2a.	Hodgkin	5	9.1	3.9	1	2.8	0.8
2b.	Non-Hodgkin except BL	4	7.3	4.0	4	11.1	3.7
3a.	Ependymoma	1	1.8	0.7	1	2.8	1.3
3b.	Astrocytoma	1	1.8	1.2	3	8.3	2.6
3c.	CNS Embryonal	1	1.8	0.7	0	0.0	0.0
3d.	Other gliomas	0	0.0	0.0	1	2.8	1.3
3f.	Unspecified CNS	0	0.0	0.0	1	2.8	0.8
6a.	Nephroblastoma	2	3.6	2.3	3	8.3	3.9
6c.	Unspecified	1	1.8	1.2	1	2.8	1.1
7b.	Hepatic carcinoma	1	1.8	1.2	0	0.0	0.0
8a.	Osteosarcoma	0	0.0	0.0	1	2.8	1.1
8c.	Ewing & Related	2	3.6	1.5	0	0.0	0.0
9a.	Rhabdomyosarcoma	4	7.3	4.2	2	5.6	1.5
9d.	Other specified	1	1.8	0.7	0	0.0	0.0
9e.	Unspecified	2	3.6	2.3	1	2.8	1.1
11c.	Nasopharyngeal Carcinoma	1	1.8	1.0	0	0.0	0.0
11f.	Other & Unspecified	0	0.0	0.0	2	5.6	1.9
Total		55	100.0	55.0	36	100.0	36.5

13. Tobacco-related cancer

Tobacco is the common name of several plants in the genus *Nicotiana* of the family Solanaceae, and the general term for any product prepared from the cured leaves of these plants. Dried tobacco leaves are mainly used for smoking in cigarettes and cigars, as well as pipes and shishas. They can also be consumed as snuff, chewing tobacco, dipping tobacco, and snus. Tobacco contains the highly addictive stimulant alkaloid nicotine as well as harmful alkaloids.

Tobacco is known risk for a number of non-communicable diseases. All forms of tobacco are harmful, and there is no safe level of exposure to tobacco. Tobacco kills 8 million people in a year, this includes 1.2 million second-hand exposed people ^[16].

Tobacco is a risk factor for a number of cancers. The anatomical sites are included to calculate the tobacco-related cancer burden based on the guidelines of the International Agency for Research on Cancer (IARC), WHO, Lyon, France^[17]. Lip (C00), tongue (C01-C02), mouth (C03-C06), pharynx (C10, C12-C14), oesophagus (C15), larynx (C32), lung (C33-C34) and urinary bladder (C67) are associated with the use to tobacco.

As per the Visakhapatnam registry data, the tobacco-related cancer burden is 41.1% in males (1 out of 2 cancer cases is tobacco-related) while it is 15.8% in females (1 out of 6 cancer cases is tobacco-related). The leading site under tobacco-related cancer are lung, mouth, tongue, hypopharynx, and larynx in males; and in females, mouth, lung, hypopharynx, esophagus, and tongue.

Table 14: Tobacco-related cancer in male: 2017 – 2018

ICD-10 Code	Site Description	Number	%	CR	AAR	TR
C00	Lip	9	0.4	0.2	0.2	0.3
C01-C02	Tongue	187	8.5	4.1	3.8	9.2
C03-C06	Mouth	191	8.6	4.2	4.0	8.5
C10	Other oropharynx	12	0.5	0.3	0.3	0.6
C12-C13	Hypopharynx	88	4.0	1.9	2.0	3.5
C14	Pharynx	30	1.4	0.7	0.7	0.7
C15	Oesophagus	70	3.2	1.5	1.6	2.4
C32	Larynx	72	3.3	1.6	1.7	2.8
C33-C34	Trachea, bronchus and lung	219	9.9	4.8	5.2	8.2
C67	Urinary bladder	31	1.4	0.7	0.7	0.8
C00-C06, C10, C12-C15, C32-C34 & C67	Tobacco-related cancer	909	41.1	20.0	20.3	37.0

Table 15: Tobacco-related cancer in female: 2017 - 2018

ICD-10 Code	Site Description	Number	%	CR	AAR	TR
C00	Lip	2	0.1	0.0	0.0	0.1
C01-C02	Tongue	60	1.9	1.3	1.3	2.4
C03-C06	Mouth	141	4.4	3.1	3.0	6.5
C10	Other oropharynx	1	0.0	0.0	0.0	0.1
C12-C13	Hypopharynx	94	2.9	2.0	1.9	4.5
C14	Pharynx	24	0.7	0.5	0.5	1.2
C15	Oesophagus	76	2.4	1.7	1.6	3.4
C32	Larynx	8	0.2	0.2	0.2	0.3
C33-C34	Trachea, bronchus and lung	93	2.9	2.0	2.0	4.6
C67	Urinary bladder	8	0.2	0.2	0.2	0.3
C00-C06, C10, C12-C15, C32-C34 & C67	Tobacco-related cancer	507	15.8	11.0	10.6	23.3

Table 16: Educational status of the patients with tobacco related cancers: 2017 - 2018

Education	Male		Female		Total	
	Number	%	Number	%	Number	%
Illiterate	427	47.0	351	69.2	778	54.9
Literate	208	22.9	66	13.0	274	19.4
Primary (1-7 std)	72	7.9	34	6.7	106	7.5
Secondary (8-10 std)	72	7.9	17	3.4	89	6.3
Technical after 10th	19	2.1	3	0.6	22	1.6
College	62	6.8	6	1.2	68	4.8
Post graduate	5	0.6	0	0.0	5	0.4
Other	1	0.1	0	0.0	1	0.1
Not applicable for children	0	0.0	0	0.0	0	0.0
Unknown / No Information	43	4.7	30	5.9	73	5.2
Total	909	100.0	507	100.0	1416	100.0

Table 17: Tobacco-related cancer cases by sex and religion 2017 - 2018

Religion	Male		Female		Total	
	Number	%	Number	%	Number	%
Hindu	888	97.7	501	98.8	1389	98.1
Muslim	16	1.8	2	0.4	18	1.3
Christian	1	0.1	0	0.0	1	0.1
Sikh	1	0.1	3	0.6	4	0.3
Others	3	0.3	1	0.2	4	0.3
Unknown	0	0.0	0	0.0	0	0.0
Total	909	100.0	507	100.0	1416	100.0

Table 18: Tobacco-related cancer cases by sex and occupation 2017 - 2018

Occupation	Male		Female		Total	
	Number	%	Number	%	Number	%
Professional	4	0.4	1	0.0	5	0.1
Semi-Professional	2	0.2	0	0.0	2	0.0
Clerical/Shop owner	13	1.4	0	0.0	13	0.2
Farmer	157	17.3	15	0.5	172	3.2
Skilled Worker	52	5.7	2	0.1	54	1.0
Semi-Skilled Worker	100	11.0	1	0.0	101	1.9
Unskilled Worker	274	30.1	11	0.3	285	5.3
Unemployed	5	0.6	1	0.0	6	0.1
Student	5	0.6	3	0.1	8	0.1
Housewife	13	1.4	428	13.4	441	8.1
Govt Employee	41	4.5	3	0.1	44	0.8
Pvt Employee	40	4.4	1	0.0	41	0.8
Other	160	17.6	21	0.7	181	3.3
Not applicable for children	0	0.0	0	0.0	0	0.0
Not recorded	43	4.7	20	0.6	63	1.2
Total	909	100.0	507	15.8	1416	26.2

14. Cancer burden as per anatomical system

The cancer burden can be distributed as per the anatomical sites. Among the males, head and neck cancers (31.8%) were the most commonest cancers followed by the gastro-intestinal cancers (24.8%) with the age-adjusted rates 14.2 and 11.5 per 100,000 population respectively. Oral cavity (C00-C06) is observed to have the highest incidence rate (6.7 per 100,000 population) among the head and neck cancers whereas stomach (3.9 per 100,000) has the highest incidence among the gastrointestinal cancers.

Among the females, gynaecological cancers (35.5%) were the most commonest cancers followed by the breast (25.7%) with age-adjusted rates 22.2 and 15.8 per 100,000 population respectively. The system-wise burden of cancer is given below in the Figure 39.

Figure 37: System-wise cancer burden (Visakhapatnam district)




Table 19: Cancer rates by different anatomical sites 2017 - 2018

System	Male					Female				
	Nos.	%	CR	AAR	TR	Nos.	%	CR	AAR	TR
Head & Neck	641	29.0	14.1	13.8	27.9	355	11.1	7.7	7.4	16.2
<i>Oral Cavity</i>	383	17.3	8.4	7.9	17.7	199	6.2	4.3	4.2	8.8
<i>Oropharynx</i>	37	1.7	0.8	0.8	1.9	11	0.3	0.2	0.2	0.6
<i>Nasopharynx</i>	11	0.5	0.2	0.3	0.4	6	0.2	0.1	0.1	0.3
<i>Hypopharynx</i>	118	5.3	2.6	2.7	4.2	118	3.7	2.6	2.4	5.7
<i>Larynx</i>	72	3.3	1.6	1.7	2.8	8	0.2	0.2	0.2	0.3
<i>Para Nasal Sinus</i>	6	0.3	0.1	0.1	0.3	7	0.2	0.2	0.1	0.3
<i>Salivary Gland (Major)</i>	14	0.6	0.3	0.3	0.5	6	0.2	0.1	0.1	0.1
Gastro-intestinal	567	25.7	12.5	12.9	23.7	371	11.6	8.1	7.8	16.4
<i>Oesophagus</i>	70	3.2	1.5	1.6	2.4	76	2.4	1.7	1.6	3.4
<i>Stomach</i>	189	8.6	4.2	4.3	8.3	106	3.3	2.3	2.2	4.5
<i>Small Intestine</i>	14	0.6	0.3	0.3	0.9	8	0.2	0.2	0.2	0.3
<i>Colon</i>	85	3.8	1.9	1.9	3.4	51	1.6	1.1	1.1	2.2
<i>Rectum</i>	66	3.0	1.5	1.5	3.1	40	1.2	0.9	0.8	2.0
<i>Anus</i>	15	0.7	0.3	0.3	0.7	13	0.4	0.3	0.3	0.6
<i>Liver</i>	59	2.7	1.3	1.4	2.1	19	0.6	0.4	0.4	0.6
<i>Gall Bladder</i>	36	1.6	0.8	0.8	1.5	35	1.1	0.8	0.7	1.8
<i>Pancreas</i>	33	1.5	0.7	0.8	1.4	23	0.7	0.5	0.5	1.0
Lung	219	9.9	4.8	5.2	8.2	93	2.9	2.0	2.0	4.6
<i>Lung</i>	219	9.9	4.8	5.2	8.2	93	2.9	2.0	2.0	4.6
Other Thoracic Organs	1	0.0	0.0	0.0	0.0	2	0.1	0.0	0.0	0.1
<i>Other Thoracic Organs</i>	1	0.0	0.0	0.0	0.0	2	0.1	0.0	0.0	0.1
Bone	19	0.9	0.4	0.5	0.1	8	0.2	0.2	0.2	0.1
<i>Bone</i>	19	0.9	0.4	0.5	0.1	8	0.2	0.2	0.2	0.1
Peripheral Nerves & Soft Tissue	34	1.5	0.7	0.7	1.4	38	1.2	0.8	0.8	1.3
<i>Peripheral Nerves & Soft Tissue</i>	34	1.5	0.7	0.7	1.4	38	1.2	0.8	0.8	1.3
Melanoma of Skin	3	0.1	0.1	0.1	0.1	12	0.4	0.3	0.2	0.4
<i>Melanoma of Skin</i>	3	0.1	0.1	0.1	0.1	12	0.4	0.3	0.2	0.4
Skin	29	1.3	0.6	0.6	1.2	26	0.8	0.6	0.5	1.3
<i>Skin</i>	29	1.3	0.6	0.6	1.2	26	0.8	0.6	0.5	1.3
Breast	4	0.2	0.1	0.1	0.3	804	25.1	17.5	16.4	40.5
<i>Breast</i>	4	0.2	0.1	0.1	0.3	804	25.1	17.5	16.4	40.5

System	Male					Female				
	Nos.	%	CR	AAR	TR	Nos.	%	CR	AAR	TR
Genito Urinary Organs	232	10.5	5.1	5.4	7.8	1128	35.2	24.5	23.3	56.0
<i>Cervix</i>	-	-	-	-	-	738	23.0	16.0	15.1	38.3
<i>Corpus Uteri</i>	-	-	-	-	-	100	3.1	2.2	2.1	4.4
<i>Other Uterus, part unspecified</i>	-	-	-	-	-	0	0.0	0.0	0.0	0.0
<i>Ovary</i>	-	-	-	-	-	199	6.2	4.3	4.0	9.8
<i>Vagina</i>	-	-	-	-	-	23	0.7	0.5	0.5	0.9
<i>Vulva</i>	-	-	-	-	-	38	1.2	0.8	0.8	1.8
<i>Other Female Genital Organs</i>	-	-	-	-	-	2	0.1	0.0	0.0	0.1
<i>Penis</i>	48	2.2	1.1	1.1	2.2	-	-	-	-	-
<i>Prostate</i>	84	3.8	1.8	2.2	2.0	-	-	-	-	-
<i>Testis</i>	23	1.0	0.5	0.4	0.7	-	-	-	-	-
<i>Other Male Genital Organs</i>	1	0.0	0.0	0.0	0.0	-	-	-	-	-
<i>Kidney</i>	44	2.0	1.0	1.0	2.1	19	0.6	0.4	0.5	0.4
<i>Urinary Bladder</i>	31	1.4	0.7	0.7	0.8	8	0.2	0.2	0.2	0.3
<i>Ureter</i>	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
<i>Unspecified Urinary Organs</i>	1	0.0	0.0	0.0	0.1	1	0.0	0.0	0.0	0.0
Eye	0	0.0	0.0	0.0	0.0	1	0.0	0.0	0.0	0.1
<i>Eye</i>	0	0.0	0.0	0.0	0.0	1	0.0	0.0	0.0	0.1
Brain & Nervous System	50	2.3	1.1	1.1	2.1	32	1.0	0.7	0.7	1.0
<i>Brain & Nervous System</i>	50	2.3	1.1	1.1	2.1	32	1.0	0.7	0.7	1.0
Endocrine Glands	53	2.4	1.2	1.1	2.3	92	2.9	2.0	1.7	2.9
<i>Other Endocrine Glands</i>	1	0.0	0.0	0.0	0.1	1	0.0	0.0	0.0	0.1
<i>Thyroid</i>	52	2.4	1.1	1.1	2.2	91	2.8	2.0	1.7	2.8
Haematopoietic Cancers	282	12.8	6.2	6.3	8.7	174	5.4	3.8	3.7	6.2
<i>Hodgkins Disease</i>	43	1.9	0.9	0.9	1.3	11	0.3	0.2	0.2	0.2
<i>Non-Hodgkins Lymphoma</i>	90	4.1	2.0	2.0	3.2	57	1.8	1.2	1.2	2.6
<i>Multiple Myeloma</i>	28	1.3	0.6	0.6	1.6	24	0.7	0.5	0.5	1.0
<i>Lymphoid Leukemia</i>	42	1.9	0.9	1.1	0.5	26	0.8	0.6	0.7	0.3
<i>Myeloid Leukemia</i>	77	3.5	1.7	1.6	2.1	51	1.6	1.1	1.0	1.9
<i>Leukemia Unspecified</i>	2	0.1	0.0	0.0	0.0	5	0.2	0.1	0.1	0.0
Other & Unspecified Sites	76	3.4	1.7	1.7	2.8	68	2.1	1.5	1.4	3.6
<i>Other & Unspecified Sites</i>	76	3.4	1.7	1.7	2.8	68	2.1	1.5	1.4	3.6
Grand Total	2210	100.0	48.6	49.6	86.7	3204	100.0	69.7	66.0	150.6

15. Socio-demographic information

The socio-demographic information is collected by the registry field staff during the interaction with the cancer patients or their relatives during the house visits.

Based on the information collected by the Visakhapatnam cancer registry, cancer cases were highest among the Hindu community (97.0%). This can be observed in table 20. Illiteracy was higher among the female patients (59.1%) than the male patients (39.0%) which can be seen in table 21. Furthermore, the details in regard to the occupation are given in table 22 which shows that cancer cases were more commonly observed among the unskilled workers (24.8%) in males and housewives (83.8%) among the females. It can be observed from the table 23, that the number of cancer cases were more among the population with an income below Rs.5000/- per month followed by the income range Rs. 5000/- to Rs. 10,000/-.

Table 20: Cancer cases by religion and sex

Religion	Male		Female		Grand Total	
	Nos	%	Nos	%	Nos	%
Hindu	2144	97.0	3139	98.0	5283	97.6
Muslim	52	2.4	50	1.6	102	1.9
Christian	11	0.5	12	0.4	23	0.4
Sikh	3	0.1	3	0.1	6	0.1
Grand Total	2210	100.0	3204	100.0	5414	100.0

Table 21: Cancer cases by education and sex

Education	Male		Female		Grand Total	
	Nos	%	Nos	%	Nos	%
Illiterate	863	39.0	1893	59.1	2756	50.9
Literate	545	24.7	541	16.9	1086	20.1
Primary (1-7 std)	184	8.3	280	8.7	464	8.6
Secondary (8-10 std)	209	9.5	218	6.8	427	7.9
Technical after 10th	54	2.4	17	0.5	71	1.3
College	182	8.2	83	2.6	265	4.9
Post graduate	30	1.4	9	0.3	39	0.7
Other	5	0.2	5	0.2	10	0.2
Not applicable for children	18	0.8	8	0.2	26	0.5
Unknown / No Information	120	5.4	150	4.7	270	5.0
Grand Total	2210	100.0	3204	100.0	5414	100.0

Table 22: Cancer cases by occupation and sex

Occupation	Male		Female		Grand Total	
	Nos	%	Nos	%	Nos	%
Professional	15	0.7	6	0.2	21	0.4
Semi-Professional	10	0.5	1	0	11	0.2
Clerical/Shop owner	32	1.4	2	0.1	34	0.6
Farmer	372	16.8	68	2.1	440	8.1
Skilled Worker	114	5.2	11	0.3	125	2.3
Semi-Skilled Worker	215	9.7	6	0.2	221	4.1
Unskilled Worker	548	24.8	50	1.6	598	11.0
Unemployed	21	1.0	14	0.4	35	0.6
Student	81	3.7	57	1.8	138	2.5
Housewife	30	1.4	2685	83.8	2715	50.1
Govt Employee	118	5.3	18	0.6	136	2.5
Pvt Employee	97	4.4	9	0.3	106	2.0
Other	417	18.9	136	4.2	553	10.2
Not applicable to children	24	1.1	14	0.4	38	0.7
Unknown/Not recorded	116	5.2	127	4.0	243	4.5
Grand Total	2210	100	3204	100	5414	100


Table 23: Cancer cases by income and sex

Income	Male		Female		Grand Total	
	Nos	%	Nos	%	Nos	%
Less than Rs. 5000/-	636	28.8	1432	44.7	2068	38.2
Rs. 5000/- to 10000/-	690	31.2	838	26.2	1528	28.2
Rs. 10000/- to 15000/-	315	14.3	325	10.1	640	11.8
Rs. 15000/- to 20000/-	144	6.5	99	3.1	243	4.5
More than Rs. 20000/-	251	11.4	171	5.3	422	7.8
Unknown/No Information	174	7.9	339	10.6	513	9.5
Grand Total	2210	100.0	3204	100.0	5414	100.0

16. Comparison of cancer incidence rate with other Indian registries


The incidence rates observed among the males and females in the Indian cancer registries are compared in the figure 38 and figure 39 respectively, The incidence rates observed in the Visakhapatnam Cancer Registry are much lower than those observed among the other Indian registries^[13].

Figure 38: Age-adjusted incidence rate of all cancer sites in male



[References: 13, 18-23]


Figure 39: Age-adjusted incidence rate of all cancer sites in females



[References: 13, 18-23]


The figures 40 to 44, show the comparison of the incidence rates of leading sites of cancer observed in Visakhapatnam with those observed in other Indian cancer registries.

Figure 40: Age-adjusted incidence rate of mouth cancer in males (C03-C06)




[References: 13, 18-23]

Figure 41: Age-adjusted incidence rate of stomach cancer (C16)




[References: 13, 18-23]

Figure 42: Age-adjusted incidence rate of lung cancer



[References: 13, 18-23]

Figure 43: Age-adjusted incidence rate of breast cancer (C50)



[References: 13, 18-23]

Figure 44: Age-adjusted incidence rate of cervical cancer (C53)



[References: 13, 18-23]

17. Abstracts presented at the IACR Conferences

The International Association for Cancer Registries (IACR), is an international association to support, formulate research studies and aid the establishment of cancer registries all over the world. The IACR holds an annual conference so that the cancer registry and registrars can exchange the study results in their population. During the years 2021 and 2022, the conference was held virtually. The following abstracts based on the Visakhapatnam population based cancer registry were selected for poster presentation at the conferences in 2021 and 2022.

IACR 2021 – 1 abstract selected for Poster Presentation



Paper No. 144. CHILDHOOD CANCER – A POPULATION BASED CANCER REGISTRY REPORT OF VISAKHAPATNAM, ANDHRA PRADESH, INDIA

Sushama Saoba¹, Sandhya Cheulkar¹, Monika Sarade¹, Deepali Lokhande¹, Suvarna Kolekar², Amruta Mhatre¹, Narpat Padavi¹, Kumar VVSSS¹, Ganesh B¹, Umesh Mahantsheety²

1. Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India
2. Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India



1. Background

- Population-based Cancer Registry was started (PBCR) along with Homi Bhabha Cancer Hospital and Research Centre, in Visakhapatnam district (Vizag), Andhra Pradesh state, India in the year 2014 by Tata Memorial Centre (TMC), Mumbai, India.
- The objective of the study is to present the burden and pattern of pediatric cancer in rural and costal area of Visakhapatnam, Andhra Pradesh state, India

2. Registry Location



- Population covered for the year 2015-2016 is 4.6 million with 50% approximately rural and nearly 1 million (22.7%) population is of age-group of 0-14 years.

3. Methodology

- Cancer registration method comprises both active and passive approaches for data collection.
- Sources for data collection include regular visits to the community, village panchayat, primary health care centers, cancer and general hospitals, pathology laboratories, radiological centers and registrar offices (birth & death).
- Data checking and quality control is done by the senior staff from the Tata Memorial Centre, Mumbai. Furthermore, cancer patients from these places also travel to Vijaywada (350 kms), Hyderabad (616 kms), Chennai (780 km) for treatment, requiring extensive tracing.
- Data entry is carried out in the in-house software developed by the TMC, Mumbai.
- Registry regularly updates the status of the cancer cases.

4. Results

- Visakhapatnam (Vizag) PBCR data (2015-2016) indicate:
 - 1.1% are pediatric cancer cases (age 0-14 years) out of 4,074 total cancer incident cases.
 - Out of 46 cases, 42 (91.3%) are microscopically confirmed and 2.2% were DCOs.

- Age-adjusted incidence rates (AAR) per million population for age groups 0-14 years is 23.7 for boys and 18.1 for girls.

Leading Sites of Cancer - Boys

Cancer Site	AAR per 100,000
Lymphoid leukaemia	6.3
Osteosarcoma	2.2
Intracranial and intraspinal embryonal tumors	1.6
Hodgkin lymphomas	1.6
Other specified malignant bone tumors	1.3

Leading Sites of Cancer - Girls


Cancer Site	AAR per 100,000
Lymphoid leukaemia	5.5
Osteosarcoma	1.5
Non-Hodgkin lymphomas	1.5
Other gliomas	1.3
Intracranial and intraspinal embryonal tumors	1.3
Negligible tumors and other non-epithelial renal tumors	1.3

- Of the total 46 cases 73.9% cases has completed the treatment whereas 13% received incomplete treatment and remaining 13% have not taken any treatment.
- Fifteen patients are alive, 26 have expired and 5 could not be followed up due to change in address & missing contact numbers.

5. Discussion and Conclusion


- Pediatric cancer incidence rate appears to be fairly low which may be due to the under-reporting of the cases.
- Rates reported are approximately 78% lower for both boys & girls as compared to Hyderabad district registry

Comparison of Incidence Rates



- Leading cancer site for both boys (6.8) & girls (5.5) is Lymphoid leukemia.
- There is under-reporting of pediatric cancer cases in Visakhapatnam district.
- Patients travel to neighboring cities for cancer treatment.
- There are lot of challenges in running a population based cancer registry in Visakhapatnam.
- Efforts to improve the under-reporting of pediatric cancers are required.
- If the low incidence of pediatric cancer is true, then further research is required for better understanding.

IACR 2022 – In total, five abstracts selected for Poster Presentation based on PBCR Visakhapatnam



IMPACT OF COVID-19 PANDEMIC ON FUNCTIONING OF THE VISAKHAPATNAM CANCER REGISTRY, ANDHRA PRADESH, INDIA

Fernandes D¹, SAOBA S², MAHANTSSETTY U¹, BUDUKH A^{2,3}, KUMAR V²

1. Hemi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India

2. Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India

3. Hemi Bhabha National Institute, Training School Complex, Annabhakti Nagar, Mumbai 400094, India

*Corresponding author: drdolorosa@gmail.com

P163



1. Background

- The Population Based Cancer Registry(PBCR) in Visakhapatnam, Andhra Pradesh was established by Tata Memorial Centre, Mumbai in 2014.
- It is the only PBCR in Andhra Pradesh
- The main sources of data for the registry are through active data collection by the cancer registry staff visiting the labs and hospitals.

2. Objectives

- To describe the impact of the Covid-19 pandemic on the functioning of cancer registry.

3. Registry Location



Fig1: Location of Visakhapatnam Cancer Registry, INDIA

- Population covered for the year 2017 is 4.6 million with 52.55% rural.

3. Methodology

- This is a time line study, where the impact of Covid 19 was correlated to the cancer registry reporting system through its impact on monthly cases reported and changes in staff working hours and numbers.
- The number of new cases reported were compared to the baseline year of 2019.
- The data was analyzed by calculating the percentage change in the monthly cases reported in reference to the same month in 2019.
- Staff was encouraged to attend online training sessions for quality control of data conducted by the TMC senior staff.
- Follow up status was updated by phone due to restriction in travelling

4. Results

- Fig.2 shows in January 2020, the new case recording was similar to January 2019 (increased by 3.82%) however from February to August 2020 the new cases reported decreased significantly.
- During the initial first wave of the pandemic, the cancer registry work was put on hold due to the travel restrictions in place resulting in a stoppage of new case data collection from April 2020 to June 2020 and during the second wave during April 2021 to June 2021.
- After the restrictions were reduced, due to the reduction of the patients seeking care, the number of case details collected reduced.
- The registry staff focused on the updating of cases by follow up of registered cases through phone call for vital status and completion of survival data.

Fig2: Comparison of Collection of New Cancers





Fig3: Comparison of Follow-up of Cancer cases



5. Discussion and Conclusion

Negative impact:

- The population based cancer registry work suffered due to the Covid-19 pandemic, with a reduction in cancers cases reported overall of 41.6% for 2020 and 33.46% for 2021 over the baseline year of 2019.
- Covid-19 resulted in significant disruption of cancer registry functioning in Visakhapatnam and delay in the verification of the cancers cases.

Positive impact:

- The pandemic also provided an opportunity to the staff to upgrade themselves by attending online training.
- The survival study data for the cancer registry was completed.



Descriptive Epidemiology of Hematolymphoid Malignancies in Visakhapatnam Population-Based Cancer Registry, Andhra Pradesh, INDIA

Ms. Sushama Saoba¹, Mr. Kumar VVSSS¹, Dr. Dolorosa Fernandes², Dr. Umesh Mahantshetty², Dr. Avinash Bonda²,
Dr. Pradeep Ventrapathi², Dr. Sambasivaiah Kuraparthi², Dr. Shwetha Velagala²

1. Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India
2. Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India

*Corresponding author: sushasaoba91@gmail.com

Paper No. 162



1. Background

- The hematological malignancies in India are more prominently seen in males than females; male hematolymphoid malignancies are 64,422 with an incidence rate of 9.5 per 10⁵ and female hematolymphoid malignancies are 43,687 with an incidence rate of 6.5 per 10⁵.

2. Objective

- We here present the descriptive epidemiology of Hematological malignancies registered in 2017 from Visakhapatnam district, Andhra

3. Registry Location



Fig1: Location of Visakhapatnam Cancer Registry, INDIA

- Population covered for the year 2017 is 4.6 million with 52.55% rural.

4. Methodology

- The staff of Visakhapatnam Cancer Registry actively collect the data from sources like primary health centers, hospitals, diagnostic centers, pathology laboratories and Birth and death registration offices.
- The information collected is verified by the senior staff and then entered in the CanReg5 software.
- The senior staff visit the Visakhapatnam registry regularly for performing quality and consistency checks.
- The patients are actively followed telephonically or by house visits.
- Date of diagnosis was taken as starting date and 31st December 2021 was taken as last follow-up date. Here, as 5-years after incidence are not complete, we present 3 years survival data.
- The observed survival rate was calculated using SPSS and Stata software was used for calculating the Relative Survival.

5. Results

- The Visakhapatnam population-based cancer registry registered 201 hematolymphoid malignancies (8.0%) during 2017; 63.2% males and 36.8% females; leukemia: 82, multiple myeloma: 28, Hodgkin's Disease (HD): 27, Non-Hodgkin's Lymphoma (NHL): 64.
- Mean age for males was 41.9 and for females, it was 44.2 years.

- The incidence rate for hematological malignancies among males and females are shown in Fig. 2 below.
- Chemotherapy was main treatment modality, received by 45.8% patients followed by chemotherapy with radiotherapy (13.4%).
- At the end of follow-up, 97 patients (48.2%) were 'Alive', 103 'Deaths' (51.2%) and 1 'Migrant' (0.5%). This analysis is based on information of 200 patients.
- The 3-year relative survival was 53.2%. Amongst hematolymphoid malignancies, HD had the best 3-year observed survival of 70% followed by NHL (58%), Leukemia (50%) and Multiple myeloma (30%).

Fig2: Incidence Rates of Hematological Malignancies observed in Visakhapatnam Cancer Registry, INDIA





Fig3: Survival Rates of Hematological Malignancies

Table 1: Survival Rates of Hematological Malignancies

6. Discussion and Conclusion

- The 3-year relative survival was 53.2%.
- The hematolymphoid malignancies rank 3rd in males and 5th in female malignancies and provide scope for study to researchers.
- Leukemia incidence is highest among Hematolymphoid malignancies
- As compared to Mumbai and Barshi, the survival rates of hematological malignancies observed in Visakhapatnam are higher.
- Completion of treatment is challenging and a more detailed study is required to investigate stage and treatments facilities available in Visakhapatnam so that facilities like bone marrow transplant centers can be planned in the near future and health authorities can make provisions for affordable care for all.



Rural-Urban difference in Cervical Cancer in Vishakhapatnam, Andhra Pradesh, India

Narpat Padvi¹, Mahadev Bhise¹, Sushama Saoba¹, Kumar VVSSS¹, Dolorosa Fernandes², Atul Budukh^{1,3}, Umesh Mahantshetty²

1. Centre for Cancer Epidemiology, ACTREC, Navi Mumbai, Maharashtra, India
2. Homi Bhabha Cancer Hospital & Research Centre Aganampudi Village, Visakhapatnam, Andhra Pradesh
3. Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India

*Corresponding Author- narpatpadvi19@gmail.com

Paper No-161

INTRODUCTION:

Cervical cancer is a major cause of cancer mortality in women and more than a quarter of its global burden is contributed by developing countries. The data obtained from these Indian Cancer Registries indicate that cervical cancer contributes to approximately 6–29% of all cancer in females.

OBJECTIVE:

The study aims to examine the urban-rural differential in cervical cancer in Vishakhapatnam, India.

METHODOLOGY:

Data has been taken from Visakhapatnam PBCR (Fig 2) for the year 2017. Data collection was done by trained registry staff.

Data from different sources was collected by regular visits to the community, village panchayat, primary health care centers, cancer and general hospitals along with pathology laboratories, radiological centers as well as death and birth registrar office.

The collected data scrutinized by the senior staff and verified data is entered into the CanReg5 software.

The rate ratio was calculated between urban and rural.

Rate ratio was calculated using Boyle and Parkin, 1991.

✓ Out of total 350 cervical cases 60.6 % cases registered were rural, where as 39.4% cases were of urban population.

✓ Overall, the incidence of cervical cancer in Visakhapatnam is 14.5 per 100,000 population.

✓ Cervical cancer is 1.6 (95% CI, 1.29-1.98) times higher in rural areas as compared to urban areas.

✓ Cervical cancer mortality is 50% (95% CI, 1.07- 2.08) higher in rural areas as compared to urban areas.

✓ The incidence rate and mortality rate is shown in table no 2 and table no 3 respectively.

Region	AAR	SE	Rate Ratio	95% CI
Urban	11.2	0.96	1.0	-
Rural	17.9	1.24	1.6	1.29-1.98

Table 2: Cervical cancer incidence rate for 2017

Region	AAR	SE	Rate Ratio	95% CI
Urban	4.7	0.63	1.0	-
Rural	7.0	0.75	1.5	1.07-2.08

Table 3: Cervical cancer mortality rate for 2017




Fig 2: Graphical representation of incidence and mortality rate of cervical cancer for 2017

REGISTRY LOCATION



Fig 1: Registry Location (Vishakhapatnam)

RESULT:

✓ According to 2011, Visakhapatnam had population of 42,90,589. Out of which, 47.45 percent population lives in urban whereas 52.55 % population lives in rural areas of the district.

✓ The total registered cases for incidence as well as mortality of cervical cancer is shown in table no1.

Region	Incidence	Mortality
Urban	138	57
Rural	212	89
Total No of cases	350	146

Table 1: Incidence and mortality for cervical cancer- 2017

DISCUSSION AND CONCLUSION:

• There are urban-rural differences in the incidence of cervical cancer in Visakhapatnam, rural rates are 60% higher than in urban areas. As well as mortality rate is 50% higher in rural areas

• Similar observation was made in other Indian registries such as Sangrur, Mansa and Varanasi.

• There is a need for early detection services for cervical cancer in this population.

• We need to implement intervention programs and create awareness about the risk factors in providing easy access to symptomatic diagnosis and treatment.



Descriptive Epidemiology of Gastro-intestinal Cancers in Visakhapatnam Population Based Cancer Registry, Andhra Pradesh, INDIA

Mr. Kumar VVSS¹, Ms. Sushama Saoba¹, Dr. Dolorosa Fernandes², Dr. Umesh Mahantshetty², Dr. Chidananda Murthy Giridhar², Dr. Rohit Vadgaonkar², Dr. Sambasivaiah Kuraparthi², Dr. Praneeth Aregala², Dr. Soujanya Ferdinand², Dr. Ankita Mehta²

¹ Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai, India
² Hemi Bhakha Cancer Hospital and Research Centre, Visakhapatnam, India

*Corresponding author: sushasoba91@gmail.com

Paper No. 158

1. Background

- The burden of gastro-intestinal cancers is 2,55,715 in India with ASR of 19.0 per 100,000.

2. Objectives

- To present the descriptive epidemiology of gastro-intestinal Cancers registered during the year 2017 in Visakhapatnam population-based, Andhra Pradesh in Southern India.

3. Registry Location




Fig1: Location of Visakhapatnam Cancer Registry, INDIA

- Population covered for the year 2017 is 4.6 million with 52.55% rural.

3. Methodology

- The field staff from the Visakhapatnam PBCR collect information actively from the sources like primary health centers, medical colleges, pathology laboratories and other diagnostic centers.
- The data collected is verified by the senior staff of the registry and then entered into the CanReg5 software.
- The senior staff from Centre from Cancer Epidemiology, Tata Memorial Centre, Mumbai regularly visit the Visakhapatnam PBCR for quality-checking of data.
- The patients are followed up actively by the field staff either telephonically or by house visits.
- Date of diagnosis was taken as starting date and 31st December, 2021 was taken as last follow-up date. Here, as 5-years after incidence are not complete, we present 3-years survival data.
- The observed survival rate was calculated using SPSS and Stata software was used for calculating the Relative Survival.


4. Results

- In the year 2017, the Visakhapatnam PBCR registered 404 (16.1%) gastro-intestinal cancers of which 61.9% were males and 38.1% were females.
- At the end of follow-up, 111 patients were 'Alive'(27.8%), 293 'Deaths'(72.2%). This analysis is based on information of 404 patients.
- The average age of the patients was 57.9 and 52.4 years for males and females respectively.
- The burden of GI cancers are given in table 1.
- Chemotherapy was the most common treatment (25.2%) followed by combination of radiation with chemotherapy (10.9%) and radiation alone (10.6%).
- The 3-year overall relative survival was 28.7% for GI cancers.

Table 1: Burden of Gastro-intestinal Cancers observed in Visakhapatnam Cancer Registry, INDIA

Site	Male		Female	
	Incidence	Mortality	Incidence	Mortality
C15 Oesophagus	1.5	1.1	1.7	1.2
C16 Stomach	3.9	3.6	1.8	1.6
C17 Small Intestine	0.2	0.1	0.1	0.1
C18 Colon	1.4	0.9	0.9	0.3
C19-C20 Rectum	1.4	0.9	0.6	0.2
C21 Anal Canal	0.4	0.1	0.2	0.1
C22 Liver	1.2	0.8	0.2	0.3
C23-C24 Gall Bladder	0.7	0.3	0.6	0.5
C25 Pancreas	0.7	0.8	0.2	0.2

Fig2: Survival Rates of Gastro-intestinal Cancers



5. Discussion and Conclusion

- The 3-year overall relative survival was 26.7% for males and 31.7% for females for GI cancers incident in the year 2017.
- As compared to Mumbai, the survival rates for GI cancers are lower in Visakhapatnam and are higher than those observed in Barshi.
- Although stage of presentation of cancer could not be recorded in majority of the cases, the choice of treatment modality suggests a late stage of presentation which has an effect on the survival.
- Awareness needs to be created about the dietary practices and early signs and symptoms of gastro-intestinal cancers amongst the population and also regarding the government health schemes for cancer patient treatment.

18. The COVID-19 pandemic effect

The outbreak of the COVID-19 pandemic in 2020 led to major disruption of health-related services globally, cancer registry operations being one of them. A nationwide lockdown was imposed from 24th March - 31st May, 2020. India witnessed another devastating second wave which started in mid-march of 2021 and peaked on 1st May with over 400,000 daily cases. The first case of the COVID-19 pandemic in the Indian state of Andhra Pradesh was reported in Nellore on 12 March 2020. A 24-year-old who was confirmed positive for coronavirus. He had travel history to Italy^[23]. The virus has spread in 13 districts of the state, of which East Godavari has the highest number of cases^[24]. Andhra Pradesh entered complete lockdown from 22nd March 2020 and the restrictions were gradually lifted later with decreasing cases. The Andhra Pradesh Health department has confirmed a total of 5,37,687 cases, including 4,702 deaths and 4,35,467 recoveries, as of 10 September^[24].

Cancer is not a notifiable disease in India, hence cancer registration approach in Visakhapatnam PBCR was through active case-finding, where the field investigators visit the community, diagnostic facilities and cancer treatment centres to collect information. The cancer registry team faced several challenges to carry out cancer registry operations. They adopted local measures to ensure that the cancer registration process remains uninterrupted. We have several hurdles in data collection.

Challenges

Hurdles in active case finding: Registry faced disruption in the data collection concerning the access of medical records and laboratory reports of the cancer patients from the treatment centres and diagnostic facilities. Registry also faced resistance in communicating with the identified sources for cancer information such as treating hospitals, diagnostic facilities, and grass-level workers like ASHA and ANM because the entire healthcare system efforts were concentrated on pandemic control and management. Many hospitals were converted to COVID isolation centres. Access to death records from the Death Registration office was completely restricted. The fear of COVID-19 infection was a major deterrent in cancer operations. Many times, the community refused interaction fearing COVID testing. Most of the grass-level workers, key informants in the community and the cancer patients and their family members refused one-to-one and group interactions due to the existing fear.

Several cancer patients reported dissatisfaction as they were unable to access cancer treatment during COVID restrictions because of which registry staff faced resistance in collecting information from them.

Manpower crisis: Some of the staff members and / or their family members were infected with COVID-19 during the first or second wave of the pandemic and they had to apply for leaves for recovery and quarantine. None of the staff resigned and salaries were timely disbursed.

Local measures: During the period of the lockdown and restrictions, regular telephonic interaction with the diagnosed cancer patients and their family members helped in cancer registration. The staff visiting the office was reduced as per the social-distancing protocols and this period was utilized to improve the quality of the filled PBCR proformas for ICD-O coding, completing missing and follow-up information through telephonic interaction with the cancer patients and their relatives. With the slight relaxations in the restrictions, the PHCs were visited and information on cancer cases was obtained from them which were confirmed telephonically. The period was also utilized to prepare the second report of the PBCR Visakhapatnam for the year 2015-16 which was released in June 2020. Since the registry team is part of the HBCH&RC, Visakhapatnam, many cancer patients who were under the registry follow-up inquired about hospital updates

for the treatment-related queries. This helped the registry for follow-up of cancer patients. The survival data was also updated largely during this period.

Despite various hurdles, the cancer registry team ensured that the cancer registry operations remain uninterrupted by adopting flexible remedial measures. Support from the hospital administration and the technical team from the Centre for Cancer Epidemiology has been critical for the continuation of cancer registration.

19. Hurdles in Cancer Registration

Cancer Registration involves visits to the various sources like Hospitals, PHCs, pathology laboratories and radiological diagnostic centres, vital statistics departments where the cancer patients visit for the establishment of cancer diagnosis and treatment. The field staff later visit the patients' homes to confirm the residence, obtain the demographic, diagnostic and treatment information.

The registry covers the Visakhapatnam district which has a geographical area of 11,161 square kilometers. This area consists of hilly terrains like the Eastern Ghats, plains as well as the coastal areas. The field staff visit all the patients located in the various corners of Visakhapatnam in spite of the various hurdles of transportation while commuting to these areas.

During the COVID-19 pandemic period, the lockdown was imposed for limiting the spread of COVID-19 virus. The transportation was restricted to the staff in emergency services only. Hospitals, PHCs and pathology centres were busy diagnosing and treating the COVID-19 positives and could not give time to data collection by the registry staff. Needless to say, the patients could not be accessed and community interaction was restricted as the village boundaries were closed. Only possible work was updation of the cancer patient survival data which was carried out using phone call method. Few centres shared their data via emails. Some of the staff members / staff family members were infected with COVID-19 and quarantined and the registry had to continue its functions with limited staff at times.

Some private hospitals opt not to share the cancer patient data from their centres as they feel a potential threat of business competition. The data of the patients going to these centres has to be collected by indirect means such as PHCs and pathology centres.

In India, Cancer is not a reportable or notifiable disease. Some states have made 'Cancer as a Notifiable Disease'.

Also, the cause of death is not recorded on the Death Certificates. This information is incompletely obtained from the Vital Statistics Departments.

Some of the pathology laboratories and radiology centres refuse to share the information or share partial data, i.e. name of patient, age, gender and diagnosis, as they feel maintaining such data or additional variable like address, phone number etc will cost them time.

As per the Census 2011, the tribal population in Visakhapatnam district is 6,18,500. The illiteracy rate amongst this population is high (51.8% among males and 69.8% among females). The tribal population due to illiteracy, do not come forward for diagnosis to the allopathy doctors and prefer to go to local healers or perform 'pooja' for the various ailments in the community. Hence the cancer diagnosis is low or we could say, there is underdiagnosis of 'Cancer' in this community.

Due to the above reasons, there is an under-reporting of cancer cases and hence the cancer incidence and mortality mentioned in this report is lower than expected.

20. Under-reporting of Cancer Cases in Visakhapatnam Cancer Registry

The Visakhapatnam district is divided into 43 Mandals or blocks comprising of both rural and urban areas. Depending on the Rural and Urban distribution, the Mandal-wise incidence was calculated. There exist under-reporting mainly in the rural / tribal areas of mandals like Pedagantyada, Paravada urban, G. Madugula, Gudem Kotha Veedhi, Paderu, Araku, Pedabayalu, Munchingi Puttu, Hukumpeta, Chintapalli, Ananthagiri, Dumbriguda, Paderu, Koyyuru, Chodavaram mandals especially in the rural areas. The distribution of cancer cases for both sexes is given in the table

Table 24: Distribution of Cancer Cases by Mandal-areas – both sex

Mandal Name	Both Sexes			
	Population	Cancer Nos	%	Crude Rate
Anakapalli Rural	101672	106	2.0	52.1
Anakapalli Urban	97518	148	2.7	75.9
Anandapuram Rural	64770	75	1.4	57.9
Ananthagiri Rural	52231	14	0.3	13.4
Araku Urban	7150	1	0.0	7.0
Araku Valley Rural	53243	20	0.4	18.8
Atchutapuram Rural	70938	69	1.3	48.6
Bheemili Urban	63507	88	1.6	69.3
Bheemunipatnam Rural	60470	62	1.1	51.3
Butchayyapeta Rural	70554	73	1.3	51.7
Cheedikada Rural	49702	43	0.8	43.3
Chintapalli Urban	8403	2	0.0	11.9
Chinthapalli Rural	67935	19	0.4	14.0
Chodavaram Rural	72715	60	1.1	41.3
Chodavaram Urban	21580	45	0.8	104.3
Devarapalli Rural	62132	82	1.5	66.0
Dumbriguda Rural	52246	18	0.3	17.2
G. Madugula Rural	57414	5	0.1	4.4
Gajuwaka Urban	266815	709	13.1	132.9
Golugonda Rural	56315	54	1.0	47.9
Gudem Kotha Veedhi Rural	62387	6	0.1	4.8
Gudem Kotha Veedhi Urban	4933	2	0.0	20.3
Hukumpeta Rural	55089	12	0.2	10.9
K. Kotapadu Rural	64463	80	1.5	62.1
Kasimkota Rural	71675	88	1.6	61.4
Kotavurtla Rural	58084	57	1.1	49.1
Koyyuru Rural	53959	20	0.4	18.5
Madugula Rural	76729	94	1.7	61.3
Makavarapalem Rural	61343	58	1.1	47.3
Munagapaka Rural	59157	60	1.1	50.7

Mandal Name	Both Sexes			
	Population	Cancer Nos	%	Crude Rate
Munchingi Puttu Rural	50530	10	0.2	9.9
Nakkapalle Rural	78290	67	1.2	42.8
Nakkapallei Urban	8103	12	0.2	74.0
Narsipatnai Urban	49592	82	1.5	82.7
Narsipatnam Rural	48030	51	0.9	53.1
Nathavaram Rural	68841	63	1.2	45.8
Paderu Rural	53491	17	0.3	15.9
Paderu Urban	9362	2	0.0	10.7
Padmanabham Rural	55492	60	1.1	54.1
Paravada Rural	56051	72	1.3	64.2
Paravada Urban	27233	0	0.0	0.0
Payakaraopeta Rural	70419	78	1.4	55.4
Payakaraopi Urban	28772	34	0.6	59.1
Pedabayalu Rural	55293	10	0.2	9.0
Pedagantyada	101527	0	0.0	0.0
Pendurthi Rural	34502	39	0.7	56.5
Pendurthi Urban	121755	340	6.3	139.6
Rambilli Rural	57446	67	1.2	58.3
Ravikamatham Rural	75406	89	1.6	59.0
Rolugunta Rural	51563	43	0.8	41.7
S.Rayavaram Rural	78961	71	1.3	45.0
Sabbavaram Rural	66820	72	1.3	53.9
Sabbavarami Urban	4923	15	0.3	152.3
Visakhapatnam Rural	277230	337	6.2	60.8
Visakhapatnam Urban	1041806	1527	28.2	73.3
Yelamanchili Rural	46130	43	0.8	46.6
Yelamanchii Urban	29053	43	0.8	74.0
Grand Total	4571750	5414	100.0	59.2

Table 25: Distribution of Cancer Cases by Mandal-areas - Male

Mandal Name	Male			
	Population	Cancer Nos	%	CR
Anakapalli Rural	50133	26	1.2	25.9
Anakapalli Urban	48356	60	2.7	62.0
Anandapuram Rural	32649	32	1.4	49.0
Ananthagiri Tribal	25945	7	0.3	13.5
Araku Urban	4165	1	0.0	12.0
Araku vally Tribal	25036	6	0.3	12.0
Atchutapuram Rural	35585	28	1.3	39.3
Bheemili Urban	30506	26	1.2	42.6
Bheemunipatnam Rural	30470	24	1.1	39.4
Butchayyapeta Rural	34940	26	1.2	37.2
Cheedikada Rural	24331	14	0.6	28.8
Chintapalli Urban	4457	0	0.0	0.0
Chinthapalli Tribal	32949	7	0.3	10.6
Chodavaram Rural	35891	23	1.0	32.0
Chodavarami Urban	10481	14	0.6	66.8
Devarapalli Rural	31036	36	1.6	58.0
Dumbriguda Tribal	25280	10	0.5	19.8
G. Madugula Tribal	28642	1	0.0	1.7
Gajuwaka Urban	135505	311	14.1	114.8
Golugonda Rural	27991	22	1.0	39.3
Gudem Kotha Veedhi Tribal	29601	2	0.1	3.4
Gudem Kotha veedhi urban	2780	1	0.0	18.0
Hukumpeta Tribal	26699	8	0.4	15.0
K. Kotapadu Rural	31899	34	1.5	53.3
Kasimkota Rural	34804	24	1.1	34.5
Kotavurtla Rural	28583	20	0.9	35.0
Koyyuru Tribal	26604	10	0.5	18.8
Madugula Rural	37409	31	1.4	41.4
Makavarapalem Rural	30088	17	0.8	28.3
Munagapaka Rural	29551	21	1.0	35.5
Munchingi Puttu Tribal	24362	7	0.3	14.4
Nakkapalle Rural	39088	31	1.4	39.7
Nakkapallei Urban	3772	3	0.1	39.8
Narsipatnai Urban	23941	34	1.5	71.0
Narsipatnam Rural	23489	16	0.7	34.1
Nathavaram Rural	34203	18	0.8	26.3
Paderu Tribal	25624	3	0.1	5.9
Paderu Urban	4800	1	0.0	10.4
Padmanabham Rural	27558	21	1.0	38.1
Paravada Rural	28064	26	1.2	46.3

Mandal Name	Male			
	Population	Cancer Nos	%	CR
Paravada Urban	13816	0	0.0	0.0
Payakaraopeta Rural	35659	34	1.5	47.7
Payakaraopi Urban	14076	12	0.5	42.6
Pedabayalu Tribal	27129	3	0.1	5.5
Pedagantyada	51830	0	0.0	0.0
Pendurthi Rural	17069	20	0.9	58.6
Pendurthi Urban	60929	142	6.4	116.5
Rambilli Rural	28478	24	1.1	42.1
Ravikamatham Rural	36228	30	1.4	41.4
Rolugunta Rural	24933	18	0.8	36.1
S.Rayavaram Rural	38645	32	1.4	41.4
Sabbavaram Rural	33682	27	1.2	40.1
Sabbavarami Urban	2508	8	0.4	159.5
Visakhapatnam Rural	139648	145	6.6	51.9
Visakhapatnam Urban	523654	678	30.7	64.7
Yelamanchili Rural	22087	21	1.0	47.5
Yelamanchii Urban	14196	14	0.6	49.3
Grand Total	2271835	2210	100.0	48.6

Among females the distribution of cases and incidence rate is given below:

Table 26: Distribution of Cancer Cases by Mandal-areas - Female

Mandal Name	Female			
	Population	Cancer Nos	%	CR
Anakapalli Rural	51539	80	2.5	77.6
Anakapalli Urban	49162	88	2.7	89.5
Anandapuram Rural	32120	43	1.3	66.9
Ananthagiri Tribal	26286	7	0.2	13.3
Araku Urban	2985	0	0.0	0.0
Araku vally Tribal	28207	14	0.4	24.8
Atchutapuram Rural	35353	41	1.3	58.0
Bheemili Urban	33001	62	1.9	93.9
Bheemunipatnam Rural	30001	38	1.2	63.3
Butchayyapeta Rural	35613	47	1.5	66.0
Cheedikada Rural	25371	29	0.9	57.2
Chintapalli Urban	3946	2	0.1	25.3
Chinthapalli Tribal	34986	12	0.4	17.1
Chodavaram Rural	36824	37	1.2	50.2
Chodavarami Urban	11098	31	1.0	139.7
Devarapalli Rural	31096	46	1.4	74.0
Dumbriguda Tribal	26966	8	0.2	14.8

Mandal Name	Female			
	Population	Cancer Nos	%	CR
G. Madugula Tribal	28772	4	0.1	7.0
Gajuwaka Urban	131309	398	12.4	151.6
Golugonda Rural	28325	32	1.0	56.5
Gudem Kotha Veedhi Tribal	32786	4	0.1	6.1
Gudem Kotha veedhi urban	2154	1	0.0	23.2
Hukumpeta Tribal	28390	4	0.1	7.0
K. Kotapadu Rural	32564	46	1.4	70.6
Kasimkota Rural	36870	64	2.0	86.8
Kotavurtla Rural	29500	37	1.2	62.7
Koyyuru Tribal	27355	10	0.3	18.3
Madugula Rural	39320	63	2.0	80.1
Makavarapalem Rural	31254	41	1.3	65.6
Munagapaka Rural	29606	39	1.2	65.9
Munchingi Puttu Tribal	26168	3	0.1	5.7
Nakkapalle Rural	39202	36	1.1	45.9
Nakkapallei Urban	4331	9	0.3	103.9
Narsipatnai Urban	25651	48	1.5	93.6
Narsipatnam Rural	24541	35	1.1	71.3
Nathavaram Rural	34637	45	1.4	65.0
Paderu Tribal	27867	14	0.4	25.1
Paderu Urban	4562	1	0.0	11.0
Padmanabham Rural	27933	39	1.2	69.8
Paravada Rural	27987	46	1.4	82.2
Paravada Urban	13417	0	0.0	0.0
Payakaraopeta Rural	34759	44	1.4	63.3
Payakaraopi Urban	14696	22	0.7	74.9
Pedabayalu Tribal	28163	7	0.2	12.4
Pedagantyada	49697	0	0.0	0.0
Pendurthi Rural	17434	19	0.6	54.5
Pendurthi Urban	60826	198	6.2	162.8
Rambilli Rural	28968	43	1.3	74.2
Ravikamatham Rural	39178	59	1.8	75.3
Rolugunta Rural	26630	25	0.8	46.9
S.Rayavaram Rural	40315	39	1.2	48.4
Sabbavaram Rural	33138	45	1.4	67.9
Sabbavarami Urban	2416	7	0.2	144.9
Visakhapatnam Rural	137583	192	6.0	69.8
Visakhapatnam Urban	518152	849	26.5	81.9
Yelamanchili Rural	24043	22	0.7	45.8
Yelamanchii Urban	14858	29	0.9	97.6
Grand Total	2299915	3204	100.0	69.7

21. Continuing Medical Education (CME) in Visakhapatnam District of Andhra Pradesh State

Continuing Medical Education (CME) is essential to update the medical professionals to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. CME refers to educational events that have been approved for CME credits. CME credits are important to physicians because some states require a specified number of credits annually to maintain medical licenses, and because most hospitals require a specified number of credits for their physicians to remain credentialed to see patients.

A CME was organised in the Homi Bhabha Cancer Hospital and Research Institute, Visakhapatnam on the 12th July 2022 to help the district medical professional to update the knowledge in 'Prevention and Early Detection of Common Cancers'. This CME was conducted in hybrid mode.


The main objective of the CME was to sensitize the Government Medical Officers about the Early Detection of Breast, Cervix and Oral Cavity Cancers in Visakhapatnam and the newly established Paderu and Annakapalli districts. In all 83 participants attended the CME which included primary health centre medical officers, community health centre medical officers and medical officers from district hospitals.

Prevention, screening and diagnostic tools for oral cancers, breast cancer and cervical cancer, Role of cancer registry in cancer control and Role of PHCs in cancer registration activities were the main topics covered during the sessions.

Dr. Umesh Mahantshetty, Director, HBCH & RC, Visakhapatnam giving the welcome speech



Sessions by the TMC, Mumbai faculty (hybrid mode: virtual and physical)



22. Description of statistical terms used

Incidence: Cancer incidence denotes new cancer cases diagnosed in a defined population in a specified period. For this report, all cancer cases diagnosed from 1st January 2017 - 2018 to 31st December 2017 - 2018 in the Visakhapatnam district have been included.

Mortality: Cancer mortality is defined as the number of cancer deaths occurring in a defined population, in a defined geographic area, during a particular year(s) per 100,000 population. All cancer deaths from 1st January 2017 - 2018 to 31st December 2017 - 2018 in the Visakhapatnam district have been included.

Rates: Rates for cancer are always expressed per 100,000 population. Crude Incidence Rate (CIR): The crude incidence is the rate at which new cases occur in a population during a specific period.

$$\text{CIR} = \frac{\text{Number of new cancer cases observed in the period} \times 100,000}{\text{Estimated population of the same year}}$$

This rate is also called the crude rate because it relates to each population as a whole and is influenced by the age structure of each population.

Age-Specific Rate (ASR): This refers to the rate obtained by the division of the total number of cancer cases by the corresponding estimated population in that age group and sex/site/geographic area/time and multiplying by 100,000.

Age-Adjusted or Age-Standardized Rate (AAR): Age adjustment is a statistical method that corrects for the changing age distribution of the population and allows comparisons to be made in the adjusted rates between different population sub-groups over time.

Truncated Rates (TR): This is similar to the age-adjusted rate except that it is calculated to the truncated age group 35-64 years of age.

Paediatric cancer incidence rate: Age-specific rates are shown for 0-4, 5-9, 10-14, and 15-19 age groups. Age-adjusted incidence rates were calculated by the direct method, using the age-specific rates for the age groups 0-4, 5-9, 10-14, and 15-19 and the weights of the World Standard population for these age groups according to Segi, namely 12, 10, 9, and 9. The cumulative incidence rates were calculated as the sum of the age-specific incidence rates for the 5-year age groups, each multiplied by 5, the number of years contained in each age group.

23. Standard registry tables

Table 27: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018

Males – Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	2	1	1	1	2	1	0	0	0	1	0	9	0.4
C01-C02	Tongue	0	0	0	0	0	8	15	32	27	29	26	16	15	7	5	7	187	8.5
C03-C06	Mouth	0	0	0	0	0	3	11	21	23	21	26	21	19	26	11	9	191	8.6
C07-C08	Salivary Gland	0	0	0	0	1	0	1	3	1	0	2	2	0	1	1	2	14	0.6
C09	Tonsil	0	0	0	0	0	0	0	1	1	2	3	5	3	3	2	1	21	1.0
C10	Oropharynx	0	0	0	0	0	0	0	0	1	1	2	1	4	1	1	1	12	0.5
C11	Nasopharynx	0	1	0	0	0	0	0	0	1	2	2	1	0	3	1	0	11	0.5
C12-C13	Hypopharynx	0	0	0	0	2	2	1	5	5	10	10	13	9	14	10	7	88	4.0
C14	Pharynx	0	0	0	0	0	2	2	0	3	3	0	3	1	7	3	6	30	1.4
C15	Oesophagus	0	0	0	0	0	2	2	2	1	7	6	7	11	17	5	10	70	3.2
C16	Stomach	0	0	0	0	1	4	6	7	15	15	26	29	29	24	21	12	189	8.6
C17	Small Intestine	0	0	0	0	0	0	0	1	2	5	4	1	1	0	0	0	14	0.6
C18	Colon	0	0	0	0	0	2	4	3	6	15	11	8	8	16	5	7	85	3.8
C19-C20	Rectum	0	0	0	0	0	0	4	6	7	5	11	12	5	3	2	11	66	3.0
C21	Anus	0	0	0	0	0	0	2	0	0	4	3	0	3	2	1	0	15	0.7
C22	Liver	1	0	0	0	0	0	0	2	1	6	4	7	11	13	9	5	59	2.7
C23-C24	Gall Bladder	0	0	0	0	0	0	1	0	2	4	1	5	9	5	5	4	36	1.6
C25	Pancreas	0	0	0	0	0	0	2	1	1	3	5	5	5	5	2	4	33	1.5
C30-C31	Nose& Sinus	0	0	0	1	0	0	0	1	1	0	2	1	0	0	0	0	6	0.3
C32	Larynx	0	0	0	1	0	1	0	0	1	4	9	13	12	16	9	6	72	3.3
C33-C34	Lung	0	0	0	0	0	0	1	5	5	13	20	33	41	41	36	24	219	9.9
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.0
C40-C41	Bone	3	2	3	1	4	1	2	1	0	0	0	0	1	1	0	0	19	0.9
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	3	0.1
C44	Other Skin	0	0	0	0	0	0	3	0	2	4	2	4	6	4	2	2	29	1.3
C47&C49	Conn & Soft Tiss	0	0	2	1	0	3	3	2	5	4	5	4	2	2	0	1	34	1.5
C50	Breast	0	0	0	0	0	0	0	0	1	0	1	1	1	0	0	0	4	0.2
C60	Penis	0	0	0	0	0	0	1	2	3	8	7	7	5	8	6	1	48	2.2
C61	Prostate	0	0	0	0	0	0	0	0	2	0	5	9	12	19	19	18	84	3.8
C62	Testis	0	0	0	1	1	3	4	4	4	2	1	1	0	2	0	0	23	1.0
C63	Oth Male Genital Org	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.0
C64	Kidney	2	1	0	0	0	0	3	5	4	4	5	8	5	3	2	2	44	2.0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	1	2	0	2	1	4	3	8	6	4	31	1.4
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain& CNS	1	0	2	0	0	3	5	4	5	7	5	7	4	3	3	1	50	2.3
C73	Thyroid	0	0	0	2	2	2	0	4	3	4	7	9	6	7	6	0	52	2.4
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.0
C81	Hodgkin's Dis	0	1	4	2	3	3	4	7	2	2	5	4	0	3	2	1	43	1.9
C82-C85 & C96	NHL	2	2	1	5	5	4	4	5	10	8	5	15	6	3	9	6	90	4.1
C90	M.Myeloma	0	0	0	0	0	0	0	0	0	4	5	7	7	2	3	0	28	1.3
C91	Leuk Lymphoid	7	8	4	5	6	1	2	1	1	1	1	2	1	0	1	1	42	1.9
C92-C94	Leuk Myeloid	2	4	2	6	7	6	8	9	6	7	3	6	2	5	2	2	77	3.5
C95	Leuk. Uns	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0.1
Oth.& Uns. Sites		0	0	0	0	2	0	3	3	7	5	9	9	8	13	10	7	76	3.4
Grand Total		18	19	18	27	34	52	96	140	160	215	242	281	255	290	201	162	2210	100.0

Table 28: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Females – Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0.1
C01-C02	Tongue	0	0	0	0	0	1	1	3	3	4	14	5	7	13	4	5	60	1.9
C03-C06	Mouth	0	0	0	0	0	0	2	5	8	12	25	22	26	18	18	5	141	4.4
C07-C08	Salivary Gl	0	1	0	0	1	0	1	0	0	0	0	1	1	1	0	0	6	0.2
C09	Tonsil	0	0	0	0	0	0	0	0	1	1	2	2	0	0	0	0	6	0.2
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.0
C11	Nasopharynx	0	0	0	1	0	0	0	2	0	1	1	1	0	0	0	0	6	0.2
C12-C13	Hypopharynx	0	0	0	0	2	5	5	10	8	16	15	14	6	6	6	1	94	2.9
C14	Pharynx	0	0	0	0	0	1	1	0	1	5	2	5	5	3	0	1	24	0.7
C15	Oesophagus	0	0	0	1	0	1	1	4	12	11	12	7	6	7	8	6	76	2.4
C16	Stomach	0	0	0	2	1	3	5	7	7	15	18	8	13	21	5	1	106	3.3
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	2	0	1	0	2	2	8	0.2
C18	Colon	0	0	0	0	0	1	3	3	3	6	6	10	6	6	4	3	51	1.6
C19-C20	Rectum	0	0	0	0	2	1	1	0	2	5	8	5	10	4	2	0	40	1.2
C21	Anus	0	0	0	0	0	0	1	0	0	3	1	2	3	1	1	1	13	0.4
C22	Liver	0	1	0	1	0	0	0	0	0	0	3	2	4	3	2	3	19	0.6
C23-C24	Gall Bladder	0	0	0	0	0	1	0	4	5	8	4	3	5	0	2	3	35	1.1
C25	Pancreas	0	0	0	0	0	0	1	0	2	2	6	3	1	4	2	2	23	0.7
C30-C31	Nose & Sinus	0	0	1	0	0	0	1	0	1	1	2	1	0	0	0	0	7	0.2
C32	Larynx	0	0	0	0	0	0	1	1	2	2	0	0	0	0	1	1	8	0.2
C33-C34	Lung	0	0	0	0	0	1	1	4	3	14	14	19	16	11	2	8	93	2.9
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0.1
C40-C41	Bone	0	0	2	2	0	2	0	2	0	0	0	0	0	0	0	0	8	0.2
C43	Melanoma Skin	0	0	0	0	1	1	0	2	1	1	0	2	1	2	1	0	12	0.4
C44	Other Skin	0	0	0	0	0	1	1	3	3	3	3	3	5	2	0	2	26	0.8
C47&C49	Conn S Tiss	0	1	0	1	0	2	2	4	8	3	2	2	3	4	2	4	38	1.2
C50	Breast	0	0	0	0	2	9	22	78	107	131	120	105	89	65	41	35	804	25.1
C51	Vulva	0	0	0	0	0	0	0	0	2	3	3	1	4	6	3	1	23	0.7
C52	Vagina	0	0	0	0	0	0	1	0	2	9	2	7	7	5	1	4	38	1.2
C53	Cervix Uteri	0	0	0	0	1	3	13	59	92	122	112	111	96	65	46	18	738	23.0
C54	Corpus Uteri	0	0	0	0	1	0	1	1	6	9	15	16	13	16	11	5	94	2.9
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	1	3	1	0	0	0	1	6	0.2
C56	Ovary	0	0	0	4	3	6	6	16	26	30	33	24	23	16	4	8	199	6.2
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	0.1
C64	Kidney	3	1	0	1	0	0	1	0	0	2	0	2	2	3	2	2	19	0.6
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	1	1	1	2	0	1	2	0	8	0.2
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.0
C69	Eye	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.0
C70-C72	Brain& CNS	2	1	3	3	0	0	5	2	1	3	4	2	4	2	0	0	32	1.0
C73	Thyroid	0	0	0	1	4	13	11	12	12	8	5	8	1	10	5	1	91	2.8
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.0
C81	Hodg Dis	0	0	1	1	2	1	1	0	2	1	0	1	0	0	1	0	11	0.3
C82-C85 & C96	NHL	0	2	2	0	3	0	2	5	4	12	8	5	6	5	1	2	57	1.8
C90	M. Myeloma	0	0	0	0	0	0	0	2	1	1	5	3	4	3	5	0	24	0.7
C91	Leuk Lymph	3	5	3	3	4	0	0	0	1	0	2	2	0	2	0	1	26	0.8
C92-C94	Leuk Myel	0	1	1	1	2	4	4	6	2	4	7	5	6	3	4	1	51	1.6
C95	LeukUns	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	5	0.2
Other & Uns Sites		0	0	0	0	0	1	1	6	5	10	12	12	11	3	4	3	68	2.1
Grand Total		8	14	14	23	30	59	96	241	336	461	473	427	387	312	193	130	3204	100.0

Table 29: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.3	0.3	0.7	0.5	0.0	0.0	0.0	1.4	0.0	0.2	0.2	0.3
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	1.8	4.0	8.6	7.7	9.7	11.8	9.3	8.2	5.1	6.8	12.0	4.1	3.8	9.2
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.7	2.9	5.7	6.5	7.0	11.8	12.1	10.4	19.0	14.9	15.4	4.2	4.0	8.5
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.8	0.3	0.0	0.9	1.2	0.0	0.7	1.4	3.4	0.3	0.3	0.5
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.7	1.4	2.9	1.6	2.2	2.7	1.7	0.5	0.5	1.0
C10	Oth. Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.9	0.6	2.2	0.7	1.4	1.7	0.3	0.3	0.6
C11	Nasopharynx	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.9	0.6	0.0	2.2	1.4	0.0	0.2	0.3	0.4
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.5	0.5	0.3	1.3	1.4	3.3	4.5	7.5	4.9	10.2	13.6	12.0	1.9	2.0	3.5
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.9	1.0	0.0	1.7	0.5	5.1	4.1	10.3	0.7	0.7	0.7
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.5	0.3	2.3	2.7	4.0	6.0	12.4	6.8	17.1	1.5	1.6	2.4
C16	Stomach	0.0	0.0	0.0	0.0	0.2	0.9	1.6	1.9	4.3	5.0	11.8	16.8	15.9	17.5	28.5	20.5	4.2	4.3	8.3
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	1.7	1.8	0.6	0.5	0.0	0.0	0.0	0.3	0.3	0.9
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.5	1.1	0.8	1.7	5.0	5.0	4.6	4.4	11.7	6.8	12.0	1.9	1.9	3.4
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.6	2.0	1.7	5.0	6.9	2.7	2.2	2.7	18.8	1.5	1.5	3.1
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.3	1.4	0.0	1.6	1.5	1.4	0.0	0.3	0.3	0.7
C22	Liver	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	2.0	1.8	4.0	6.0	9.5	12.2	8.5	1.3	1.4	2.1
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	1.3	0.5	2.9	4.9	3.6	6.8	6.8	0.8	0.8	1.5
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.3	1.0	2.3	2.9	2.7	3.6	2.7	6.8	0.7	0.8	1.4
C30-C31	Nose& Sinus	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.3	0.0	0.9	0.6	0.0	0.0	0.0	0.0	0.1	0.1	0.3
C32	Larynx	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.3	1.3	4.1	7.5	6.6	11.7	12.2	10.3	1.6	1.7	2.8
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	1.4	4.4	9.1	19.1	22.4	29.9	48.8	41.0	4.8	5.2	8.2
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	1.0	0.6	0.8	0.2	0.9	0.2	0.5	0.3	0.0	0.0	0.0	0.0	0.5	0.7	0.0	0.0	0.4	0.5	0.1
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.0	0.7	0.0	0.0	0.1	0.1	0.1
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.6	1.3	0.9	2.3	3.3	2.9	2.7	3.4	0.6	0.6	1.2
C47&C49	Conn & Soft Tiss	0.0	0.0	0.5	0.2	0.0	0.7	0.8	0.5	1.4	1.3	2.3	2.3	1.1	1.5	0.0	1.7	0.7	0.7	1.4
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.5	0.6	0.5	0.0	0.0	0.0	0.1	0.1	0.3
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.9	2.7	3.2	4.0	2.7	5.8	8.1	1.7	1.1	1.1	2.2
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.3	5.2	6.6	13.8	25.7	30.8	1.8	2.2	2.0
C62	Testis	0.0	0.0	0.0	0.2	0.2	0.7	1.1	1.1	1.1	0.7	0.5	0.6	0.0	1.5	0.0	0.0	0.5	0.4	0.7
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.6	0.3	0.0	0.0	0.0	0.0	0.8	1.3	1.1	1.3	2.3	4.6	2.7	2.2	2.7	3.4	1.0	1.0	2.1
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.7	0.5	2.3	1.6	5.8	8.1	6.8	0.7	0.7	0.8
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.3	0.0	0.5	0.0	0.0	0.7	1.3	1.1	1.4	2.3	2.3	4.0	2.2	2.2	4.1	1.7	1.1	1.1	2.1
C73	Thyroid	0.0	0.0	0.0	0.5	0.5	0.5	0.0	1.1	0.9	1.3	3.2	5.2	3.3	5.1	8.1	0.0	1.1	1.1	2.2
C75	Endo gl.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C81	Hodgkins Dis	0.0	0.3	1.0	0.5	0.7	0.7	1.1	1.9	0.6	0.7	2.3	2.3	0.0	2.2	2.7	1.7	0.9	0.9	1.3
C82-C85 & C96	NHL	0.6	0.6	0.3	1.2	1.1	0.9	1.1	1.3	2.8	2.7	2.3	8.7	3.3	2.2	12.2	10.3	2.0	2.0	3.2
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	2.3	4.0	3.8	1.5	4.1	0.0	0.6	0.6	1.6
C91	Leuk Lymph	2.2	2.6	1.0	1.2	1.4	0.2	0.5	0.3	0.3	0.3	0.5	1.2	0.5	0.0	1.4	1.7	0.9	1.1	0.5
C92-C94	Leuk Myel	0.6	1.3	0.5	1.5	1.6	1.4	2.1	2.4	1.7	2.3	1.4	3.5	1.1	3.6	2.7	3.4	1.7	1.6	2.1
C95	Leuk Uns	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Uns. Sites		0.0	0.0	0.0	0.0	0.5	0.0	0.8	0.8	2.0	1.7	4.1	5.2	4.4	9.5	13.6	12.0	1.7	1.7	1.7
Grand Total		5.8	6.1	4.5	6.7	7.8	12.0	25.3	37.7	45.4	72.0	109.9	162.6	139.5	211.4	272.4	276.8	48.6	49.6	86.7

Table 30: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.2	0.0	0.0	0.0	0.1
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.8	0.9	1.4	6.6	2.6	3.3	8.8	5.0	6.7	1.3	1.3	2.4
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.3	2.4	4.3	11.7	11.3	12.3	12.1	22.5	6.7	3.1	3.0	6.5
C07-C08	Salivary Gl	0.0	0.3	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.5	0.7	0.0	0.0	0.1	0.1	0.1
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.9	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4
C10	Oth. Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C11	Nasopharynx	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.0	0.4	0.5	0.5	0.0	0.0	0.0	0.0	0.1	0.1	0.3
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.4	1.1	1.3	2.5	2.4	5.7	7.0	7.2	2.8	4.0	7.5	1.3	2.0	1.9	4.5
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.3	1.8	0.9	2.6	2.4	2.0	0.0	1.3	0.5	0.5	1.2
C15	Oesophagus	0.0	0.0	0.0	0.3	0.0	0.2	0.3	1.0	3.5	4.0	5.6	3.6	2.8	4.7	10.0	8.0	1.7	1.6	3.4
C16	Stomach	0.0	0.0	0.0	0.5	0.2	0.7	1.3	1.8	2.1	5.4	8.5	4.1	6.1	14.2	6.2	1.3	2.3	2.2	4.5
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.9	0.0	0.5	0.0	2.5	2.7	0.2	0.2	0.3
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.8	0.9	2.2	2.8	5.2	2.8	4.0	5.0	4.0	1.1	1.1	2.2
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.4	0.2	0.3	0.0	0.6	1.8	3.8	2.6	4.7	2.7	2.5	0.0	0.9	0.8	2.0
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.1	0.5	1.0	1.4	0.7	1.2	1.3	0.3	0.3	0.6
C22	Liver	0.0	0.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.0	1.9	2.0	2.5	4.0	0.4	0.4	0.6
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.0	1.5	2.9	1.9	1.5	2.4	0.0	2.5	4.0	0.8	0.7	1.8
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.7	2.8	1.5	0.5	2.7	2.5	2.7	0.5	0.5	1.0
C30-C31	Nose & Sinus	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.3	0.4	0.9	0.5	0.0	0.0	0.0	0.0	0.2	0.1	0.3
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.6	0.7	0.0	0.0	0.0	0.0	1.2	1.3	0.2	0.2	0.3
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.2	0.3	1.0	0.9	5.0	6.6	9.8	7.5	7.4	2.5	10.7	2.0	2.0	4.6
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C40-C41	Bone	0.0	0.0	0.5	0.5	0.0	0.4	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.1
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.5	0.3	0.4	0.0	1.0	0.5	1.3	1.2	0.0	0.3	0.2	0.4
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.8	0.9	1.1	1.4	1.5	2.4	1.3	0.0	2.7	0.6	0.5	1.3
C47&C49	Conn S Tiss	0.0	0.3	0.0	0.3	0.0	0.4	0.5	1.0	2.4	1.1	0.9	1.0	1.4	2.7	2.5	5.3	0.8	0.8	1.3
C50	Breast	0.0	0.0	0.0	0.0	0.4	2.0	5.6	19.5	31.5	47.1	56.4	54.2	42.0	43.8	51.2	46.7	17.5	16.4	40.5
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.1	1.4	0.5	1.9	4.0	3.7	1.3	0.5	0.5	0.9
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	3.2	0.9	3.6	3.3	3.4	1.2	5.3	0.8	0.8	1.8
C53	Cervix Uteri	0.0	0.0	0.0	0.0	0.2	0.7	3.3	14.8	27.1	43.8	52.6	57.2	45.3	43.8	57.4	24.0	16.0	15.1	38.3
C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.3	1.8	3.2	7.0	8.3	6.1	10.8	13.7	6.7	2.0	2.0	4.0
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.4	0.5	0.0	0.0	0.0	1.3	0.1	0.1	0.4
C56	Ovary	0.0	0.0	0.0	1.0	0.7	1.3	1.5	4.0	7.6	10.8	15.5	12.4	10.8	10.8	5.0	10.7	4.3	4.0	9.8
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.1
C64	Kidney	1.0	0.3	0.0	0.3	0.0	0.0	0.3	0.0	0.0	0.7	0.0	1.0	0.9	2.0	2.5	2.7	0.4	0.5	0.4
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.5	1.0	0.0	0.7	2.5	0.0	0.2	0.2	0.3
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C70-C72	Brain& CNS	0.7	0.3	0.8	0.8	0.0	0.0	1.3	0.5	0.3	1.1	1.9	1.0	1.9	1.3	0.0	0.0	0.7	0.7	1.0
C73	Thyroid	0.0	0.0	0.0	0.3	0.9	2.9	2.8	3.0	3.5	2.9	2.3	4.1	0.5	6.7	6.2	1.3	2.0	1.7	2.8
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C81	Hodg Dis	0.0	0.0	0.3	0.3	0.4	0.2	0.3	0.0	0.6	0.4	0.0	0.5	0.0	0.0	1.2	0.0	0.2	0.2	0.2
C82-C85 & C96	NHL	0.0	0.7	0.5	0.0	0.7	0.0	0.5	1.3	1.2	4.3	3.8	2.6	2.8	3.4	1.2	2.7	1.2	1.2	2.6
C90	M. Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.4	2.3	1.5	1.9	2.0	6.2	0.0	0.5	0.5	1.0
C91	Leuk Lymph	1.0	1.7	0.8	0.8	0.9	0.0	0.0	0.0	0.3	0.0	0.9	1.0	0.0	1.3	0.0	1.3	0.6	0.7	0.3
C92-C94	Leuk Myel	0.0	0.3	0.3	0.3	0.4	0.9	1.0	1.5	0.6	1.4	3.3	2.6	2.8	2.0	5.0	1.3	1.1	1.0	1.9
C95	Leuk Uns	0.0	0.3	0.3	0.3	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Other & Uns Sites		0.0	0.0	0.0	0.0	0.0	0.2	0.3	1.5	1.5	3.6	5.6	6.2	5.2	2.0	5.0	4.0	1.5	1.4	3.6
Grand Total		2.7	4.8	3.6	5.9	6.5	13.3	24.6	60.3	98.8	165.6	222.2	220.2	182.5	210.2	240.8	173.5	69.7	66.0	150.6

Table 31: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Males

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0001	0.0001	0.0002	0.0002
C01-C02	Tongue	0.0031	0.0030	0.0036	0.0036
C03-C06	Mouth	0.0029	0.0029	0.0046	0.0045
C07-C08	Salivary Gland	0.0002	0.0002	0.0003	0.0003
C09	Tonsil	0.0004	0.0004	0.0006	0.0006
C10	Oth. Oropharynx	0.0002	0.0002	0.0003	0.0003
C11	Nasopharynx	0.0001	0.0001	0.0003	0.0003
C12-C13	Hypopharynx	0.0012	0.0012	0.0024	0.0024
C14	Pharynx	0.0003	0.0003	0.0007	0.0007
C15	Oesophagus	0.0008	0.0008	0.0018	0.0018
C16	Stomach	0.0029	0.0029	0.0052	0.0052
C17	Small Intestine	0.0003	0.0003	0.0003	0.0003
C18	Colon	0.0012	0.0012	0.0021	0.0021
C19-C20	Rectum	0.0011	0.0010	0.0013	0.0013
C21	Anus	0.0002	0.0002	0.0004	0.0004
C22	Liver	0.0008	0.0008	0.0018	0.0018
C23-C24	Gall Bladder	0.0005	0.0005	0.0010	0.0010
C25	Pancreas	0.0005	0.0005	0.0008	0.0008
C30-C31	Nose & Sinus	0.0001	0.0001	0.0001	0.0001
C32	Larynx	0.0010	0.0010	0.0022	0.0022
C33-C34	Lung	0.0029	0.0029	0.0068	0.0068
C37-C38	Oth Thoracic	0.0000	0.0000	0.0000	0.0000
C40-C41	Bone	0.0003	0.0003	0.0003	0.0003
C43	Melanoma Skin	0.0000	0.0000	0.0001	0.0001
C44	Other Skin	0.0005	0.0005	0.0007	0.0007
C47&C49	Conn & Soft Tiss	0.0006	0.0006	0.0006	0.0006
C50	Breast	0.0001	0.0001	0.0001	0.0001
C60	Penis	0.0007	0.0007	0.0014	0.0014
C61	Prostate	0.0007	0.0007	0.0027	0.0027
C62	Testis	0.0003	0.0003	0.0004	0.0004
C63	Oth Male Genital	0.0000	0.0000	0.0000	0.0000
C64	Kidney	0.0008	0.0008	0.0010	0.0010
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0003	0.0003	0.0010	0.0010
C68	Urethra	0.0000	0.0000	0.0000	0.0000
C69	Eye	0.0000	0.0000	0.0000	0.0000
C70-C72	Brain & CNS	0.0008	0.0008	0.0011	0.0011
C73	Thyroid	0.0008	0.0008	0.0015	0.0015
C75	Endo gl.	0.0000	0.0000	0.0000	0.0000
C81	Hodgkins Dis	0.0006	0.0006	0.0008	0.0008
C82-C85 & C96	NHL	0.0013	0.0013	0.0021	0.0021
C90	Multiple Myeloma	0.0006	0.0006	0.0009	0.0009
C91	Leuk Lymphoid	0.0006	0.0006	0.0007	0.0007
C92-C94	Leuk Myeloid	0.0011	0.0011	0.0014	0.0014
C95	Leukaemia Uns	0.0000	0.0000	0.0000	0.0000
Other & Unspecified Sites		0.0010	0.0010	0.0021	0.0021
Grand Total		0.0318	0.0313	0.0559	0.0544

Table 32: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Females

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0000	0.0024	0.0001	0.0086
C01-C02	Tongue	0.0008	0.0800	0.0015	0.1487
C03-C06	Mouth	0.0022	0.2186	0.0039	0.3911
C07-C08	Salivary Gl	0.0001	0.0090	0.0001	0.0124
C09	Tonsil	0.0001	0.0131	0.0001	0.0131
C10	Oth. Oropharynx	0.0000	0.0026	0.0000	0.0026
C11	Nasopharynx	0.0001	0.0105	0.0001	0.0105
C12-C13	Hypopharynx	0.0015	0.1526	0.0021	0.2101
C14	Pharynx	0.0004	0.0422	0.0005	0.0523
C15	Oesophagus	0.0011	0.1064	0.0018	0.1798
C16	Stomach	0.0015	0.1528	0.0025	0.2546
C17	Small Intestine	0.0001	0.0089	0.0002	0.0213
C18	Colon	0.0008	0.0779	0.0012	0.1230
C19-C20	Rectum	0.0007	0.0717	0.0010	0.0977
C21	Anus	0.0002	0.0212	0.0003	0.0309
C22	Liver	0.0002	0.0246	0.0005	0.0472
C23-C24	Gall Bladder	0.0006	0.0567	0.0007	0.0692
C25	Pancreas	0.0003	0.0320	0.0006	0.0579
C30-C31	Nose & Sinus	0.0001	0.0131	0.0001	0.0131
C32	Larynx	0.0001	0.0091	0.0002	0.0153
C33-C34	Lung	0.0016	0.1564	0.0021	0.2059
C37-C38	Oth Thoracic	0.0000	0.0038	0.0000	0.0038
C40-C41	Bone	0.0001	0.0099	0.0001	0.0099
C43	Melanoma Skin	0.0002	0.0155	0.0003	0.0285
C44	Other Skin	0.0004	0.0425	0.0005	0.0493
C47&C49	Conn S Tiss	0.0005	0.0469	0.0007	0.0728
C50	Breast	0.0129	1.2848	0.0177	1.7524
C51	Vulva	0.0003	0.0274	0.0007	0.0663
C52	Vagina	0.0006	0.0596	0.0008	0.0827
C53	Cervix Uteri	0.0122	1.2174	0.0173	1.7160
C54	CorpusUteri	0.0014	0.1357	0.0026	0.2580
C55	Oth Uterus	0.0001	0.0114	0.0001	0.0114
C56	Ovary	0.0033	0.3280	0.0041	0.4066
C57	Placenta	0.0000	0.0049	0.0000	0.0049
C64	Kidney	0.0002	0.0228	0.0005	0.0454
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0001	0.0108	0.0003	0.0266
C68	Urethra	0.0000	0.0000	0.0000	0.0034
C69	Eye	0.0000	0.0015	0.0000	0.0015
C70-C72	Brain& CNS	0.0005	0.0526	0.0006	0.0593
C73	Thyroid	0.0012	0.1160	0.0018	0.1808
C75	Endocrine gl	0.0000	0.0026	0.0000	0.0026
C81	Hodg Dis	0.0001	0.0145	0.0002	0.0207
C82-C85 & C96	NHL	0.0009	0.0913	0.0011	0.1144
C90	M. Myeloma	0.0003	0.0347	0.0008	0.0760
C91	Leuk Lymph	0.0004	0.0370	0.0004	0.0438
C92-C94	Leuk Myel	0.0008	0.0772	0.0011	0.1122
C95	LeukUns	0.0001	0.0065	0.0001	0.0065
Other & Uns Sites		0.0012	0.1202	0.0016	0.1552
Grand Total		0.0505	4.9293	0.0731	7.0495

Table 33: Number (#) and Proportion (%) of cancers by site (ICD10) and method of diagnosis: 2017 - 2018
– Males Visakhapatnam district

ICD-10	Site	DCO		Cln Only		Cl. Inv.		Cytology		Hist Met		Primary Hist		Grand Total	
		Nos	%	Nos	%	Nos	%	Nos	%	Nos	%	Nos	%	Nos	%
C00	Lip	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	9	0.4	9	0.4
C01-C02	Tongue	1	0.0	2	0.1	0	0.0	1	0.0	0	0.0	183	8.3	187	8.5
C03-C06	Mouth	1	0.0	3	0.1	0	0.0	2	0.1	1	0.0	184	8.3	191	8.6
C07-C08	Salivary Gl.	0	0.0	0	0.0	0	0.0	5	0.2	0	0.0	9	0.4	14	0.6
C09	Tonsil	0	0.0	3	0.1	0	0.0	0	0.0	0	0.0	18	0.8	21	1.0
C10	Oropharynx	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	11	0.5	12	0.5
C11	Nasopharynx	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	11	0.5	11	0.5
C12-C13	Hypopharynx	0	0.0	1	0.0	0	0.0	1	0.0	0	0.0	86	3.9	88	4.0
C14	Pharynx	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	30	1.4	30	1.4
C15	Oesophagus	1	0.0	3	0.1	0	0.0	1	0.0	0	0.0	65	2.9	70	3.2
C16	Stomach	0	0.0	5	0.2	1	0.0	2	0.1	2	0.1	179	8.1	189	8.6
C17	Small Intestine	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	14	0.6	14	0.6
C18	Colon	1	0.0	3	0.1	0	0.0	1	0.0	2	0.1	78	3.5	85	3.8
C19-C20	Rectum	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	64	2.9	66	3.0
C21	Anus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	15	0.7	15	0.7
C22	Liver	0	0.0	0	0.0	0	0.0	15	0.7	0	0.0	44	2.0	59	2.7
C23-C24	Gall Bladder	3	0.1	1	0.0	0	0.0	2	0.1	0	0.0	30	1.4	36	1.6
C25	Pancreas	0	0.0	1	0.0	0	0.0	5	0.2	3	0.1	24	1.1	33	1.5
C30-C31	Nose & Sinus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	0.3	6	0.3
C32	Larynx	0	0.0	2	0.1	0	0.0	0	0.0	1	0.0	69	3.1	72	3.3
C33-C34	Lung	6	0.3	9	0.4	0	0.0	24	1.1	0	0.0	180	8.1	219	9.9
C37-C38	Oth Thoracic	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
C40-C41	Bone	0	0.0	0	0.0	0	0.0	2	0.1	1	0.0	16	0.7	19	0.9
C43	Melanoma Skin	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	2	0.1	3	0.1
C44	Other Skin	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	28	1.3	29	1.3
C47&C49	Conn & Soft Tiss	0	0.0	1	0.0	0	0.0	2	0.1	0	0.0	31	1.4	34	1.5
C50	Breast	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	3	0.1	4	0.2
C60	Penis	0	0.0	0	0.0	0	0.0	2	0.1	2	0.1	44	2.0	48	2.2
C61	Prostate	0	0.0	4	0.2	0	0.0	1	0.0	2	0.1	77	3.5	84	3.8
C62	Testis	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	21	1.0	23	1.0
C63	Oth Male Genital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
C64	Kidney	1	0.0	1	0.0	0	0.0	2	0.1	0	0.0	40	1.8	44	2.0
C66	Ureter	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
C67	Urin Bladder	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	29	1.3	31	1.4
C68	Urethra	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
C69	Eye	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
C70-C72	Brain & CNS	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	48	2.2	50	2.3
C73	Thyroid	0	0.0	1	0.0	0	0.0	14	0.6	0	0.0	37	1.7	52	2.4
C75	Endo. Glands	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
C81	Hodgkins Dis	0	0.0	0	0.0	0	0.0	2	0.1	1	0.0	40	1.8	43	1.9
C82-C85 & C96	NHL	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	88	4.0	90	4.1
C90	M. Myeloma	0	0.0	0	0.0	0	0.0	4	0.2	0	0.0	24	1.1	28	1.3
C91	Leuk Lymphoid	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	42	1.9	42	1.9
C92-C94	Leuk Myeloid	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	75	3.4	77	3.5
C95	Leuk. Uns	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	1	0.0	2	0.1
Other & Unspecified Sites		0	0.0	3	0.1	0	0.0	7	0.3	53	2.4	13	0.6	76	3.4
Grand Total		14	0.6	47	2.1	2	0.1	104	4.7	72	3.3	1971	89.2	2210	100.0

Table 34: Number (#) and Proportion (%) of cancers by site (ICD10) and method of diagnosis: 2017 - 2018
– Females Visakhapatnam district

ICD-10	Site	DCO		Cln Only		Cln Inv		Cytology		Hist Met		Primary Hist		Grand Total	
		Nos	%	Nos	%	Nos	%	Nos	%	Nos	%	Nos	%	Nos	%
C00	Lip	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	2	0.1
C01-C02	Tongue	0	0.0	1	0.0	0	0.0	2	0.1	0	0.0	57	1.8	60	1.9
C03-C06	Mouth	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	139	4.3	141	4.4
C07-C08	Salivary Gl	0	0.0	0	0.0	0	0.0	3	0.1	0	0.0	3	0.1	6	0.2
C09	Tonsil	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	0.2	6	0.2
C10	Oropharynx	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0
C11	Nasopharynx	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	0.2	6	0.2
C12-C13	Hypopharynx	0	0.0	2	0.1	0	0.0	1	0.0	0	0.0	91	2.8	94	2.9
C14	Pharynx	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	23	0.7	24	0.7
C15	Oesophagus	0	0.0	5	0.2	0	0.0	0	0.0	0	0.0	71	2.2	76	2.4
C16	Stomach	1	0.0	2	0.1	0	0.0	2	0.1	2	0.1	99	3.1	106	3.3
C17	Small Intestine	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	8	0.2	8	0.2
C18	Colon	1	0.0	3	0.1	0	0.0	2	0.1	0	0.0	45	1.4	51	1.6
C19-C20	Rectum	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	39	1.2	40	1.2
C21	Anus	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	12	0.4	13	0.4
C22	Liver	0	0.0	1	0.0	0	0.0	6	0.2	0	0.0	12	0.4	19	0.6
C23-C24	Gall Bladder	0	0.0	1	0.0	0	0.0	3	0.1	2	0.1	29	0.9	35	1.1
C25	Pancreas	0	0.0	1	0.0	0	0.0	7	0.2	0	0.0	15	0.5	23	0.7
C30-C31	Nose & Sinus	0	0.0	0	0.0	1	0.0	0	0.0	1	0.0	5	0.2	7	0.2
C32	Larynx	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	8	0.2	8	0.2
C33-C34	Lung	0	0.0	2	0.1	0	0.0	9	0.3	1	0.0	81	2.5	93	2.9
C37-C38	Oth Thoracic	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	2	0.1
C40-C41	Bone	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	8	0.2	8	0.2
C43	Melanoma Skin	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	10	0.3	12	0.4
C44	Other Skin	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	25	0.8	26	0.8
C47&C49	Conn S Tiss	0	0.0	0	0.0	0	0.0	9	0.3	0	0.0	29	0.9	38	1.2
C50	Breast	2	0.1	23	0.7	0	0.0	160	5.0	5	0.2	614	19.2	804	25.1
C51	Vulva	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	21	0.7	23	0.7
C52	Vagina	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	36	1.1	38	1.2
C53	Cervix Uteri	4	0.1	22	0.7	0	0.0	1	0.0	3	0.1	708	22.1	738	23.0
C54	Corpus Uteri	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	92	2.9	94	2.9
C55	Oth Uterus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	0.2	6	0.2
C56	Ovary	1	0.0	5	0.2	0	0.0	30	0.9	5	0.2	158	4.9	199	6.2
C57	Placenta	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	1	0.0	2	0.1
C64	Kidney	1	0.0	3	0.1	0	0.0	3	0.1	0	0.0	12	0.4	19	0.6
C67	Urin Bladder	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	8	0.2	8	0.2
C68	Urethra	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
C69	Eye	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
C70-C72	Brain& CNS	0	0.0	1	0.0	1	0.0	2	0.1	0	0.0	28	0.9	32	1.0
C73	Thyroid	0	0.0	3	0.1	0	0.0	36	1.1	0	0.0	52	1.6	91	2.8
C75	Endocrine gl	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
C81	Hodg Dis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	11	0.3	11	0.3
C82-C85 & C96	NHL	0	0.0	0	0.0	0	0.0	8	0.2	0	0.0	49	1.5	57	1.8
C90	M. Myeloma	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	22	0.7	24	0.7
C91	Leuk Lymph	0	0.0	0	0.0	0	0.0	3	0.1	0	0.0	23	0.7	26	0.8
C92-C94	Leuk Myel	0	0.0	0	0.0	0	0.0	4	0.1	0	0.0	47	1.5	51	1.6
C95	Leuk Uns	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	5	0.2	5	0.2
Other & Unspecified Sites		0	0.0	0	0.0	1	0.0	7	0.2	53	1.7	7	0.2	68	2.1
Grand Total		11	0.3	79	2.5	3	0.1	308	9.6	75	2.3	2728	85.1	3204	100.0

Table 35: Number of cancer deaths by five year age group and site (ICD 10): 2017 - 2018 Males Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	1	0	0	1	0	0	0	0	1	0	0	3	0.2
C01-C02	Tongue	0	0	0	0	0	4	7	12	23	12	14	7	8	5	4	7	103	7.8
C03-C06	Mouth	0	0	0	0	0	0	2	12	11	10	15	10	13	12	9	14	108	8.2
C07-C08	Salivary Gland	0	0	0	0	0	1	0	0	1	0	2	1	0	0	1	1	7	0.5
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	4	0	7	2	2	1	16	1.2
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	2	1	2	1	0	1	7	0.5
C11	Nasopharynx	0	0	0	0	0	0	0	0	1	2	0	2	0	3	2	0	10	0.8
C12-C13	Hypopharynx	0	0	0	0	2	0	2	3	3	7	10	8	4	14	2	7	62	4.7
C14	Pharynx	0	0	0	0	0	1	0	1	2	2	3	2	2	6	2	7	28	2.1
C15	Oesophagus	0	0	0	0	0	2	0	0	1	2	3	7	6	16	5	6	48	3.6
C16	Stomach	0	0	0	0	1	2	3	4	9	16	24	23	18	18	23	15	156	11.8
C17	Small Intestine	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	4	0.3
C18	Colon	0	0	0	0	1	0	2	3	2	3	4	9	4	8	0	4	40	3.0
C19-C20	Rectum	0	0	0	0	0	0	4	1	3	4	7	4	5	6	4	7	45	3.4
C21	Anus	0	0	0	0	0	0	1	1	0	3	2	0	1	1	1	1	11	0.8
C22	Liver	0	0	0	0	0	0	0	3	2	3	4	5	7	8	5	4	41	3.1
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	1	1	1	3	5	4	3	2	20	1.5
C25	Pancreas	0	0	0	0	0	0	0	1	0	1	5	5	5	4	2	4	27	2.0
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.1
C32	Larynx	0	0	0	0	0	0	0	0	1	2	5	6	7	12	5	7	45	3.4
C33-C34	Lung	0	0	0	0	0	0	1	5	10	7	10	20	34	27	33	24	171	13.0
C37-C38	Oth. Thoracic Org	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	4	5	2	1	0	0	0	0	1	0	1	1	0	0	15	1.1
C43	Malenoma Skin	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C44	Skin Oth	0	0	0	0	0	0	0	0	0	1	2	1	0	1	0	0	5	0.4
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C46	Kaposi Sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C47&C49	Conn Soft Tiss	0	1	0	1	0	0	3	1	1	1	3	0	2	2	2	1	18	1.4
C50	Breast	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	2	0.2
C60	Penis	0	0	0	0	0	0	0	0	4	2	3	5	3	1	1	3	22	1.7
C61	Prostate	0	0	0	0	0	0	0	0	1	0	2	1	4	3	7	6	24	1.8
C62	Testis	0	0	0	0	2	0	0	1	1	0	1	0	1	0	0	0	6	0.5
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	0	0	0	0	0	1	3	1	3	1	4	3	4	0	1	21	1.6
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	U. Bladder	0	0	0	0	0	0	1	0	0	1	1	0	3	4	5	6	21	1.6
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	1	3	0	2	1	1	4	5	4	5	5	3	2	1	37	2.8
C73	Thyroid	0	0	0	0	0	0	0	0	0	1	3	3	0	0	0	1	8	0.6
C74	Adrenal glands	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.1
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkin's Dis	0	1	0	0	1	0	1	1	0	1	3	0	0	1	1	1	11	0.8
C82-C85 & C96	NHL	0	0	0	1	2	1	0	6	2	2	3	6	4	3	7	3	40	3.0
C90	M. Myeloma	0	0	0	0	0	0	0	0	1	2	1	2	7	2	5	2	22	1.7
C91	Leuk Lymphoid	2	2	1	3	2	0	1	1	1	0	1	3	0	0	1	0	18	1.4
C92-C94	Leuk. Myeloid	2	1	1	1	3	0	3	4	2	2	2	4	2	2	2	1	32	2.4
C95	Leuk. Unsp	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unspecified Sites		0	0	0	0	0	0	2	3	1	7	9	4	12	9	9	7	63	4.8
Grand Total		4	5	7	14	16	15	35	67	90	107	157	153	176	184	145	145	1320	100.0

Table 36: Number of cancer deaths by five year age group and site (ICD 10): 2017 - 2018 Females
Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0.1
C01-C02	Tongue	0	0	0	0	0	0	0	0	2	0	6	3	2	4	1	2	20	1.4
C03-C06	Mouth	0	0	0	0	0	0	1	2	1	5	19	15	17	14	9	5	88	6.1
C07-C08	Salivary Gland	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	1	4	0.3
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	3	0.2
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	3	0.2
C11	Nasopharynx	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	4	0.3
C12-C13	Hypopharynx	0	0	0	0	0	4	3	5	3	11	8	10	4	5	2	1	56	3.9
C14	Pharynx	0	0	0	0	0	1	0	0	1	3	1	4	2	3	0	2	17	1.2
C15	Oesophagus	0	0	0	0	1	1	3	4	4	9	8	6	9	2	7	3	57	3.9
C16	Stomach	0	0	0	1	0	3	2	3	9	12	6	10	11	14	7	6	84	5.8
C17	Small Intestine	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	1	4	0.3
C18	Colon	0	0	0	0	0	0	3	1	1	2	3	5	2	6	5	0	28	1.9
C19-C20	Rectum	0	0	0	0	1	1	1	1	3	2	3	1	5	1	0	0	19	1.3
C21	Anus	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	3	0.2
C22	Liver	0	1	0	1	0	0	0	0	0	0	2	1	5	2	1	2	15	1.0
C23-C24	Gall Bladder	0	0	0	0	0	1	0	3	2	7	6	1	4	0	0	2	26	1.8
C25	Pancreas	0	0	0	0	0	0	1	1	2	2	4	1	0	2	1	0	14	1.0
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	3	0.2
C32	Larynx	0	0	0	0	0	1	2	1	0	1	0	0	0	2	1	0	8	0.6
C33-C34	Lung	0	0	0	0	0	1	4	2	2	5	4	10	10	8	0	9	55	3.8
C40-C41	Bone	0	0	0	3	0	0	1	1	0	0	0	0	0	0	0	0	5	0.3
C43	Melanoma Skin	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	3	0.2
C44	Other Skin	0	0	0	0	0	0	0	1	1	1	0	1	1	1	1	1	8	0.6
C47&C49	Kaposi Sarcoma	0	1	0	0	1	1	2	1	4	1	1	6	2	1	1	2	24	1.7
C50	Conn & Soft Tiss	0	0	0	0	0	3	7	15	30	51	41	37	25	20	13	16	258	17.8
C51	Breast	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	2	6	0.4
C52	Vulva	0	0	0	0	0	0	0	0	1	0	4	2	2	4	2	0	15	1.0
C53	Vagina	0	0	0	0	1	0	12	25	30	36	47	59	39	26	17	9	301	20.8
C54	Cervix Uteri	0	0	0	0	0	0	0	0	1	2	2	1	4	3	1	3	17	1.2
C55	Corpus Uteri	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	3	0.2
C56	Ovary	0	0	0	0	1	0	1	9	4	18	13	24	20	7	4	3	104	7.2
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2	0.1
C64	Kidney	1	1	0	0	0	0	0	0	0	2	0	0	3	3	1	1	12	0.8
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	2	0	0	1	1	0	2	0	6	0.4
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	0.1
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	1	0	1	1	0	0	0	3	1	2	4	3	3	3	0	0	22	1.5
C73	Thyroid	0	0	0	0	0	0	0	0	0	2	4	1	1	1	1	1	11	0.8
C81	Hodgkins Disease	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	2	0.1
C82-C85 & C96	NHL	0	0	2	0	1	0	1	1	1	6	4	2	3	2	1	3	27	1.9
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	3	3	2	2	1	2	1	14	1.0
C91	Leuk Lymphoid	0	1	1	2	3	0	0	0	1	0	1	0	0	1	0	0	10	0.7
C92-C94	Leuk Myeloid	0	0	1	0	1	1	1	3	0	1	2	4	3	2	3	0	22	1.5
C95	Leuk.Uns	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	3	0.2
Other & Unsp. Sites		0	0	0	0	0	0	1	4	5	9	6	15	7	5	5	2	59	4.1
Grand Total		2	5	6	8	11	19	47	88	113	198	207	230	193	149	91	81	1448	100.0

Table 37: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.1	0.1
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.9	1.8	3.2	6.5	4.0	6.4	4.0	4.4	3.6	5.4	12.0	2.3	2.1	4.8
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.5	3.2	3.1	3.3	6.8	5.8	7.1	8.7	12.2	23.9	2.4	2.5	4.6
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.9	0.6	0.0	0.0	1.4	1.7	0.2	0.2	0.3
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	3.8	1.5	2.7	1.7	0.4	0.4	0.8
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.6	1.1	0.7	0.0	1.7	0.2	0.2	0.4
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.0	1.2	0.0	2.2	2.7	0.0	0.2	0.2	0.3
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.8	0.9	2.3	4.5	4.6	2.2	10.2	2.7	12.0	1.4	1.4	2.4
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.6	0.7	1.4	1.2	1.1	4.4	2.7	12.0	0.6	0.7	0.8
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	0.7	1.4	4.0	3.3	11.7	6.8	10.3	1.1	1.1	1.4
C16	Stomach	0.0	0.0	0.0	0.0	0.2	0.5	0.8	1.1	2.6	5.4	10.9	13.3	9.8	13.1	31.2	25.6	3.4	3.6	6.5
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.5	0.6	0.0	0.0	0.0	0.0	0.1	0.1	0.3
C18	Colon	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.8	0.6	1.0	1.8	5.2	2.2	5.8	0.0	6.8	0.9	0.9	1.7
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.3	0.9	1.3	3.2	2.3	2.7	4.4	5.4	12.0	1.0	1.1	1.6
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	1.0	0.9	0.0	0.5	0.7	1.4	1.7	0.2	0.2	0.5
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.6	1.0	1.8	2.9	3.8	5.8	6.8	6.8	0.9	0.9	1.6
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	1.7	2.7	2.9	4.1	3.4	0.4	0.5	0.8
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3	2.3	2.9	2.7	2.9	2.7	6.8	0.6	0.7	1.2
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	2.3	3.5	3.8	8.7	6.8	12.0	1.0	1.1	1.5
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	2.8	2.3	4.5	11.6	18.6	19.7	44.7	41.0	3.8	4.1	5.9
C37-C38	Oth. Thoracic Org	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	1.0	1.2	0.5	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.7	0.0	0.0	0.3	0.3	0.1
C43	Malenoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C44	Skin Oth	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.9	0.6	0.0	0.7	0.0	0.0	0.1	0.1	0.3
C45	Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C46	Kaposi Sarcoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C47&C49	Conn Soft Tiss	0.0	0.3	0.0	0.2	0.0	0.0	0.8	0.3	0.3	0.3	1.4	0.0	1.1	1.5	2.7	1.7	0.4	0.4	0.5
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.7	1.4	2.9	1.6	0.7	1.4	5.1	0.5	0.5	1.2
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.9	0.6	2.2	2.2	9.5	10.3	0.5	0.6	0.6
C62	Testis	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	0.3	0.0	0.5	0.0	0.5	0.0	0.0	0.0	0.1	0.1	0.3
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.8	0.3	1.0	0.5	2.3	1.6	2.9	0.0	1.7	0.5	0.4	1.0
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	U. Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.5	0.0	1.6	2.9	6.8	10.3	0.5	0.6	0.3
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.0	0.0	0.3	0.7	0.0	0.5	0.3	0.3	1.1	1.7	1.8	2.9	2.7	2.2	2.7	1.7	0.8	0.8	1.6
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.4	1.7	0.0	0.0	0.0	0.0	1.7	0.2	0.2	0.5
C74	Adrenal gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin's Dis	0.0	0.3	0.0	0.0	0.2	0.0	0.3	0.3	0.0	0.3	1.4	0.0	0.0	0.7	1.4	1.7	0.2	0.3	0.3
C82-C85 & C96	NHL	0.0	0.0	0.0	0.2	0.5	0.2	0.0	1.6	0.6	0.7	1.4	3.5	2.2	2.2	9.5	5.1	0.9	0.9	1.5
C90	M.Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.5	1.2	3.8	1.5	6.8	3.4	0.5	0.5	0.9
C91	Leuk Lymphoid	0.6	0.6	0.3	0.7	0.5	0.0	0.3	0.3	0.3	0.0	0.5	1.7	0.0	0.0	1.4	0.0	0.4	0.4	0.4
C92-C94	Leuk. Myeloid	0.6	0.3	0.3	0.2	0.7	0.0	0.8	1.1	0.6	0.7	0.9	2.3	1.1	1.5	2.7	1.7	0.7	0.7	1.0
C95	Leuk. Unsp	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unsp. Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.8	0.3	2.3	4.1	2.3	6.6	6.6	12.2	12.0	1.4	1.5	2.5
Grand Total		1.3	1.6	1.8	3.5	3.7	3.5	9.2	18.0	25.8	35.5	71.3	88.5	96.3	134.1	196.5	247.8	29.1	30.5	50.7

Table 38: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam district

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.8	1.5	0.9	2.7	1.2	0.4	0.4	0.9	0.4
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.3	1.8	8.9	7.7	8.0	9.4	11.2	1.9	1.9	4.0	1.9
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.5	0.7	0.0	0.1	0.1	0.1	0.1
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.5	0.0	0.0	0.0	0.1	0.1	0.2	0.1
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	1.2	0.1	0.1	0.1	0.1
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.5	0.0	0.5	0.0	1.2	0.1	0.1	0.2	0.1
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.9	0.8	1.3	0.9	4.0	3.8	5.2	1.9	3.4	2.5	1.2	1.1	2.7	1.2
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	1.1	0.5	2.1	0.9	2.0	0.0	0.4	0.4	0.7	0.4
C15	Oesophagus	0.0	0.0	0.0	0.0	0.2	0.2	0.8	1.0	1.2	3.2	3.8	3.1	4.2	1.3	8.7	1.2	1.2	2.6	1.2
C16	Stomach	0.0	0.0	0.0	0.3	0.0	0.7	0.5	0.8	2.6	4.3	2.8	5.2	5.2	9.4	8.7	1.8	1.7	3.3	1.8
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.5	0.0	0.0	0.1	0.1	0.2	0.1
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.3	0.3	0.7	1.4	2.6	0.9	4.0	6.2	0.6	0.6	0.9	0.6
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.2	0.2	0.3	0.3	0.9	0.7	1.4	0.5	2.4	0.7	0.0	0.4	0.4	1.0	0.4
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.5	0.5	0.0	0.0	0.1	0.1	0.2	0.1
C22	Liver	0.0	0.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.5	2.4	1.3	1.2	0.3	0.3	0.5	0.3
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.8	0.6	2.5	2.8	0.5	1.9	0.0	0.0	0.6	0.5	1.5	0.6
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.6	0.7	1.9	0.5	0.0	1.3	1.2	0.3	0.3	0.7	0.3
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.7	0.0	0.1	0.1	0.2	0.1
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.3	0.0	0.4	0.0	0.0	0.0	1.3	1.2	0.2	0.2	0.1	0.2
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.5	0.6	1.8	1.9	5.2	4.7	5.4	0.0	1.2	1.1	2.1	1.2
C40-C41	Bone	0.0	0.0	0.0	0.8	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.4	0.0	0.5	0.5	0.7	1.2	0.2	0.2	0.3	0.2
C47&C49	Kaposi Sarcoma	0.0	0.3	0.0	0.0	0.2	0.2	0.5	0.3	1.2	0.4	0.5	3.1	0.9	0.7	1.2	0.5	0.5	0.9	0.5
C50	Conn Soft Tiss	0.0	0.0	0.0	0.0	0.0	0.7	1.8	3.8	8.8	18.3	19.3	19.1	11.8	13.5	16.2	5.6	5.4	13.1	5.6
C51	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.3	1.2	0.1	0.1	0.1	0.1
C52	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.9	1.0	0.9	2.7	2.5	0.3	0.3	0.6	0.3
C53	Vagina	0.0	0.0	0.0	0.0	0.2	0.0	3.1	6.3	8.8	12.9	22.1	30.4	18.4	17.5	21.2	6.5	6.1	15.3	6.5
C54	Cervix Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.9	0.5	1.9	2.0	1.2	0.4	0.4	0.7	0.4
C55	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1
C56	Ovary	0.0	0.0	0.0	0.0	0.2	0.0	0.3	2.3	1.2	6.5	6.1	12.4	9.4	4.7	5.0	2.3	2.1	5.7	2.3
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C64	Kidney	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.4	2.0	1.2	0.3	0.3	0.3	0.3
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.5	0.5	0.0	2.5	0.1	0.1	0.2	0.1
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.3	0.0	0.3	0.3	0.0	0.0	0.0	0.8	0.3	0.7	1.9	1.5	1.4	2.0	0.0	0.5	0.5	1.0	0.5
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.9	0.5	0.5	0.7	1.2	0.2	0.2	0.6	0.2
C81	Hodgkins Disease	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C82-C85 & C96	NHL	0.0	0.0	0.5	0.0	0.2	0.0	0.3	0.3	0.3	2.2	1.9	1.0	1.4	1.3	1.2	0.6	0.6	1.1	0.6
C90	M. Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.4	1.0	0.9	0.7	2.5	0.3	0.3	0.7	0.3
C91	Leuk Lymphoid	0.0	0.3	0.3	0.5	0.7	0.0	0.0	0.0	0.3	0.0	0.5	0.0	0.0	0.7	0.0	0.2	0.2	0.1	0.2
C92-C94	Leuk Myeloid	0.0	0.0	0.3	0.0	0.2	0.2	0.3	0.8	0.0	0.4	0.9	2.1	1.4	1.3	3.7	0.5	0.4	0.8	0.5
C95	Leuk. Uns	0.0	0.3	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1
Other & Unsp Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.0	1.5	3.2	2.8	7.7	3.3	3.4	6.2	2.7	1.3	1.2	3.0
Grand Total		0.7	1.7	1.6	2.0	2.4	4.3	12.1	22.0	33.2	71.1	97.2	118.6	91.0	100.4	113.6	108.1	31.5	30.1	67.2

24. Standard Registry tables for Visakhapatnam Urban

Table 39: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Males – Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	3	0.2
C01-C02	Tongue	0	0	0	0	0	4	4	17	14	15	15	8	10	5	3	5	100	7.7
C03-C06	Mouth	0	0	0	0	0	0	6	14	13	9	13	10	7	13	7	3	95	7.3
C07-C08	Salivary Gl	0	0	0	0	1	0	0	3	1	0	1	0	0	0	1	1	8	0.6
C09	Tonsil	0	0	0	0	0	0	0	1	1	2	3	3	1	0	0	1	12	0.9
C10	Oropharynx	0	0	0	0	0	0	0	0	1	1	1	1	4	0	1	1	10	0.8
C11	Nasopharynx	0	1	0	0	0	0	0	0	0	0	1	0	0	2	1	0	5	0.4
C12-C13	Hypopharynx	0	0	0	0	1	2	0	1	4	4	4	7	5	8	3	4	43	3.3
C14	Pharynx	0	0	0	0	0	2	2	0	1	3	0	1	0	4	2	3	18	1.4
C15	Oesophagus	0	0	0	0	0	2	2	0	0	4	2	6	6	11	1	7	41	3.1
C16	Stomach	0	0	0	0	1	2	1	2	8	9	15	17	16	15	12	10	108	8.3
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	2	1	1	0	0	0	5	0.4
C18	Colon	0	0	0	0	0	0	4	2	4	11	6	4	6	10	4	5	56	4.3
C19-C20	Rectum	0	0	0	0	0	0	2	2	3	4	10	7	2	0	0	8	38	2.9
C21	Anus	0	0	0	0	0	0	2	0	0	3	2	0	2	1	0	0	10	0.8
C22	Liver	1	0	0	0	0	0	0	0	1	3	1	5	6	9	7	3	36	2.8
C23-C24	Gall Bladder	0	0	0	0	0	0	1	0	2	2	1	5	7	5	3	3	29	2.2
C25	Pancreas	0	0	0	0	0	0	1	0	1	2	4	2	3	5	0	3	21	1.6
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	3	0.2
C32	Larynx	0	0	0	0	0	0	0	0	1	3	3	10	10	9	8	4	48	3.7
C33-C34	Lung	0	0	0	0	0	0	1	3	4	8	11	22	29	22	21	19	140	10.7
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.1
C40-C41	Bone	1	2	3	1	2	1	2	1	0	0	0	0	1	0	0	0	14	1.1
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.1
C44	Other Skin	0	0	0	0	0	0	1	0	1	0	0	2	3	2	1	2	12	0.9
C47&C49	Conn & Soft Tiss	0	0	1	0	0	1	1	1	5	3	5	4	2	2	0	1	26	2.0
C50	Breast	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	3	0.2
C60	Penis	0	0	0	0	0	0	1	0	1	2	3	4	2	1	1	1	16	1.2
C61	Prostate	0	0	0	0	0	0	0	0	0	0	3	6	9	14	13	14	59	4.5
C62	Testis	0	0	0	0	0	1	1	2	2	2	1	0	0	1	0	0	10	0.8
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.1
C64	Kidney	1	0	0	0	0	0	0	4	4	3	3	7	5	3	1	1	32	2.4
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.1
C67	Urin Bladder	0	0	0	0	0	0	0	1	0	1	1	4	2	7	4	4	24	1.8
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain& CNS	1	0	1	0	0	3	4	2	4	4	3	5	3	2	2	1	35	2.7
C73	Thyroid	0	0	0	0	1	1	0	2	3	2	6	5	3	2	4	0	29	2.2
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.1
C81	Hodgkins Dis	0	0	4	1	1	1	2	2	1	1	4	4	0	2	2	1	26	2.0
C82-C85 & C96	NHL	2	2	1	3	4	2	2	3	4	4	3	8	4	2	9	6	59	4.5
C90	M Myeloma	0	0	0	0	0	0	0	0	0	1	3	6	3	2	2	0	17	1.3
C91	Leuk Lymphoid	3	4	1	3	3	1	0	0	0	1	1	2	1	0	1	1	22	1.7
C92-C94	Leuk Myeloid	1	1	1	1	3	4	5	6	3	2	2	5	1	3	2	2	42	3.2
C95	Leuk.Uns	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0.2
Other & Uns. Sites		0	0	0	0	0	0	2	1	3	5	6	4	3	9	7	5	45	3.4
Total		10	10	12	11	17	28	48	71	93	116	142	176	157	174	123	119	1307	100.0

Table 40: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Females – Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.1
C01-C02	Tongue	0	0	0	0	0	1	0	1	1	0	8	4	5	7	2	3	32	1.8
C03-C06	Mouth	0	0	0	0	0	0	0	2	1	4	8	9	4	3	7	3	41	2.4
C07-C08	Salivary Gl	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	0	4	0.2
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	3	0.2
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C11	Nasopharynx	0	0	0	0	0	0	0	2	0	0	1	1	0	0	0	0	4	0.2
C12-C13	Hypopharynx	0	0	0	0	0	3	2	2	2	7	9	5	2	2	4	1	39	2.2
C14	Pharynx	0	0	0	0	0	1	1	0	1	2	0	2	1	2	0	1	11	0.6
C15	Oesophagus	0	0	0	0	0	0	0	1	7	4	7	5	4	3	5	3	39	2.2
C16	Stomach	0	0	0	2	0	1	1	3	2	9	7	7	8	10	4	1	55	3.2
C17	Small Intestine	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	2	6	0.3
C18	Colon	0	0	0	0	0	0	1	3	3	5	4	8	4	5	1	3	37	2.1
C19-C20	Rectum	0	0	0	0	1	1	0	0	1	2	4	1	2	3	1	0	16	0.9
C21	Anus	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	1	5	0.3
C22	Liver	0	1	0	1	0	0	0	0	0	0	1	1	3	2	2	2	13	0.7
C23-C24	Gall Bladder	0	0	0	0	0	1	0	3	2	7	3	2	4	0	2	3	27	1.6
C25	Pancreas	0	0	0	0	0	0	0	0	0	0	5	1	0	4	1	2	13	0.7
C30-C31	Nose & Sinus	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	0	4	0.2
C32	Larynx	0	0	0	0	0	0	0	0	1	2	0	0	0	0	1	0	4	0.2
C33-C34	Lung	0	0	0	0	0	1	1	1	3	9	10	13	12	6	2	6	64	3.7
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0.1
C40-C41	Bone	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C43	Melanoma Skin	0	0	0	0	1	0	0	0	0	0	0	0	1	2	1	0	5	0.3
C44	Skin	0	0	0	0	0	0	0	2	1	2	1	1	1	1	0	1	10	0.6
C47&C49	Conn & Soft Tiss	0	1	0	0	0	2	2	3	6	3	1	1	3	2	2	2	28	1.6
C50	Breast	0	0	0	0	0	3	13	47	66	82	78	75	61	49	23	27	524	30.1
C51	Vulva	0	0	0	0	0	0	0	0	1	2	2	1	1	3	1	1	12	0.7
C52	Vagina	0	0	0	0	0	0	1	0	1	3	0	5	2	3	1	1	17	1.0
C53	Cervix Uteri	0	0	0	0	1	0	8	17	50	53	48	49	35	20	15	8	304	17.5
C54	CorpusUteri	0	0	0	0	0	0	1	0	3	8	12	10	11	11	8	4	68	3.9
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	4	0.2
C56	Ovary	0	0	0	3	0	1	4	7	17	22	21	16	17	8	1	6	123	7.1
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	1	0	1	0	0	1	0	0	1	0	2	1	1	2	0	10	0.6
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	3	0.2
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.1
C69	Eye	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.1
C70-C72	Brain&CNS	0	1	3	1	0	0	2	1	0	2	3	0	1	2	0	0	16	0.9
C73	Thyroid	0	0	0	0	2	9	5	7	4	4	3	5	1	7	1	1	49	2.8
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C81	Hodgkins Dis	0	0	1	1	2	1	1	0	1	0	0	0	0	0	1	0	8	0.5
C82-C85 & C96	NHL	0	2	2	0	1	0	1	2	3	5	5	2	2	3	0	2	30	1.7
C90	M.Myeloma	0	0	0	0	0	0	0	1	1	0	2	1	3	3	3	0	14	0.8
C91	Leuk Lymphoid	1	3	3	1	3	0	0	0	1	0	1	1	0	0	0	1	15	0.9
C92-C94	Leuk Myeloid	0	0	0	1	1	3	3	4	1	2	3	4	4	1	4	1	32	1.8
C95	Leuk Uns	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	0.2
Other & Unsp.Sites		0	0	0	0	0	0	1	4	3	5	6	6	8	1	3	2	39	2.2
Total		1	10	9	12	14	28	51	113	185	247	262	246	204	166	101	89	1738	100.0

Table 41: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	1.7	1.9	8.2	7.1	9.0	12.1	7.8	11.4	9.4	8.9	14.6	4.3	3.8	9.1
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	2.9	6.7	6.6	5.4	10.5	9.7	8.0	24.5	20.8	8.8	4.1	3.9	7.6
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.4	0.5	0.0	0.8	0.0	0.0	0.0	3.0	2.9	0.3	0.3	0.5
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	1.2	2.4	2.9	1.1	0.0	0.0	2.9	0.5	0.5	1.3
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.6	0.8	1.0	4.6	0.0	3.0	2.9	0.4	0.4	1.1
C11	Nasopharynx	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	3.8	3.0	0.0	0.2	0.3	0.1
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.5	0.9	0.0	0.5	2.0	2.4	3.2	6.8	5.7	15.1	8.9	11.7	1.8	1.9	3.1
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.9	1.0	0.0	0.5	1.8	0.0	1.0	0.0	7.5	6.0	8.8	0.8	0.8	0.6
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.9	1.0	0.0	0.0	2.4	1.6	5.8	6.8	20.7	3.0	20.4	1.7	1.9	2.4
C16	Stomach	0.0	0.0	0.0	0.0	0.5	0.9	0.5	1.0	4.1	5.4	12.1	16.5	18.2	28.2	35.7	29.2	4.6	4.9	8.4
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.6	1.0	1.1	0.0	0.0	0.0	0.2	0.2	0.6
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	1.9	1.0	2.0	6.6	4.8	3.9	6.8	18.8	11.9	14.6	2.4	2.5	4.0
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	1.5	2.4	8.1	6.8	2.3	0.0	0.0	23.3	1.6	1.6	3.4
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.8	1.6	0.0	2.3	1.9	0.0	0.0	0.4	0.4	0.9
C22	Liver	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.8	0.8	4.9	6.8	16.9	20.8	8.8	1.5	1.8	2.1
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.0	1.2	0.8	4.9	8.0	9.4	8.9	8.8	1.2	1.4	2.2
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5	1.2	3.2	1.9	3.4	9.4	0.0	8.8	0.9	1.0	1.5
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.8	2.4	9.7	11.4	16.9	23.8	11.7	2.0	2.3	3.6
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.4	2.0	4.8	8.9	21.4	33.0	41.4	62.5	55.4	6.0	6.7	10.0
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.1	0.0
C40-C41	Bone	0.7	1.4	1.6	0.5	0.9	0.4	1.0	0.5	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.6	0.6	0.2
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.0	0.0	1.9	3.4	3.8	3.0	5.8	0.5	0.6	0.8
C47 & C49	Conn & Soft Tiss	0.0	0.0	0.5	0.0	0.0	0.4	0.5	0.5	2.5	1.8	4.0	3.9	2.3	3.8	0.0	2.9	1.1	1.0	2.4
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.8	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5	1.2	2.4	3.9	2.3	1.9	3.0	2.9	0.7	0.7	1.5
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	5.8	10.2	26.4	38.7	40.8	2.5	3.1	2.5
C62	Testis	0.0	0.0	0.0	0.0	0.0	0.4	0.5	1.0	1.0	1.2	0.8	0.0	0.0	1.9	0.0	0.0	0.4	0.4	0.7
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.1	0.0
C64	Kidney	0.7	0.0	0.0	0.0	0.0	0.0	0.0	1.9	2.0	1.8	2.4	6.8	5.7	5.6	3.0	2.9	1.4	1.3	3.1
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.1	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.6	0.8	3.9	2.3	13.2	11.9	11.7	1.0	1.2	1.1
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.7	0.0	0.5	0.0	0.0	1.3	1.9	1.0	2.0	2.4	2.4	4.9	3.4	3.8	6.0	2.9	1.5	1.4	2.5
C73	Thyroid	0.0	0.0	0.0	0.0	0.5	0.4	0.0	1.0	1.5	1.2	4.8	4.9	3.4	3.8	11.9	0.0	1.2	1.2	2.6
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C81	Hodgkins Dis	0.0	0.0	2.1	0.5	0.5	0.4	1.0	1.0	0.5	0.6	3.2	3.9	0.0	3.8	6.0	2.9	1.1	1.1	1.4
C82-C85 & C96	NHL	1.3	1.4	0.5	1.6	1.9	0.9	1.0	1.4	2.0	2.4	2.4	7.8	4.6	3.8	26.8	17.5	2.5	2.7	3.1
C90	M. Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	2.4	5.8	3.4	3.8	6.0	0.0	0.7	0.8	1.7
C91	Leuk Lymph	2.0	2.7	0.5	1.6	1.4	0.4	0.0	0.0	0.0	0.6	0.8	1.9	1.1	0.0	3.0	2.9	0.9	1.2	0.6
C92-C94	Leuk Myeloid	0.7	0.7	0.5	0.5	1.4	1.7	2.4	2.9	1.5	1.2	1.6	4.9	1.1	5.6	6.0	5.8	1.8	1.7	2.1
C95	Leuk. Uns	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Other & Unsp. Sites		0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.5	1.5	3.0	4.8	3.9	3.4	16.9	20.8	14.6	1.9	2.1	2.7
Total		6.7	6.8	6.2	5.8	8.0	12.1	22.9	34.2	47.1	69.5	114.6	170.9	178.6	327.6	365.9	347.2	55.8	58.4	92.8

Table 42: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.4	0.0	0.5	0.5	0.0	6.9	3.9	5.8	12.4	5.9	6.9	1.4	1.5	2.6	0.0
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.5	2.6	6.9	8.9	4.6	5.3	20.7	6.9	1.8	1.8	3.6	0.0
C07-C08	Salivary Gland	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.2	1.8	0.0	0.0	0.2	0.2	0.3	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	2.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.0
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.9	1.0	0.0	0.0	0.0	0.0	0.2	0.1	0.4	0.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	1.2	0.9	0.9	1.1	4.5	7.7	4.9	2.3	3.5	11.8	2.3	1.7	1.6	3.4	0.0
C14	Pharynx	0.0	0.0	0.0	0.0	0.4	0.5	0.0	0.5	1.3	0.0	2.0	1.2	3.5	0.0	2.3	0.5	0.4	0.8	0.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.5	3.8	2.6	6.0	4.9	4.6	5.3	14.8	6.9	1.7	1.7	3.5	0.0
C16	Stomach	0.0	0.0	1.1	0.0	0.4	0.5	1.4	1.1	5.8	6.0	6.9	9.2	17.7	11.8	2.3	2.4	2.4	4.7	0.0
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	1.2	0.0	3.0	4.6	0.3	0.3	0.4	0.0
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.5	1.4	1.6	3.2	3.4	7.9	4.6	8.8	3.0	6.9	1.6	1.5	3.4	0.0
C19-C20	Rectum	0.0	0.0	0.0	0.4	0.4	0.0	0.0	0.5	1.3	3.4	1.0	2.3	5.3	3.0	0.0	0.7	0.7	1.3	0.0
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.0	0.0	0.0	3.0	2.3	0.2	0.2	0.4	0.0
C22	Liver	0.7	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.0	3.5	3.5	5.9	4.6	0.6	0.7	0.7	0.7
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.4	0.0	1.4	1.1	4.5	2.6	2.0	4.6	0.0	5.9	6.9	1.2	1.1	2.6	0.0
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	1.0	0.0	7.1	3.0	4.6	0.6	0.6	0.8	0.0
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.6	0.9	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.4	0.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.3	0.0	0.0	0.0	0.0	3.0	0.0	0.2	0.2	0.4	0.0
C33-C34	Lung	0.0	0.0	0.0	0.0	0.4	0.5	0.5	1.6	5.8	8.6	12.8	13.8	10.6	5.9	13.8	2.7	2.7	6.3	0.0
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.0
C40-C41	Bone	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	3.5	3.0	0.0	0.2	0.2	0.1	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.5	1.3	0.9	1.0	1.2	1.8	0.0	2.3	0.4	0.4	0.9	0.0
C47&C49	ConnSoft Tiss	0.7	0.0	0.0	0.0	0.8	0.9	1.4	3.2	1.9	0.9	1.0	3.5	3.5	5.9	4.6	1.2	1.1	2.0	0.7
C50	Breast	0.0	0.0	0.0	0.0	1.2	6.1	21.8	35.7	52.8	67.0	74.1	70.2	86.6	68.0	62.0	22.4	21.4	50.8	0.0
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.3	1.7	1.0	1.2	5.3	3.0	2.3	0.5	0.5	0.9	0.0
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5	1.9	0.0	4.9	2.3	5.3	3.0	2.3	0.7	0.7	1.4	0.0
C53	Cervix Uteri	0.0	0.0	0.0	0.4	0.0	3.7	7.9	27.0	34.1	41.3	48.4	40.3	35.4	44.4	18.4	13.0	12.3	31.5	0.0
C54	CorpusUteri	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.6	5.2	10.3	9.9	12.7	19.4	23.7	9.2	2.9	3.1	5.9	0.0
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	2.3	0.2	0.2	0.4	0.0
C56	Ovary	0.0	0.0	1.6	0.0	0.4	1.9	3.2	9.2	14.2	18.1	15.8	19.6	14.1	3.0	13.8	5.3	5.0	12.6	0.0
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.7	0.0	0.5	0.0	0.0	0.5	0.0	0.0	0.6	0.0	2.0	1.2	1.8	5.9	0.0	0.4	0.5	0.5	0.7
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.0	0.0	0.0	3.0	0.0	0.1	0.1	0.3	0.0
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.1	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.7	1.7	0.5	0.0	0.0	0.9	0.5	0.0	1.3	2.6	0.0	1.2	3.5	0.0	0.0	0.7	0.7	0.9	0.7
C73	Thyroid	0.0	0.0	0.0	0.8	3.7	2.3	3.2	2.2	2.6	2.6	4.9	1.2	12.4	3.0	2.3	2.1	1.8	2.7	0.0
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
C81	Hodgkins Dis	0.0	0.6	0.5	0.8	0.4	0.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.3	0.3	0.1	0.0
C82-C85 & C96	NHL	1.5	1.1	0.0	0.4	0.0	0.5	0.9	1.6	3.2	4.3	2.0	2.3	5.3	0.0	4.6	1.3	1.3	2.4	1.5
C90	M.Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	1.7	1.0	3.5	5.3	8.9	0.0	0.6	0.7	1.0	0.0
C91	Leuk Lymphoid	2.2	1.7	0.5	1.2	0.0	0.0	0.0	0.5	0.0	0.9	1.0	0.0	0.0	0.0	2.3	0.6	0.8	0.4	2.2
C92-C94	Leuk Myeloid	0.0	0.0	0.5	0.4	1.2	1.4	1.9	0.5	1.3	2.6	3.9	4.6	1.8	11.8	2.3	1.4	1.3	2.2	0.0
C95	Leuk. Uns	0.7	0.0	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.7
Other & Unsp.Sites		0.0	0.0	0.0	0.0	0.0	0.5	1.9	1.6	3.2	5.2	5.9	9.2	1.8	8.9	4.6	1.7	1.6	4.1	0.0
Total		7.4	5.0	6.4	5.8	11.7	23.8	52.3	99.9	159.1	225.2	242.9	234.7	293.4	298.8	204.5	74.5	72.6	158.2	7.4

Table 43: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Males Visakhapatnam Urban

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0001	0.0071	0.0001	0.0071
C01-C02	Tongue	0.0030	0.2954	0.0039	0.3868
C03-C06	Mouth	0.0025	0.2485	0.0048	0.4742
C07-C08	Salivary Gland	0.0002	0.0161	0.0003	0.0310
C09	Tonsil	0.0004	0.0433	0.0004	0.0433
C10	Oth. Oropharynx	0.0004	0.0372	0.0005	0.0520
C11	Nasopharynx	0.0001	0.0074	0.0004	0.0411
C12-C13	Hypopharynx	0.0011	0.1097	0.0023	0.2294
C14	Pharynx	0.0003	0.0255	0.0009	0.0928
C15	Oesophagus	0.0009	0.0924	0.0021	0.2106
C16	Stomach	0.0030	0.2947	0.0061	0.6130
C17	Small Intestine	0.0002	0.0216	0.0002	0.0216
C18	Colon	0.0014	0.1351	0.0029	0.2884
C19-C20	Rectum	0.0011	0.1148	0.0011	0.1148
C21	Anus	0.0003	0.0332	0.0004	0.0426
C22	Liver	0.0008	0.0773	0.0027	0.2658
C23-C24	Gall Bladder	0.0008	0.0815	0.0017	0.1731
C25	Pancreas	0.0005	0.0538	0.0010	0.1008
C30-C31	Nose & Sinus	0.0001	0.0090	0.0001	0.0090
C32	Larynx	0.0013	0.1290	0.0033	0.3322
C33-C34	Lung	0.0036	0.3592	0.0088	0.8755
C37-C38	Oth Thoracic	0.0000	0.0000	0.0001	0.0094
C40-C41	Bone	0.0004	0.0402	0.0004	0.0402
C43	Melanoma Skin	0.0000	0.0040	0.0000	0.0040
C44	Other Skin	0.0003	0.0317	0.0007	0.0654
C47&C49	Conn & Soft Tiss	0.0008	0.0822	0.0010	0.1010
C50	Breast	0.0001	0.0114	0.0001	0.0114
C60	Penis	0.0005	0.0538	0.0008	0.0781
C61	Prostate	0.0009	0.0924	0.0042	0.4167
C62	Testis	0.0002	0.0245	0.0003	0.0339
C63	Oth Male Genital	0.0000	0.0000	0.0001	0.0094
C64	Kidney	0.0011	0.1066	0.0015	0.1496
C66	Ureter	0.0000	0.0000	0.0001	0.0094
C67	Urin Bladder	0.0004	0.0402	0.0017	0.1655
C68	Urethra	0.0000	0.0000	0.0000	0.0000
C69	Eye	0.0000	0.0000	0.0000	0.0000
C70-C72	Brain & CNS	0.0010	0.1023	0.0015	0.1508
C73	Thyroid	0.0009	0.0884	0.0017	0.1667
C75	Endocrine gl	0.0000	0.0030	0.0000	0.0030
C81	Hodgkins Dis	0.0007	0.0682	0.0012	0.1167
C82-C85 & C96	NHL	0.0015	0.1453	0.0030	0.2977
C90	Multiple Myeloma	0.0006	0.0613	0.0011	0.1098
C91	Leuk Lymphoid	0.0007	0.0656	0.0008	0.0805
C92-C94	Leuk Myeloid	0.0011	0.1055	0.0016	0.1635
C95	Leukaemia Uns	0.0001	0.0052	0.0001	0.0052
Other & Unspecified Sites		0.0009	0.0904	0.0028	0.2789
Total		0.0342	3.3591	0.0688	6.6529

Table 44: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Females Visakhapatnam Urban

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0001	0.0058	0.0001	0.0058
C01-C02	Tongue	0.0009	0.0900	0.0018	0.1813
C03-C06	Mouth	0.0012	0.1220	0.0025	0.2518
C07-C08	Salivary Gland	0.0001	0.0128	0.0002	0.0216
C09	Tonsil	0.0001	0.0142	0.0001	0.0142
C10	Oth. Oropharynx	0.0000	0.0049	0.0000	0.0049
C11	Nasopharynx	0.0001	0.0139	0.0001	0.0139
C12-C13	Hypopharynx	0.0012	0.1183	0.0020	0.1950
C14	Pharynx	0.0003	0.0292	0.0005	0.0468
C15	Oesophagus	0.0011	0.1118	0.0021	0.2121
C16	Stomach	0.0016	0.1616	0.0031	0.3088
C17	Small Intestine	0.0001	0.0143	0.0003	0.0291
C18	Colon	0.0011	0.1131	0.0017	0.1720
C19-C20	Rectum	0.0005	0.0469	0.0009	0.0882
C21	Anus	0.0001	0.0131	0.0003	0.0279
C22	Liver	0.0003	0.0329	0.0008	0.0801
C23-C24	Gall Bladder	0.0008	0.0827	0.0011	0.1123
C25	Pancreas	0.0003	0.0264	0.0008	0.0765
C30-C31	Nose & Sinus	0.0001	0.0126	0.0001	0.0126
C32	Larynx	0.0001	0.0091	0.0002	0.0239
C33-C34	Lung	0.0022	0.2198	0.0030	0.3022
C37-C38	Oth Thoracic	0.0001	0.0070	0.0001	0.0070
C40-C41	Bone	0.0000	0.0000	0.0000	0.0000
C43	Melanoma Skin	0.0001	0.0078	0.0004	0.0403
C44	Other Skin	0.0003	0.0288	0.0004	0.0376
C47&C49	Conn & Soft Tiss	0.0007	0.0718	0.0012	0.1190
C50	Breast	0.0164	1.6308	0.0242	2.3885
C51	Vulva	0.0003	0.0284	0.0007	0.0697
C52	Vagina	0.0005	0.0509	0.0009	0.0921
C53	Cervix Uteri	0.0102	1.0103	0.0141	1.4041
C54	CorpusUteri	0.0020	0.2002	0.0042	0.4151
C55	Oth Uterus	0.0001	0.0129	0.0001	0.0129
C56	Ovary	0.0042	0.4185	0.0050	0.5036
C57	Placenta	0.0000	0.0000	0.0000	0.0000
C64	Kidney	0.0003	0.0275	0.0007	0.0659
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0001	0.0092	0.0002	0.0240
C68	Urethra	0.0000	0.0000	0.0001	0.0088
C69	Eye	0.0000	0.0023	0.0000	0.0023
C70-C72	Brain & CNS	0.0005	0.0468	0.0006	0.0644
C73	Thyroid	0.0012	0.1177	0.0019	0.1942
C75	Endocrine gl	0.0000	0.0049	0.0000	0.0049
C81	Hodgkins Disease	0.0002	0.0167	0.0003	0.0315
C82-C85 & C96	NHL	0.0009	0.0891	0.0012	0.1155
C90	Multiple Myeloma	0.0004	0.0358	0.0011	0.1066
C91	Leuk Lymphoid	0.0004	0.0438	0.0004	0.0438
C92-C94	Leuk Myeloid	0.0009	0.0920	0.0016	0.1599
C95	Leukaemia Uns	0.0001	0.0084	0.0001	0.0084
Other & Unspecified Sites		0.0014	0.1371	0.0019	0.1903
Total		0.0537	5.2329	0.0834	7.9977

Table 45: Number of cancer deaths by five year age group and site (ICD 10): 2017 - 2018 Males
Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	2	0.3
C01-C02	Tongue	0	0	0	0	0	3	2	6	12	7	7	1	5	3	4	6	56	7.2
C03-C06	Mouth	0	0	0	0	0	0	1	6	6	5	8	4	8	5	3	5	51	6.5
C07-C08	Salivary Gland	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	3	0.4
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	4	0	3	0	2	1	10	1.3
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	1	4	0.5
C11	Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	0	5	0.6
C12-C13	Hypopharynx	0	0	0	0	1	0	1	0	2	6	4	4	2	8	2	4	34	4.3
C14	Pharynx	0	0	0	0	0	1	0	1	1	2	1	1	0	4	2	4	17	2.2
C15	Oesophagus	0	0	0	0	0	2	0	0	1	2	1	3	5	12	2	5	33	4.2
C16	Stomach	0	0	0	0	1	1	1	0	3	12	12	12	9	9	10	13	83	10.6
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.1
C18	Colon	0	0	0	0	1	0	1	2	1	2	4	7	2	7	0	2	29	3.7
C19-C20	Rectum	0	0	0	0	0	0	2	1	3	2	5	2	5	3	3	2	28	3.6
C21	Anus	0	0	0	0	0	0	1	1	0	3	2	0	1	1	0	1	10	1.3
C22	Liver	0	0	0	0	0	0	0	0	1	1	2	3	3	6	3	2	21	2.7
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	1	1	1	3	4	3	3	1	17	2.2
C25	Pancreas	0	0	0	0	0	0	0	0	0	1	4	2	4	4	1	3	19	2.4
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C32	Larynx	0	0	0	0	0	0	0	0	1	2	2	3	4	7	4	5	28	3.6
C33-C34	Lung	0	0	0	0	0	0	1	3	3	3	6	14	28	16	21	20	115	14.7
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	2	3	1	1	0	0	0	0	0	0	0	0	0	0	7	0.9
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C44	Other Skin	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C47&C49	Conn & Soft Tiss	0	1	0	1	0	0	2	0	1	1	3	0	2	1	1	1	14	1.8
C50	Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C60	Penis	0	0	0	0	0	0	0	0	2	1	1	3	1	1	1	2	12	1.5
C61	Prostate	0	0	0	0	0	0	0	0	0	0	1	1	2	0	2	5	11	1.4
C62	Testis	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.1
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	0	0	0	0	0	0	2	1	1	1	4	2	3	0	0	14	1.8
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	5	11	1.4
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	0	1	0	2	0	1	3	3	3	4	3	2	2	1	25	3.2
C73	Thyroid	0	0	0	0	0	0	0	0	0	0	2	3	0	0	0	0	5	0.6
C75	Endocrine gl	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.1
C81	Hodgkins Dis	0	0	0	0	1	0	1	0	0	0	3	0	0	1	1	0	7	0.9
C82-C85 & C96	NHL	0	0	0	1	2	0	0	5	1	1	1	3	2	2	6	3	27	3.4
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	0	0	2	4	1	4	2	13	1.7
C91	Leuk Lymphoid	0	1	0	2	1	0	0	0	0	0	1	2	0	0	0	0	7	0.9
C92-C94	Leuk Myeloid	1	0	0	0	0	0	1	3	2	1	2	3	2	2	2	1	20	2.6
C95	Leukaemia Uns	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unsp.Sites		0	0	0	0	0	0	0	1	0	5	5	3	8	6	7	6	41	5.2
Total		1	2	2	8	9	11	14	32	47	63	88	90	112	112	90	102	783	100.0

Table 46: Number of cancer deaths by five year age group and site (ICD 10): 2017 - 2018 Females
Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0.1
C01-C02	Tongue	0	0	0	0	0	0	0	0	1	0	2	3	1	2	0	2	11	1.4
C03-C06	Mouth	0	0	0	0	0	0	0	1	0	3	7	4	8	2	2	3	30	3.9
C07-C08	Salivary Gland	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	3	0.4
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2	0.3
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C11	Nasopharynx	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	3	0.4
C12-C13	Hypopharynx	0	0	0	0	0	2	2	2	1	5	6	3	3	2	1	1	28	3.6
C14	Pharynx	0	0	0	0	0	1	0	0	1	1	0	2	0	1	0	2	8	1.0
C15	Oesophagus	0	0	0	0	0	0	1	2	2	3	5	4	3	1	4	1	26	3.4
C16	Stomach	0	0	0	1	0	1	1	2	6	6	3	4	7	9	4	3	47	6.1
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	3	0.4
C18	Colon	0	0	0	0	0	0	1	1	1	1	2	5	2	5	2	0	20	2.6
C19-C20	Rectum	0	0	0	0	0	1	1	0	2	1	2	1	0	1	0	0	9	1.2
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C22	Liver	0	1	0	1	0	0	0	0	0	0	1	0	4	1	0	2	10	1.3
C23-C24	Gall Bladder	0	0	0	0	0	1	0	3	0	4	6	1	3	0	0	2	20	2.6
C25	Pancreas	0	0	0	0	0	0	0	1	0	1	3	0	0	2	1	0	8	1.0
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.1
C32	Larynx	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	3	0.4
C33-C34	Lung	0	0	0	0	0	1	3	1	0	3	2	5	6	6	0	7	34	4.4
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.1
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C44	Other Skin	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	3	0.4
C47&C49	Conn & Soft Tiss	0	1	0	0	0	1	2	1	3	1	0	4	2	1	1	2	19	2.5
C50	Breast	0	0	0	0	0	2	3	9	14	32	23	23	16	14	8	15	159	20.6
C51	Vulva	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	2	4	0.5
C52	Vagina	0	0	0	0	0	0	0	0	0	0	1	1	0	4	0	0	6	0.8
C53	Cervix Uteri	0	0	0	0	1	0	5	12	11	12	13	27	16	11	8	6	122	15.8
C54	Corpus Uteri	0	0	0	0	0	0	0	0	0	2	2	1	2	2	1	3	13	1.7
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	3	0.4
C56	Ovary	0	0	0	0	0	0	0	5	3	13	7	10	13	5	1	2	59	7.7
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0.1
C64	Kidney	1	1	0	0	0	0	0	0	0	1	0	0	2	2	1	0	8	1.0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0.3
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	0.3
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	1	0	1	1	0	0	0	1	1	1	3	1	1	3	0	0	14	1.8
C73	Thyroid	0	0	0	0	0	0	0	0	0	1	4	0	1	0	0	1	7	0.9
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Disease	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.1
C82-C85 & C96	NHL	0	0	2	0	1	0	1	1	1	4	3	1	1	1	1	3	20	2.6
C90	M.Myeloma	0	0	0	0	0	0	0	0	0	1	2	1	1	1	1	1	8	1.0
C91	Leuk Lymphoid	0	0	0	2	2	0	0	0	1	0	0	0	0	0	0	0	5	0.6
C92-C94	Leuk Myeloid	0	0	0	0	0	1	0	2	0	1	0	3	2	1	3	0	13	1.7
C95	Leuk Uns	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0.3
Other Unsp.Sites		0	0	0	0	0	0	1	3	2	7	4	6	3	2	2	1	31	4.0
Total		2	4	3	5	5	11	23	48	52	107	104	114	102	84	43	64	771	100.0

Table 47: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	1.3	1.0	2.9	6.1	4.2	5.7	1.0	5.7	5.6	11.9	17.5	2.4	2.3	4.3
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.5	2.9	3.0	3.0	6.5	3.9	9.1	9.4	8.9	14.6	2.2	2.2	4.4
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	2.9	0.1	0.1	0.3
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	3.4	0.0	6.0	2.9	0.4	0.5	1.0
C10	Oth. Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	2.3	0.0	0.0	2.9	0.2	0.2	0.4
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	3.8	6.0	0.0	0.2	0.3	0.1
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.0	1.0	3.6	3.2	3.9	2.3	15.1	6.0	11.7	1.5	1.6	2.2
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.5	0.5	1.2	0.8	1.0	0.0	7.5	6.0	11.7	0.7	0.8	0.7
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.5	1.2	0.8	2.9	5.7	22.6	6.0	14.6	1.4	1.6	1.6
C16	Stomach	0.0	0.0	0.0	0.0	0.5	0.4	0.5	0.0	1.5	7.2	9.7	11.6	10.2	16.9	29.8	37.9	3.5	3.8	6.1
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C18	Colon	0.0	0.0	0.0	0.0	0.5	0.0	0.5	1.0	0.5	1.2	3.2	6.8	2.3	13.2	0.0	5.8	1.2	1.3	2.2
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.5	1.5	1.2	4.0	1.9	5.7	5.6	8.9	5.8	1.2	1.2	2.3
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	1.8	1.6	0.0	1.1	1.9	0.0	2.9	0.4	0.4	0.8
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.6	1.6	2.9	3.4	11.3	8.9	5.8	0.9	1.0	1.3
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.6	0.8	2.9	4.6	5.6	8.9	2.9	0.7	0.8	1.3
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	3.2	1.9	4.6	7.5	3.0	8.8	0.8	0.9	1.5
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.2	1.6	2.9	4.6	13.2	11.9	14.6	1.2	1.4	1.6
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.4	1.5	1.8	4.8	13.6	31.9	30.1	62.5	58.3	4.9	5.7	7.6
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	1.0	1.6	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C47&C49	Conn & Soft Tiss	0.0	0.7	0.0	0.5	0.0	0.0	1.0	0.0	0.5	0.6	2.4	0.0	2.3	1.9	3.0	2.9	0.6	0.6	0.9
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.6	0.8	2.9	1.1	1.9	3.0	5.8	0.5	0.5	1.0
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.0	2.3	0.0	6.0	14.6	0.5	0.6	0.5
C62	Testis	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.5	0.6	0.8	3.9	2.3	5.6	0.0	0.0	0.0	0.6	0.6	1.3
C66	Ureter	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	2.0	1.0	3.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	1.2
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	5.6	6.0	14.6	0.5	0.6	0.1
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.0	0.0	0.0	0.5	0.0	0.9	0.0	0.5	1.5	1.8	2.4	3.9	3.4	3.8	6.0	2.9	1.1	1.0	2.1
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	2.9	0.0	0.0	0.0	0.0	0.2	0.2	0.6
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C81	Hodgkins Di	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.0	0.0	0.0	2.4	0.0	0.0	1.9	3.0	0.0	0.3	0.3	0.4
C82-C85 & C96	NHL	0.0	0.0	0.0	0.5	0.9	0.0	0.0	2.4	0.5	0.6	0.8	2.9	2.3	3.8	17.9	8.8	1.2	1.2	1.5
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	4.6	1.9	11.9	5.8	0.6	0.7	0.8
C91	Leuk Lymphoid	0.0	0.7	0.0	1.0	0.5	0.0	0.0	0.0	0.0	0.0	0.8	1.9	0.0	0.0	0.0	0.0	0.3	0.3	0.4
C92-C94	Leuk Myeloid	0.7	0.0	0.0	0.0	0.0	0.0	0.5	1.4	1.0	0.6	1.6	2.9	2.3	3.8	6.0	2.9	0.9	0.9	1.5
C95	Leuk. Uns	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unsp. Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	3.0	4.0	2.9	9.1	11.3	20.8	17.5	1.7	2.0	2.9
Total		0.7	1.4	1.0	4.2	4.2	4.7	6.7	15.4	23.8	37.8	71.0	87.4	127.4	210.9	267.8	297.6	33.4	36.2	54.1

Table 48: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam Urban

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.7	3.0	1.2	3.5	0.0	4.6	0.5	0.5	0.9
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.9	6.0	3.9	9.2	3.5	5.9	6.9	1.3	1.3	3.1
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	1.2	1.8	0.0	0.0	0.1	0.1	0.1
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.0	1.2	0.0	0.0	0.0	0.1	0.1	0.4
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.8	0.9	0.9	0.5	3.2	5.2	3.0	3.5	3.5	3.0	2.3	1.2	1.1	2.6
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.6	0.0	2.0	0.0	1.8	0.0	4.6	0.3	0.3	0.5
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.9	1.1	1.9	4.3	3.9	3.5	1.8	11.8	2.3	1.1	1.1	2.4
C16	Stomach	0.0	0.0	0.0	0.5	0.0	0.4	0.5	0.9	3.2	3.9	2.6	3.9	8.1	15.9	11.8	6.9	2.0	2.1	3.5
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	1.2	0.0	0.0	2.3	0.1	0.1	0.3
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.5	0.6	1.7	4.9	2.3	8.8	5.9	0.0	0.9	0.9	1.5
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.0	1.1	0.6	1.7	1.0	0.0	1.8	0.0	0.0	0.4	0.3	0.7
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C22	Liver	0.0	0.7	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	4.6	1.8	0.0	4.6	0.4	0.5	0.7
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.4	0.0	2.6	5.2	1.0	3.5	0.0	0.0	4.6	0.9	0.8	2.2
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.6	2.6	0.0	0.0	3.5	3.0	0.0	0.3	0.4	0.6
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.8	3.0	0.0	0.1	0.2	0.1
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.4	1.4	0.5	0.0	1.9	1.7	4.9	6.9	10.6	0.0	16.1	1.5	1.5	2.3
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	1.2	0.0	0.0	2.3	0.1	0.1	0.2
C47&C49	Conn & Soft Tiss	0.0	0.7	0.0	0.0	0.0	0.4	0.9	0.5	1.6	0.6	0.0	3.9	2.3	1.8	3.0	4.6	0.8	0.8	1.3
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.8	1.4	4.2	7.6	20.6	19.8	22.7	18.4	24.7	23.7	34.5	6.8	6.6	14.8
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.8	0.0	4.6	0.2	0.2	0.1
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.0	0.0	7.1	0.0	0.0	0.3	0.3	0.3
C53	Cervix Uteri	0.0	0.0	0.0	0.0	0.4	0.0	2.3	5.6	5.9	7.7	11.2	26.7	18.4	19.4	23.7	13.8	5.2	5.0	11.3
C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	1.0	2.3	3.5	3.0	6.9	0.6	0.6	1.0
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	2.3	0.1	0.1	0.3
C56	Ovary	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	1.6	8.4	6.0	9.9	15.0	8.8	3.0	4.6	2.5	2.4	6.6
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0
C64	Kidney	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	2.3	3.5	3.0	0.0	0.3	0.5	0.4
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	3.0	0.0	0.1	0.1	0.1
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.1	0.1	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain&CNS	0.7	0.0	0.6	0.5	0.0	0.0	0.0	0.5	0.5	0.6	2.6	1.0	1.2	5.3	0.0	0.0	0.6	0.7	1.0
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	3.4	0.0	1.2	0.0	0.0	2.3	0.3	0.3	0.8
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C82-C85 & C96	NHL	0.0	0.0	1.1	0.0	0.4	0.0	0.5	0.5	0.5	2.6	2.6	1.0	1.2	1.8	3.0	6.9	0.9	0.8	1.4
C90	M. Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.7	1.0	1.2	1.8	3.0	2.3	0.3	0.4	0.7
C91	Leuk Lymphoid	0.0	0.0	0.0	1.1	0.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.1
C92-C94	Leuk Myeloid	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.9	0.0	0.6	0.0	3.0	2.3	1.8	8.9	0.0	0.6	0.6	1.0
C95	Leuk. Uns	0.0	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Other & Unsp Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.4	1.1	4.5	3.4	5.9	3.5	3.5	5.9	2.3	1.3	1.3	3.1
Total		1.4	3.0	1.7	2.7	2.1	4.6	10.7	22.2	28.1	68.9	89.4	112.6	117.4	148.5	127.2	147.1	33.0	32.8	67.2

25. Standard Registry tables – Visakhapatnam Rural

Table 49: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Males – Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	1	0	1	0	2	1	0	0	0	1	0	6	0.7
C01-C02	Tongue	0	0	0	0	0	4	8	12	9	13	10	8	4	2	2	2	74	8.8
C03-C06	Mouth	0	0	0	0	0	2	3	7	9	11	12	11	12	12	3	6	88	10.5
C07-C08	Salivary Gl	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	1	5	0.6
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	2	2	3	1	0	8	1.0
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	0.2
C11	Nasopharynx	0	0	0	0	0	0	0	0	1	2	1	1	0	1	0	0	6	0.7
C12-C13	Hypopharynx	0	0	0	0	1	0	1	4	0	6	6	6	3	6	7	3	43	5.1
C14	Pharynx	0	0	0	0	0	0	0	0	2	0	0	2	1	3	1	3	12	1.4
C15	Oesophagus	0	0	0	0	0	0	0	2	1	3	4	1	5	6	4	2	28	3.3
C16	Stomach	0	0	0	0	0	2	4	4	6	5	10	10	12	9	9	2	73	8.7
C17	Small Intestine	0	0	0	0	0	0	0	1	2	3	2	0	0	0	0	0	8	1.0
C18	Colon	0	0	0	0	0	2	0	1	2	4	5	4	2	6	1	2	29	3.5
C19-C20	Rectum	0	0	0	0	0	0	2	3	4	1	1	5	3	3	1	3	26	3.1
C21	Anus	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	0	4	0.5
C22	Liver	0	0	0	0	0	0	0	2	0	2	3	2	5	3	2	2	21	2.5
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	0	2	0	0	2	0	2	1	7	0.8
C25	Pancreas	0	0	0	0	0	0	1	1	0	1	1	3	2	0	2	1	12	1.4
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2	0.2
C32	Larynx	0	0	0	1	0	1	0	0	0	1	4	3	2	6	1	2	21	2.5
C33-C34	Lung	0	0	0	0	0	0	0	2	1	5	9	10	12	19	14	5	77	9.2
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	2	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	4	0.5
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	2	0.2
C44	Other Skin	0	0	0	0	0	0	2	0	1	3	2	2	3	2	1	0	16	1.9
C47&C49	Conn & Soft Tiss	0	0	1	1	0	2	2	1	0	1	0	0	0	0	0	0	8	1.0
C50	Breast	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.1
C60	Penis	0	0	0	0	0	0	0	2	2	4	4	3	2	5	5	0	27	3.2
C61	Prostate	0	0	0	0	0	0	0	0	2	0	2	3	3	5	6	4	25	3.0
C62	Testis	0	0	0	1	1	1	2	2	2	0	0	1	0	1	0	0	11	1.3
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	1	1	0	0	0	0	3	1	0	1	2	1	0	0	1	1	12	1.4
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	1	1	0	1	0	0	1	1	2	0	7	0.8
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	1	0	0	0	1	2	1	3	2	2	1	1	1	0	15	1.8
C73	Thyroid	0	0	0	2	1	1	0	2	0	2	1	4	3	5	2	0	23	2.7
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Dis	0	1	0	1	2	2	2	5	1	1	1	0	0	1	0	0	17	2.0
C82-C85 & C96	NHL	0	0	0	2	1	2	2	2	5	4	2	6	2	1	0	0	29	3.5
C90	M.Myeloma	0	0	0	0	0	0	0	0	0	3	2	1	4	0	1	0	11	1.3
C91	Leuk Lymphoid	4	4	3	1	3	0	1	1	1	0	0	0	0	0	0	0	18	2.1
C92-C94	Leuk Myeloid	1	2	1	5	3	2	3	3	3	4	1	1	1	1	0	0	31	3.7
C95	Leukaemia Uns	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unsp Sites		0	0	0	0	1	0	1	1	4	0	3	5	5	4	3	2	29	3.5
Total		8	8	6	14	14	22	39	63	59	90	95	101	94	111	73	42	839	100.0

Table 50: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Females – Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.1
C01-C02	Tongue	0	0	0	0	0	0	1	2	1	4	6	1	2	5	2	2	26	1.9
C03-C06	Mouth	0	0	0	0	0	0	2	3	6	6	14	13	21	15	11	2	93	6.7
C07-C08	Salivary Gl	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2	0.1
C09	Tonsil	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	3	0.2
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C11	Nasopharynx	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	2	0.1
C12-C13	Hypopharynx	0	0	0	0	2	2	3	8	5	9	6	9	4	4	2	0	54	3.9
C14	Pharynx	0	0	0	0	0	0	0	0	0	3	2	3	4	1	0	0	13	0.9
C15	Oesophagus	0	0	0	1	0	1	1	3	5	6	5	2	2	3	3	3	35	2.5
C16	Stomach	0	0	0	0	1	2	4	2	5	3	9	1	5	11	1	0	44	3.2
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	2	0.1
C18	Colon	0	0	0	0	0	1	1	0	0	0	2	2	2	1	3	0	12	0.9
C19-C20	Rectum	0	0	0	0	1	0	1	0	1	3	4	3	8	1	1	0	23	1.7
C21	Anus	0	0	0	0	0	0	1	0	0	2	0	0	3	1	0	0	7	0.5
C22	Liver	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	1	6	0.4
C23-C24	Gall Bladder	0	0	0	0	0	0	0	1	3	1	1	1	1	0	0	0	8	0.6
C25	Pancreas	0	0	0	0	0	0	1	0	2	2	1	2	0	0	1	0	9	0.7
C30-C31	Nose & Sinus	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	0	3	0.2
C32	Larynx	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	1	4	0.3
C33-C34	Lung	0	0	0	0	0	0	0	3	0	5	4	5	4	5	0	2	28	2.0
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	2	2	0	2	0	2	0	0	0	0	0	0	0	0	8	0.6
C43	Melanoma Skin	0	0	0	0	0	0	0	2	1	1	0	2	0	0	0	0	6	0.4
C44	Other Skin	0	0	0	0	0	1	0	1	2	1	2	1	3	1	0	1	13	0.9
C47&C49	Conn & Soft Tiss	0	0	0	1	0	0	0	1	1	0	1	1	0	2	0	2	9	0.7
C50	Breast	0	0	0	0	1	5	9	28	38	46	39	29	28	15	18	8	264	19.1
C51	Vulva	0	0	0	0	0	0	0	0	1	1	1	0	3	3	2	0	11	0.8
C52	Vagina	0	0	0	0	0	0	0	0	0	6	2	2	5	2	0	2	19	1.4
C53	Cervix Uteri	0	0	0	0	0	3	5	37	41	65	60	58	60	44	31	10	414	30.0
C54	Corpus Uteri	0	0	0	0	1	0	0	1	2	1	3	6	2	5	3	1	25	1.8
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	2	0.1
C56	Ovary	0	0	0	1	1	2	2	9	8	7	12	8	6	8	3	2	69	5.0
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.1
C64	Kidney	3	0	0	0	0	0	0	0	0	1	0	0	1	2	0	2	9	0.7
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	1	1	0	1	0	1	1	0	5	0.4
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.1
C70-C72	Brain & CNS	2	0	0	2	0	0	3	1	1	1	1	2	3	0	0	0	16	1.2
C73	Thyroid	0	0	0	0	2	4	6	5	8	4	2	3	0	3	4	0	41	3.0
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Disease	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	3	0.2
C82-C85 & C96	NHL	0	0	0	0	1	0	1	3	1	6	3	2	4	2	1	0	24	1.7
C90	M.Myeloma	0	0	0	0	0	0	0	1	0	1	3	2	1	0	2	0	10	0.7
C91	Leuk Lymphoid	2	2	0	1	1	0	0	0	0	0	1	1	0	2	0	0	10	0.7
C92-C94	Leuk Myeloid	0	1	1	0	1	1	1	2	1	2	2	1	2	2	0	0	17	1.2
C95	Leuk. Unsp	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1
Other & Unsp Sites		0	0	0	0	0	1	0	2	2	5	5	6	3	1	1	1	27	2.0
Total		7	4	5	9	12	25	44	118	140	198	195	172	178	141	92	40	1380	100.0

Table 51: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.8	0.0	2.1	1.4	0.0	0.0	0.0	3.1	0.0	0.4	0.4	0.8
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	2.9	6.3	9.8	7.7	13.8	13.7	15.4	5.4	3.3	6.3	10.5	4.7	4.4	11.0
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	1.4	2.4	5.7	7.7	11.7	16.5	21.1	16.1	20.1	9.4	31.6	5.6	5.5	12.3
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	3.8	0.0	1.7	0.0	5.3	0.3	0.4	0.7
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	2.7	5.0	3.1	0.0	0.5	0.5	0.8
C10	Oth. Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	1.7	0.0	0.0	0.1	0.1	0.2
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	2.1	1.4	1.9	0.0	1.7	0.0	0.0	0.4	0.4	1.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.6	0.0	0.8	3.3	0.0	6.4	8.2	11.5	4.0	10.0	22.0	15.8	2.7	2.8	5.2
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	3.8	1.3	5.0	3.1	15.8	0.8	0.8	1.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.9	3.2	5.5	1.9	6.7	10.0	12.6	10.5	1.8	1.7	3.1
C16	Stomach	0.0	0.0	0.0	0.0	0.0	1.4	3.2	3.3	5.2	5.3	13.7	19.2	16.1	15.1	28.3	10.5	4.7	4.5	9.4
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.7	3.2	2.7	0.0	0.0	0.0	0.0	0.0	0.5	0.5	1.6
C18	Colon	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.8	1.7	4.3	6.9	7.7	2.7	10.0	3.1	10.5	1.9	1.9	3.8
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	1.6	2.5	3.4	1.1	1.4	9.6	4.0	5.0	3.1	15.8	1.7	1.7	3.3
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.4	0.0	1.3	1.7	0.0	0.0	0.3	0.2	0.6
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	2.1	4.1	3.8	6.7	5.0	6.3	10.5	1.3	1.3	2.8
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	2.7	0.0	6.3	5.3	0.4	0.5	0.8
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	1.1	1.4	5.8	2.7	0.0	6.3	5.3	0.8	0.8	1.7
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.9	0.0	0.0	0.0	0.0	0.1	0.1	0.5
C32	Larynx	0.0	0.0	0.0	0.7	0.0	0.7	0.0	0.0	0.0	1.1	5.5	5.8	2.7	10.0	3.1	10.5	1.3	1.4	2.2
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.9	5.3	12.4	19.2	16.1	31.8	44.0	26.3	4.9	4.9	8.1
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	1.8	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.3	0.3	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.7	0.0	0.0	0.1	0.1	0.2
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.9	3.2	2.7	3.8	4.0	3.3	3.1	0.0	1.0	1.0	2.2
C47&C49	Conn & Soft Tiss	0.0	0.0	0.7	0.7	0.0	1.4	1.6	0.8	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.4
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.1	0.1	0.2
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.7	4.3	5.5	5.8	2.7	8.4	15.7	0.0	1.7	1.6	3.5
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	2.7	5.8	4.0	8.4	18.9	21.1	1.6	1.7	2.0
C62	Testis	0.0	0.0	0.0	0.7	0.6	0.7	1.6	1.6	1.7	0.0	0.0	1.9	0.0	1.7	0.0	0.0	0.7	0.6	0.9
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.9	0.9	0.0	0.0	0.0	0.0	2.4	0.8	0.0	1.1	2.7	1.9	0.0	0.0	3.1	5.3	0.8	0.8	1.1
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	1.1	0.0	0.0	1.3	1.7	6.3	0.0	0.4	0.4	0.5
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain&CNS	0.0	0.0	0.7	0.0	0.0	0.0	0.8	1.6	0.9	3.2	2.7	3.8	1.3	1.7	3.1	0.0	1.0	0.9	2.2
C73	Thyroid	0.0	0.0	0.0	1.4	0.6	0.7	0.0	1.6	0.0	2.1	1.4	7.7	4.0	8.4	6.3	0.0	1.5	1.4	2.5
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Dis	0.0	0.9	0.0	0.7	1.3	1.4	1.6	4.1	0.9	1.1	1.4	0.0	0.0	1.7	0.0	0.0	1.1	0.9	1.4
C82-C85 & C96	NHL	0.0	0.0	0.0	1.4	0.6	1.4	1.6	1.6	4.3	4.3	2.7	11.5	2.7	1.7	0.0	0.0	1.9	1.8	4.3
C90	M. Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	2.7	1.9	5.4	0.0	3.1	0.0	0.7	0.7	2.0
C91	Leuk Lymphoid	3.7	3.5	2.2	0.7	1.9	0.0	0.8	0.8	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.4	0.3
C92-C94	Leuk Myeloid	0.9	1.8	0.7	3.5	1.9	1.4	2.4	2.5	2.6	4.3	1.4	1.9	1.3	1.7	0.0	0.0	2.0	1.9	2.4
C95	Leuk. Uns	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unsp Sites		0.0	0.0	0.0	0.0	0.6	0.0	0.8	0.8	3.4	0.0	4.1	9.6	6.7	6.7	9.4	10.5	1.9	1.8	3.6
Total		7.3	7.0	4.4	9.8	9.0	15.9	30.8	51.6	50.8	95.7	130.5	194.1	126.5	185.8	229.5	221.2	53.6	52.5	100.8

Table 52: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.1	0.1	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.5	0.9	4.6	8.0	1.4	2.1	7.9	5.5	8.2	1.6	1.5	3.1
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.2	5.4	6.9	18.7	18.2	22.4	23.8	30.2	8.2	5.8	5.0	11.0
C07-C08	Salivary Gl	0.0	0.9	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.1	1.3	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.6
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	1.4	1.4	2.3	5.9	4.5	10.3	8.0	12.6	4.3	6.3	5.5	0.0	3.4	3.0	7.5
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	2.7	4.2	4.3	1.6	0.0	0.0	0.8	0.7	2.2
C15	Oesophagus	0.0	0.0	0.0	0.8	0.0	0.7	0.8	2.2	4.5	6.9	6.7	2.8	2.1	4.8	8.2	12.2	2.2	2.1	4.3
C16	Stomach	0.0	0.0	0.0	0.0	0.7	1.4	3.0	1.5	4.5	3.4	12.0	1.4	5.3	17.5	2.7	0.0	2.8	2.4	4.6
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	2.7	0.0	0.1	0.1	0.2
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.0	0.0	0.0	2.7	2.8	2.1	1.6	8.2	0.0	0.8	0.6	1.1
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.7	0.0	0.8	0.0	0.9	3.4	5.3	4.2	8.5	1.6	2.7	0.0	1.4	1.2	3.3
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	2.3	0.0	0.0	3.2	1.6	0.0	0.0	0.4	0.4	0.9
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	1.4	1.1	1.6	0.0	4.1	0.4	0.4	0.7
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.7	1.1	1.3	1.4	1.1	0.0	0.0	0.0	0.5	0.4	1.4
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.8	2.3	1.3	2.8	0.0	0.0	2.7	0.0	0.6	0.5	1.4
C30-C31	Nose&Sinus	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.4	0.0	0.0	0.0	0.0	0.2	0.2	0.4
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.3	0.2	0.3
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	5.7	5.3	7.0	4.3	7.9	0.0	8.2	1.8	1.6	3.9
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	1.5	1.5	0.0	1.4	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.3
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.9	1.1	0.0	2.8	0.0	0.0	0.0	0.0	0.4	0.3	1.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.7	1.8	1.1	2.7	1.4	3.2	1.6	0.0	4.1	0.8	0.7	1.7
C47&C49	Conn Soft Tiss	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.7	0.9	0.0	1.3	1.4	0.0	3.2	0.0	8.2	0.6	0.5	0.7
C50	Breast	0.0	0.0	0.0	0.0	0.7	3.5	6.8	20.8	33.9	52.7	52.1	40.6	29.8	23.8	49.5	32.6	16.6	15.0	38.3
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.1	1.3	0.0	3.2	4.8	5.5	0.0	0.7	0.6	1.0
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	2.7	2.8	5.3	3.2	0.0	8.2	1.2	1.1	2.8
C53	Cervix Ut	0.0	0.0	0.0	0.0	0.0	2.1	3.8	27.5	36.6	74.4	80.1	81.2	63.9	69.8	85.2	40.8	26.0	23.1	58.5
C54	CorpusUteri	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	1.8	1.1	4.0	8.4	2.1	7.9	8.2	4.1	1.6	1.4	2.7
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.1	0.4
C56	Ovary	0.0	0.0	0.0	0.8	0.7	1.4	1.5	6.7	7.1	8.0	16.0	11.2	6.4	12.7	8.2	8.2	4.3	3.9	9.1
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C64	Kidney	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	1.1	3.2	0.0	8.2	0.6	0.7	0.4
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	U. Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.1	0.0	1.4	0.0	1.6	2.7	0.0	0.3	0.3	0.6
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C70-C72	Brain CNS	1.9	0.0	0.0	1.5	0.0	0.0	2.3	0.7	0.9	1.1	1.3	2.8	3.2	0.0	0.0	0.0	1.0	1.0	1.5
C73	Thyroid	0	0.0	0.0	0.0	1.4	2.8	4.5	3.7	7.1	4.6	2.7	4.2	0.0	4.8	11.0	0.0	2.6	2.2	4.0
C75	Endocrine gl	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Dis	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.1	0.0	1.4	0.0	0.0	0.0	0.0	0.2	0.2	0.6
C82-C85 & C96	NHL	0	0.0	0.0	0.0	0.7	0.0	0.8	2.2	0.9	6.9	4.0	2.8	4.3	3.2	2.7	0.0	1.5	1.3	3.5
C90	M.Myeloma	0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.1	4.0	2.8	1.1	0.0	5.5	0.0	0.6	0.6	1.5
C91	Leuk Lymph	1.9	1.9	0.0	0.8	0.7	0.0	0.0	0.0	0.0	0.0	1.3	1.4	0.0	3.2	0.0	0.0	0.6	0.8	0.4
C92-C94	Leuk Myel	0.0	0.9	0.7	0.0	0.7	0.7	0.8	1.5	0.9	2.3	2.7	1.4	2.1	3.2	0.0	0.0	1.1	1.0	1.8
C95	Leuk Uns	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Other Unsp Sites		0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.5	1.8	5.7	6.7	8.4	3.2	1.6	2.7	4.1	1.7	1.6	4.3
Total		6.8	3.8	3.7	6.8	8.5	17.4	33.1	87.6	125.0	226.7	260.4	240.9	189.6	223.8	252.8	163.1	86.6	77.8	182.6

Table 53: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Males Visakhapatnam Rural.

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0003	0.0252	0.0004	0.0409
C01-C02	Tongue	0.0038	0.3748	0.0042	0.4228
C03-C06	Mouth	0.0041	0.4130	0.0056	0.5599
C07-C08	Salivary Gland	0.0003	0.0261	0.0003	0.0345
C09	Tonsil	0.0003	0.0327	0.0007	0.0735
C10	Oth. Oropharynx	0.0001	0.0069	0.0002	0.0152
C11	Nasopharynx	0.0003	0.0314	0.0004	0.0398
C12-C13	Hypopharynx	0.0017	0.1744	0.0033	0.3342
C14	Pharynx	0.0003	0.0346	0.0008	0.0754
C15	Oesophagus	0.0010	0.0991	0.0021	0.2121
C16	Stomach	0.0034	0.3368	0.0055	0.5526
C17	Small Intestine	0.0004	0.0424	0.0004	0.0424
C18	Colon	0.0013	0.1273	0.0019	0.1932
C19-C20	Rectum	0.0012	0.1178	0.0016	0.1585
C21	Anus	0.0002	0.0189	0.0003	0.0273
C22	Liver	0.0009	0.0923	0.0015	0.1487
C23-C24	Gall Bladder	0.0002	0.0241	0.0006	0.0555
C25	Pancreas	0.0006	0.0625	0.0009	0.0939
C30-C31	Nose & Sinus	0.0002	0.0165	0.0002	0.0165
C32	Larynx	0.0008	0.0821	0.0015	0.1480
C33-C34	Lung	0.0028	0.2774	0.0066	0.6547
C37-C38	Oth Thoracic	0.0000	0.0000	0.0000	0.0000
C40-C41	Bone	0.0001	0.0124	0.0002	0.0207
C43	Melanoma Skin	0.0001	0.0053	0.0001	0.0137
C44	Other Skin	0.0008	0.0813	0.0011	0.1137
C47&C49	Conn & Soft Tiss	0.0003	0.0317	0.0003	0.0317
C50	Breast	0.0001	0.0067	0.0001	0.0067
C60	Penis	0.0011	0.1078	0.0023	0.2280
C61	Prostate	0.0007	0.0713	0.0021	0.2073
C62	Testis	0.0004	0.0446	0.0005	0.0530
C63	Oth Male Genital	0.0000	0.0000	0.0000	0.0000
C64	Kidney	0.0005	0.0536	0.0007	0.0693
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0002	0.0201	0.0006	0.0599
C68	Urethra	0.0001	0.0096	0.0001	0.0096
C69	Eye	0.0000	0.0000	0.0000	0.0000
C70-C72	Brain & CNS	0.0008	0.0757	0.0010	0.0998
C73	Thyroid	0.0010	0.0981	0.0017	0.1713
C75	Endocrine gl	0.0000	0.0000	0.0000	0.0000
C81	Hodgkins Dis	0.0007	0.0664	0.0007	0.0747
C82-C85 & C96	NHL	0.0016	0.1610	0.0017	0.1694
C90	Multiple Myeloma	0.0007	0.0662	0.0008	0.0819
C91	Leuk Lymphoid	0.0007	0.0724	0.0007	0.0724
C92-C94	Leuk Myeloid	0.0013	0.1328	0.0014	0.1411
C95	Leukaemia Uns	0.0000	0.0000	0.0000	0.0000
Other & Unspecified Sites		0.0013	0.1307	0.0021	0.2112
Total		0.0367	3.6008	0.0574	5.5821

Table 54: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Females Visakhapatnam Rural

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0000	0.0000	0.0001	0.0137
C01-C02	Tongue	0.0010	0.0962	0.0016	0.1633
C03-C06	Mouth	0.0038	0.3754	0.0065	0.6442
C07-C08	Salivary Gland	0.0001	0.0085	0.0001	0.0085
C09	Tonsil	0.0002	0.0169	0.0002	0.0169
C10	Oth. Oropharynx	0.0000	0.0000	0.0000	0.0000
C11	Nasopharynx	0.0001	0.0095	0.0001	0.0095
C12-C13	Hypopharynx	0.0025	0.2529	0.0031	0.3120
C14	Pharynx	0.0007	0.0728	0.0008	0.0807
C15	Oesophagus	0.0014	0.1368	0.0020	0.2017
C16	Stomach	0.0017	0.1661	0.0027	0.2669
C17	Small Intestine	0.0001	0.0057	0.0002	0.0195
C18	Colon	0.0005	0.0453	0.0009	0.0944
C19-C20	Rectum	0.0012	0.1192	0.0014	0.1408
C21	Anus	0.0003	0.0312	0.0004	0.0391
C22	Liver	0.0003	0.0257	0.0003	0.0336
C23-C24	Gall Bladder	0.0004	0.0418	0.0004	0.0418
C25	Pancreas	0.0004	0.0448	0.0006	0.0585
C30-C31	Nose & Sinus	0.0002	0.0174	0.0002	0.0174
C32	Larynx	0.0001	0.0119	0.0001	0.0119
C33-C34	Lung	0.0012	0.1227	0.0016	0.1623
C37-C38	Oth Thoracic	0.0000	0.0000	0.0000	0.0000
C40-C41	Bone	0.0003	0.0293	0.0003	0.0293
C43	Melanoma Skin	0.0003	0.0316	0.0003	0.0316
C44	Other Skin	0.0006	0.0582	0.0007	0.0661
C47&C49	Conn & Soft Tiss	0.0003	0.0256	0.0004	0.0415
C50	Breast	0.0120	1.1972	0.0157	1.5584
C51	Vulva	0.0003	0.0328	0.0008	0.0841
C52	Vagina	0.0009	0.0883	0.0010	0.1042
C53	Cervix Uteri	0.0185	1.8311	0.0262	2.5890
C54	CorpusUteri	0.0009	0.0945	0.0018	0.1753
C55	Oth Uterus	0.0001	0.0127	0.0001	0.0127
C56	Ovary	0.0030	0.2987	0.0040	0.4030
C57	Placenta	0.0001	0.0070	0.0001	0.0070
C64	Kidney	0.0003	0.0256	0.0004	0.0414
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0002	0.0172	0.0004	0.0389
C68	Urethra	0.0000	0.0000	0.0000	0.0000
C69	Eye	0.0000	0.0045	0.0000	0.0045
C70-C72	Brain & CNS	0.0008	0.0790	0.0008	0.0790
C73	Thyroid	0.0016	0.1550	0.0023	0.2336
C75	Endocrine gl	0.0000	0.0000	0.0000	0.0000
C81	Hodgkins Disease	0.0002	0.0172	0.0002	0.0172
C82-C85 & C96	NHL	0.0011	0.1125	0.0014	0.1421
C90	Multiple Myeloma	0.0005	0.0488	0.0008	0.0762
C91	Leuk Lymphoid	0.0004	0.0400	0.0006	0.0559
C92-C94	Leuk Myeloid	0.0007	0.0735	0.0009	0.0894
C95	Leukaemia Uns	0.0000	0.0037	0.0000	0.0037
Other & Unspecified Sites		0.0014	0.1397	0.0016	0.1614
Total		0.0605	5.8718	0.0843	8.0882

Table 55: Number of cancer deaths by five-year age group and site (ICD 10): 2017 - 2018 Males
Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.2
C01-C02	Tongue	0	0	0	0	0	1	5	4	9	4	7	6	3	2	0	1	42	8.3
C03-C06	Mouth	0	0	0	0	0	0	1	6	5	5	6	6	5	6	6	9	55	10.8
C07-C08	Salivary Gland	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	3	0.6
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	4	2	0	0	6	1.2
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	3	0.6
C11	Nasopharynx	0	0	0	0	0	0	0	0	1	2	0	1	0	1	0	0	5	1.0
C12-C13	Hypopharynx	0	0	0	0	1	0	1	3	1	1	6	4	2	6	0	3	28	5.5
C14	Pharynx	0	0	0	0	0	0	0	0	1	0	2	1	2	2	0	3	11	2.2
C15	Oesophagus	0	0	0	0	0	0	0	0	0	0	2	4	1	4	3	1	15	3.0
C16	Stomach	0	0	0	0	0	1	2	3	5	3	12	9	9	9	13	2	68	13.4
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	3	0.6
C18	Colon	0	0	0	0	0	0	1	1	1	1	0	2	2	1	0	2	11	2.2
C19-C20	Rectum	0	0	0	0	0	0	1	0	0	2	2	2	0	3	1	4	15	3.0
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C22	Liver	0	0	0	0	0	0	0	3	1	2	2	2	4	2	2	2	20	3.9
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	3	0.6
C25	Pancreas	0	0	0	0	0	0	0	1	0	0	1	3	1	0	1	1	8	1.6
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.2
C32	Larynx	0	0	0	0	0	0	0	0	0	0	3	2	2	5	1	2	15	3.0
C33-C34	Lung	0	0	0	0	0	0	0	2	7	4	4	6	6	11	11	4	55	10.8
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	2	1	0	0	0	0	0	0	1	0	1	1	0	0	6	1.2
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.2
C44	Other Skin	0	0	0	0	0	0	0	0	0	1	2	0	0	1	0	0	4	0.8
C47&C49	Conn & Soft Tiss	0	0	0	0	0	0	1	1	0	0	0	0	0	1	1	0	4	0.8
C50	Breast	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.2
C60	Penis	0	0	0	0	0	0	0	0	1	0	1	2	2	0	0	1	7	1.4
C61	Prostate	0	0	0	0	0	0	0	0	1	0	1	0	2	3	5	1	13	2.6
C62	Testis	0	0	0	0	1	0	0	1	1	0	1	0	1	0	0	0	5	1.0
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	0	0	0	0	0	1	1	0	2	0	0	1	1	0	1	7	1.4
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	1	0	0	1	1	0	2	1	3	1	10	2.0
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	1	2	0	0	1	0	1	2	1	1	2	1	0	0	12	2.4
C73	Thyroid	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	3	0.6
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Dis	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	1	4	0.8
C82-C85 & C96	NHL	0	0	0	0	0	1	0	1	1	1	2	3	2	1	1	0	13	2.6
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	1	2	1	0	3	1	1	0	9	1.8
C91	Leuk Lymphoid	2	1	1	1	1	0	0	1	1	0	0	1	0	0	1	0	10	2.0
C92-C94	Leuk Myeloid	1	0	1	1	2	0	2	1	0	0	0	1	0	0	0	0	9	1.8
C95	Leukaemia Uns	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unspecified Sites		0	0	0	0	0	0	2	2	1	2	4	1	4	3	2	1	22	4.3
Total		3	2	5	5	5	3	19	32	40	39	67	60	62	71	53	42	508	100.0

Table 56: Number of cancer deaths by five-year age group and site (ICD 10): 2017 - 2018 Females
Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C01-C02	Tongue	0	0	0	0	0	0	0	0	1	0	4	0	1	2	1	0	9	1.4
C03-C06	Mouth	0	0	0	0	0	0	1	1	1	2	10	10	8	11	7	2	53	8.2
C07-C08	Salivary Gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0.2
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.2
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	3	0.5
C11	Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.2
C12-C13	Hypopharynx	0	0	0	0	0	2	1	3	2	6	2	7	1	3	1	0	28	4.3
C14	Pharynx	0	0	0	0	0	0	0	0	0	2	1	2	2	2	0	0	9	1.4
C15	Oesophagus	0	0	0	0	1	1	2	2	2	5	3	2	6	1	3	2	30	4.6
C16	Stomach	0	0	0	0	0	2	1	0	3	5	3	6	4	5	3	3	35	5.4
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.2
C18	Colon	0	0	0	0	0	0	1	0	0	0	1	0	0	1	3	0	6	0.9
C19-C20	Rectum	0	0	0	0	1	0	0	1	1	1	1	0	5	0	0	0	10	1.5
C21	Anus	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	2	0.3
C22	Liver	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	5	0.8
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	2	3	0	0	1	0	0	0	6	0.9
C25	Pancreas	0	0	0	0	0	0	1	0	2	1	1	1	0	0	0	0	6	0.9
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	0.3
C32	Larynx	0	0	0	0	0	1	2	1	0	0	0	0	0	1	0	0	5	0.8
C33-C34	Lung	0	0	0	0	0	0	1	1	2	2	2	4	4	2	0	2	20	3.1
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	0	3	0	0	0	1	0	0	0	0	0	0	0	0	4	0.6
C43	Melanoma Skin	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	3	0.5
C44	Other Skin	0	0	0	0	0	0	0	0	1	1	0	1	0	1	1	0	5	0.8
C47&C49	Conn & Soft Tiss	0	0	0	0	1	0	0	0	1	0	1	2	0	0	0	0	5	0.8
C50	Breast	0	0	0	0	0	1	4	6	16	18	16	13	9	6	5	1	95	14.6
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0.3
C52	Vagina	0	0	0	0	0	0	0	0	0	0	3	1	2	0	2	0	8	1.2
C53	Cervix Uteri	0	0	0	0	0	0	7	12	18	22	33	30	23	14	9	3	171	26.3
C54	Corpus Uteri	0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	0	4	0.6
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C56	Ovary	0	0	0	0	0	0	1	4	1	5	6	14	7	2	3	1	44	6.8
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.2
C64	Kidney	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	4	0.6
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	2	0	0	1	0	0	1	0	4	0.6
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	0	0	0	0	0	2	0	1	1	2	2	0	0	0	8	1.2
C73	Thyroid	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	4	0.6
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C82-C85 & C96	NHL	0	0	0	0	0	0	0	0	0	2	1	1	2	1	0	0	7	1.1
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	2	1	1	1	0	1	0	6	0.9
C91	Leuk Lymphoid	0	1	1	0	1	0	0	0	0	0	1	0	0	1	0	0	5	0.8
C92-C94	Leuk Myeloid	0	0	1	0	1	0	1	1	0	0	2	1	1	1	0	0	9	1.4
C95	Leukaemia Uns	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.2
Other & Unspecified Sites		0	0	0	0	0	0	0	1	3	2	1	9	4	3	3	1	27	4.2
Total		0	1	3	3	5	7	23	38	59	85	97	111	90	63	48	17	650	100.0

Table 57: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.1	0.1	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.7	4.0	3.3	7.7	4.3	9.6	11.5	4.0	3.3	0.0	5.3	2.7	2.5	6.5
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.8	4.9	4.3	5.3	8.2	11.5	6.7	10.0	18.9	47.4	3.5	3.7	6.5
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	1.9	0.0	0.0	3.1	0.0	0.2	0.2	0.4
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	3.3	0.0	0.0	0.4	0.3	0.7
C10	Oth. Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	1.7	0.0	0.0	0.2	0.2	0.4
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	2.1	0.0	1.9	0.0	1.7	0.0	0.0	0.3	0.3	0.8
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.6	0.0	0.8	2.5	0.9	1.1	8.2	7.7	2.7	10.0	0.0	15.8	1.8	1.8	3.5
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	2.7	1.9	2.7	3.3	0.0	15.8	0.7	0.8	1.2
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	7.7	1.3	6.7	9.4	5.3	1.0	1.0	1.6
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.7	1.6	2.5	4.3	3.2	16.5	17.3	12.1	15.1	40.9	10.5	4.3	4.2	8.4
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.4	1.9	0.0	0.0	0.0	0.0	0.2	0.2	0.7
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.9	1.1	0.0	3.8	2.7	1.7	0.0	10.5	0.7	0.7	1.4
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	2.1	2.7	3.8	0.0	5.0	3.1	21.1	1.0	1.1	1.4
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.9	2.1	2.7	3.8	5.4	3.3	6.3	10.5	1.3	1.3	2.7
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	0.0	5.3	0.2	0.2	0.2
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.4	5.8	1.3	0.0	3.1	5.3	0.5	0.6	1.3
C30-C31	Nose&Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	3.8	2.7	8.4	3.1	10.5	1.0	1.0	1.5
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	6.0	4.3	5.5	11.5	8.1	18.4	34.6	21.1	3.5	3.4	5.7
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	1.5	0.7	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	1.3	1.7	0.0	0.0	0.4	0.4	0.4
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	2.7	0.0	0.0	1.7	0.0	0.0	0.3	0.3	0.6
C47&C49	Conn & Soft Tiss	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	0.0	0.0	0.0	0.0	1.7	3.1	0.0	0.3	0.2	0.2
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	1.4	3.8	2.7	0.0	0.0	5.3	0.4	0.5	1.2
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	1.4	0.0	2.7	5.0	15.7	5.3	0.8	0.8	0.7
C62	Testis	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.8	0.9	0.0	1.4	0.0	1.3	0.0	0.0	0.0	0.3	0.3	0.7
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	2.1	0.0	0.0	1.3	1.7	0.0	5.3	0.4	0.4	0.7
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.1	1.4	0.0	2.7	1.7	9.4	5.3	0.6	0.6	0.8
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain&CNS	0.0	0.0	0.7	1.4	0.0	0.0	0.8	0.0	0.9	2.1	1.4	1.9	2.7	1.7	0.0	0.0	0.8	0.7	1.4
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.4	0.0	0.0	0.0	0.0	5.3	0.2	0.2	0.4
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Dis	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.1	0.0	0.0	0.0	0.0	0.0	5.3	0.3	0.3	0.4
C82-C85 & C96	NHL	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.8	0.9	1.1	2.7	5.8	2.7	1.7	3.1	0.0	0.8	0.8	2.1
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	2.1	1.4	0.0	4.0	1.7	3.1	0.0	0.6	0.5	1.3
C91	Leuk Lymphoid	1.8	0.9	0.7	0.7	0.6	0.0	0.0	0.8	0.9	0.0	0.0	1.9	0.0	0.0	3.1	0.0	0.6	0.7	0.6
C92-C94	Leuk Myeloid	0.9	0.0	0.7	0.7	1.3	0.0	1.6	0.8	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.6	0.6	0.4
C95	Leuk Uns	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unsp Sites		0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.6	0.9	2.1	5.5	1.9	5.4	5.0	6.3	5.3	1.4	1.3	2.7
Total		2.7	1.8	3.7	3.5	3.2	2.2	15.0	26.2	34.4	41.5	92.1	115.3	83.4	118.9	166.6	221.2	32.5	32.5	60.3

Table 58: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam Rural

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	5.3	0.0	1.1	3.2	2.7	0.0	0.6	0.5	1.2
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.7	0.9	2.3	13.4	14.0	8.5	17.5	19.2	8.2	3.3	2.9	5.8
C07-C08	Salivary Gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.1	0.1	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	2.7	0.0	0.2	0.1	0.3
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.1	0.1	0.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	1.4	0.8	2.2	1.8	6.9	2.7	9.8	1.1	4.8	2.7	0.0	1.8	1.6	3.9
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	1.3	2.8	2.1	3.2	0.0	0.0	0.6	0.5	1.3
C15	Oesophagus	0.0	0.0	0.0	0.0	0.7	0.7	1.5	1.5	1.8	5.7	4.0	2.8	6.4	1.6	8.2	8.2	1.9	1.7	3.6
C16	Stomach	0.0	0.0	0.0	0.0	0.0	1.4	0.8	0.0	2.7	5.7	4.0	8.4	4.3	7.9	8.2	12.2	2.2	2.0	3.9
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	1.3	0.0	0.0	1.6	8.2	0.0	0.4	0.3	0.2
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	0.9	1.1	1.3	0.0	5.3	0.0	0.0	0.0	0.6	0.5	1.4
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	1.1	0.0	0.0	0.0	0.1	0.1	0.4
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.4	1.1	1.6	2.7	0.0	0.3	0.3	0.5
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	3.4	0.0	0.0	1.1	0.0	0.0	0.0	0.4	0.4	1.1
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.8	1.1	1.3	1.4	0.0	0.0	0.0	0.0	0.4	0.3	1.0
C30-C31	Nose&Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	1.6	0.0	0.0	0.1	0.1	0.2
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.7	1.5	0.7	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.3	0.2	0.1
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.7	1.8	2.3	2.7	5.6	4.3	3.2	0.0	8.2	1.3	1.1	2.6
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.1
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.5
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.1	0.0	1.4	0.0	1.6	2.7	0.0	0.3	0.3	0.6
C47&C49	ConnSoft Tiss	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.9	0.0	1.3	2.8	0.0	0.0	0.0	0.0	0.3	0.3	0.7
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.7	3.0	4.5	14.3	20.6	21.4	18.2	9.6	9.5	13.7	4.1	6.0	5.4	14.6
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	2.7	0.0	0.1	0.1	0.0
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	1.4	2.1	0.0	5.5	0.0	0.5	0.5	1.1
C53	Cervix Uteri	0.0	0.0	0.0	0.0	0.0	0.0	5.3	8.9	16.1	25.2	44.1	42.0	24.5	22.2	24.7	12.2	10.7	9.6	25.4
C54	CorpusUteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	2.1	1.6	0.0	0.0	0.3	0.2	0.4
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C56	Ovary	0.0	0.0	0.0	0.0	0.0	0.0	0.8	3.0	0.9	5.7	8.0	19.6	7.5	3.2	8.2	4.1	2.8	2.4	6.6
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.1	0.2
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	1.1	1.6	0.0	4.1	0.3	0.2	0.4
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	U. Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	1.4	0.0	0.0	2.7	0.0	0.3	0.2	0.5
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain&CNS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	1.1	1.3	2.8	2.1	0.0	0.0	0.0	0.5	0.4	1.4
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.4	0.0	1.6	2.7	0.0	0.3	0.2	0.4
C75	Endocrine gl	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C82-C85 & C96	NHL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	1.3	1.4	2.1	1.6	0.0	0.0	0.4	0.4	1.1
C90	M.Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	1.3	1.4	1.1	0.0	2.7	0.0	0.4	0.4	1.0
C91	Leuk Lymp	0.0	0.9	0.7	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	1.6	0.0	0.0	0.3	0.3	0.2
C92-C94	Leuk Myel	0.0	0.0	0.7	0.0	0.7	0.0	0.8	0.7	0.0	0.0	2.7	1.4	1.1	1.6	0.0	0.0	0.6	0.5	0.9
C95	Leuk Uns	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Other & Unsp Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.7	2.3	1.3	12.6	4.3	4.8	8.2	4.1	1.7	1.5	3.5
Total		0.0	0.9	2.2	2.3	3.5	4.9	17.3	28.2	52.7	97.3	129.5	155.4	95.8	100.0	131.9	69.3	40.8	36.5	87.8

26. Standard Registry tables – Visakhapatnam Tribal

Table 59: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Males – Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C01-C02	Tongue	0	0	0	0	0	0	3	3	4	1	1	0	1	0	0	0	13	20.3
C03-C06	Mouth	0	0	0	0	0	1	2	0	1	1	1	0	0	1	1	0	8	12.5
C07-C08	Salivary Gland	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1.6
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1.6
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C11	Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	2	3.1
C14	Pharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C15	Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1.6
C16	Stomach	0	0	0	0	0	0	1	1	1	1	2	1	0	0	0	0	8	12.5
C17	Small Intestine	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1.6
C18	Colon	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C19-C20	Rectum	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	3.1
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1.6
C22	Liver	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	2	3.1
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C25	Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C30-C31	Nose & Sinus	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1.6
C32	Larynx	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	3	4.7
C33-C34	Lung	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	3.1
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1.6
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C44	Other Skin	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1.6
C47&C49	Conn & Soft Tiss	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C50	Breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C60	Penis	0	0	0	0	0	0	0	0	0	2	0	0	1	2	0	0	5	7.8
C61	Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C62	Testis	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	2	3.1
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C73	Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Dis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C82-C85 & C96	NHL	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	2	3.1
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C91	Leuk Lymphoid	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	2	3.1
C92-C94	Leuk Myeloid	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	3	4.7
C95	Leukaemia Uns	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unspecified Sites		0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	2	3.1
Total		0	0	0	2	3	2	9	6	8	9	5	4	4	6	5	1	64	100.0

Table 60: Number of incidence cancers by five-year age group and site (ICD 10): 2017 - 2018 Females – Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C01-C02	Tongue	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	2	2.3
C03-C06	Mouth	0	0	0	0	0	0	0	0	1	2	3	0	1	0	0	0	7	8.0
C07-C08	Salivary Gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C11	Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1.1
C14	Pharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C15	Oesophagus	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	2	2.3
C16	Stomach	0	0	0	0	0	0	0	2	0	3	2	0	0	0	0	0	7	8.0
C17	Small Intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C18	Colon	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	2	2.3
C19-C20	Rectum	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1.1
C21	Anus	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1.1
C22	Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C25	Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1.1
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C32	Larynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C33-C34	Lung	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1.1
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C43	Melanoma Skin	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	1.1
C44	Other Skin	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	3	3.4
C47&C49	Conn & Soft Tiss	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1.1
C50	Breast	0	0	0	0	1	1	0	3	3	3	3	1	0	1	0	0	16	18.4
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C52	Vagina	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	2	2.3
C53	Cervix Uteri	0	0	0	0	0	0	0	5	1	4	4	4	1	1	0	0	20	23.0
C54	Corpus Uteri	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	1.1
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C56	Ovary	0	0	0	0	2	3	0	0	1	1	0	0	0	0	0	0	7	8.0
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1.1
C64	Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C73	Thyroid	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1.1
C81	Hodgkins Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C82-C85 & C96	NHL	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0	3	3.4
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C91	Leuk Lymphoid	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1.1
C92-C94	Leuk Myeloid	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	2	2.3
C95	Leuk. Uns	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	1.1
Other & Unsp Sites		0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	2.3
Total		0	0	0	2	4	6	2	10	11	16	16	9	5	5	0	1	87	100.0

Table 61: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	7.0	7.2	10.2	2.7	4.2	0.0	4.8	0.0	0.0	0.0	2.0	2.0	5.2
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	1.6	4.7	0.0	2.5	2.7	4.2	0.0	0.0	4.1	11.9	0.0	1.3	1.3	1.7
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	0.0	0.2	0.2	0.0
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.3	0.3	1.1
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.0	0.2	0.4	0.0
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	2.3	2.4	2.5	2.7	4.2	11.2	4.8	0.0	0.0	0.0	1.3	1.5	4.2
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.5
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	11.9	0.0	0.3	0.4	0.5
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	0.0	0.2	0.2	0.0
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	4.1	0.0	0.0	0.3	0.3	0.5
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C30-C31	Nose & Sinus	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	0.0	0.0	4.1	0.0	0.0	0.5	0.5	1.4
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	11.9	0.0	0.3	0.5	0.7
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.5
C47&C49	Conn Soft Tiss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	4.8	8.2	0.0	0.0	0.8	0.8	1.7
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C62	Testis	0.0	0.0	0.0	0.0	0.0	1.6	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Dis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C82-C85 & C96	NHL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.3	0.4	1.2
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C91	Leuk Lymphoid	0.0	0.0	0.0	1.5	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0
C92-C94	Leuk Myeloid	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	4.1	0.0	0.0	0.5	0.4	0.5
C95	Leukaemia Uns	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unspecified Sites		0.0	0.0	0.0	0.0	1.5	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5
Total		0.0	0.0	0.0	2.9	4.5	3.1	21.1	14.3	20.4	23.9	21.2	22.4	19.4	24.6	59.7	19.0	10.1	10.7	20.2

Table 62: Average annual Age-Specific, Crude (CR), Age-Adjusted (AAR) and Truncated (35-64 yrs) (TR) incidence rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.3	0.2	0.5
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	5.6	13.9	0.0	3.2	0.0	0.0	0.0	1.0	1.3	4.2
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.5
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	3.5	0.0	0.0	0.3	0.3	0.5
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	8.4	9.2	0.0	0.0	0.0	0.0	0.0	1.0	1.2	3.9
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2	0.6
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.7
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.1	0.1	0.4
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2	0.6
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	4.7	3.2	0.0	0.0	0.0	0.4	0.5	1.0
C47&C49	Conn Soft Tiss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.5
C50	Breast	0.0	0.0	0.0	0.0	1.3	1.6	0.0	6.1	7.0	8.4	13.9	4.7	0.0	3.5	0.0	0.0	2.4	2.5	7.0
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	14.5	0.3	0.4	0.5
C53	Cervix Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	2.3	11.2	18.5	18.9	3.2	3.5	0.0	0.0	3.0	3.3	10.4
C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.5
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C56	Ovary	0.0	0.0	0.0	0.0	2.6	4.9	0.0	0.0	2.3	2.8	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.9	1.0
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.1	0.1	0.4
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C73	Thyroid	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C81	Hodgkins Dis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C82-C85 & C96	NHL	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	2.8	0.0	4.7	0.0	0.0	0.0	0.0	0.4	0.5	1.1
C90	M.Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C91	Leuk Lymphoid	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C92-C94	Leuk Myeloid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.2	0.0	0.0	0.0	0.0	0.0	0.3	0.5	1.5
C95	Leuk. Uns	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Other & Unsp. Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	3.5	0.0	0.0	0.3	0.3	0.7
Total		0.0	0.0	0.0	2.8	5.2	9.8	4.7	20.4	25.6	44.6	73.9	42.4	16.0	17.4	0.0	14.5	13.0	14.0	37.0

Table 63: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Males Visakhapatnam Tribal.

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0000	0.0000	0.0000	0.0000
C01-C02	Tongue	0.0018	0.1804	0.0018	0.1804
C03-C06	Mouth	0.0008	0.0784	0.0016	0.1586
C07-C08	Salivary Gland	0.0001	0.0117	0.0001	0.0117
C09	Tonsil	0.0000	0.0000	0.0006	0.0597
C10	Oth. Oropharynx	0.0000	0.0000	0.0000	0.0000
C11	Nasopharynx	0.0000	0.0000	0.0000	0.0000
C12-C13	Hypopharynx	0.0004	0.0370	0.0004	0.0370
C14	Pharynx	0.0000	0.0000	0.0000	0.0000
C15	Oesophagus	0.0000	0.0000	0.0000	0.0000
C16	Stomach	0.0015	0.1511	0.0015	0.1511
C17	Small Intestine	0.0001	0.0133	0.0001	0.0133
C18	Colon	0.0000	0.0000	0.0000	0.0000
C19-C20	Rectum	0.0001	0.0119	0.0007	0.0716
C21	Anus	0.0000	0.0000	0.0006	0.0597
C22	Liver	0.0001	0.0133	0.0003	0.0338
C23-C24	Gall Bladder	0.0000	0.0000	0.0000	0.0000
C25	Pancreas	0.0000	0.0000	0.0000	0.0000
C30-C31	Nose & Sinus	0.0001	0.0074	0.0001	0.0074
C32	Larynx	0.0004	0.0425	0.0006	0.0630
C33-C34	Lung	0.0003	0.0280	0.0009	0.0877
C37-C38	Oth Thoracic	0.0000	0.0000	0.0000	0.0000
C40-C41	Bone	0.0001	0.0074	0.0001	0.0074
C43	Melanoma Skin	0.0000	0.0000	0.0000	0.0000
C44	Other Skin	0.0001	0.0133	0.0001	0.0133
C47&C49	Conn & Soft Tiss	0.0000	0.0000	0.0000	0.0000
C50	Breast	0.0000	0.0000	0.0000	0.0000
C60	Penis	0.0005	0.0507	0.0009	0.0918
C61	Prostate	0.0000	0.0000	0.0000	0.0000
C62	Testis	0.0002	0.0195	0.0002	0.0195
C63	Oth Male Genital	0.0000	0.0000	0.0000	0.0000
C64	Kidney	0.0000	0.0000	0.0000	0.0000
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0000	0.0000	0.0000	0.0000
C68	Urethra	0.0000	0.0000	0.0000	0.0000
C69	Eye	0.0000	0.0000	0.0000	0.0000
C70-C72	Brain & CNS	0.0000	0.0000	0.0000	0.0000
C73	Thyroid	0.0000	0.0000	0.0000	0.0000
C81	Hodgkins Dis	0.0000	0.0000	0.0000	0.0000
C82-C85 & C96	NHL	0.0004	0.0408	0.0004	0.0408
C90	Multiple Myeloma	0.0000	0.0000	0.0000	0.0000
C91	Leuk Lymphoid	0.0002	0.0191	0.0002	0.0191
C92-C94	Leuk Myeloid	0.0002	0.0207	0.0004	0.0412
C95	Leukaemia Uns	0.0000	0.0000	0.0000	0.0000
Other & Unspecified Sites		0.0002	0.0193	0.0002	0.0193
Total		0.0077	0.7630	0.0119	1.1807

Table 64: Cumulative Rate (Cu. Rate %) & Cumulative Risk (Cu. Risk) of individual sites (ICD 10) based on age-specific rates (from 0-64 Years and 0-74 Years) 2017 - 2018: Males Visakhapatnam Tribal.

ICD-10	Site	Cumm Rt(0-64)	Cum Risk(0-64)	Cumm Rt(0-74)	Cum Risk(0-74)
C00	Lip	0.0000	0.0000	0.0000	0.0000
C01-C02	Tongue	0.0001	0.0116	0.0003	0.0290
C03-C06	Mouth	0.0012	0.1247	0.0012	0.1247
C07-C08	Salivary Gland	0.0000	0.0000	0.0000	0.0000
C09	Tonsil	0.0000	0.0000	0.0000	0.0000
C10	Oth. Oropharynx	0.0000	0.0000	0.0000	0.0000
C11	Nasopharynx	0.0000	0.0000	0.0000	0.0000
C12-C13	Hypopharynx	0.0001	0.0116	0.0001	0.0116
C14	Pharynx	0.0000	0.0000	0.0000	0.0000
C15	Oesophagus	0.0001	0.0139	0.0003	0.0313
C16	Stomach	0.0011	0.1083	0.0011	0.1083
C17	Small Intestine	0.0000	0.0000	0.0000	0.0000
C18	Colon	0.0003	0.0256	0.0003	0.0256
C19-C20	Rectum	0.0002	0.0236	0.0002	0.0236
C21	Anus	0.0002	0.0231	0.0002	0.0231
C22	Liver	0.0000	0.0000	0.0000	0.0000
C23-C24	Gall Bladder	0.0000	0.0000	0.0000	0.0000
C25	Pancreas	0.0002	0.0160	0.0002	0.0160
C30-C31	Nose & Sinus	0.0000	0.0000	0.0000	0.0000
C32	Larynx	0.0000	0.0000	0.0000	0.0000
C33-C34	Lung	0.0002	0.0236	0.0002	0.0236
C37-C38	Oth Thoracic	0.0000	0.0000	0.0000	0.0000
C40-C41	Bone	0.0000	0.0000	0.0000	0.0000
C43	Melanoma Skin	0.0001	0.0081	0.0001	0.0081
C44	Other Skin	0.0005	0.0513	0.0005	0.0513
C47&C49	Conn & Soft Tiss	0.0001	0.0116	0.0001	0.0116
C50	Breast	0.0021	0.2146	0.0023	0.2319
C51	Vulva	0.0000	0.0000	0.0000	0.0000
C52	Vagina	0.0001	0.0116	0.0001	0.0116
C53	Cervix Uteri	0.0032	0.3205	0.0034	0.3378
C54	CorpusUteri	0.0001	0.0116	0.0001	0.0116
C55	Oth Uterus	0.0000	0.0000	0.0000	0.0000
C56	Ovary	0.0006	0.0630	0.0006	0.0630
C57	Placenta	0.0002	0.0160	0.0002	0.0160
C64	Kidney	0.0000	0.0000	0.0000	0.0000
C66	Ureter	0.0000	0.0000	0.0000	0.0000
C67	Urin Bladder	0.0000	0.0000	0.0000	0.0000
C68	Urethra	0.0000	0.0000	0.0000	0.0000
C69	Eye	0.0000	0.0000	0.0000	0.0000
C70-C72	Brain & CNS	0.0000	0.0000	0.0000	0.0000
C73	Thyroid	0.0001	0.0071	0.0001	0.0071
C81	Hodgkins Disease	0.0000	0.0000	0.0000	0.0000
C82-C85 & C96	NHL	0.0004	0.0440	0.0004	0.0440
C90	Multiple Myeloma	0.0000	0.0000	0.0000	0.0000
C91	Leuk Lymphoid	0.0001	0.0071	0.0001	0.0071
C92-C94	Leuk Myeloid	0.0005	0.0462	0.0005	0.0462
C95	Leukaemia Uns	0.0001	0.0081	0.0001	0.0081
Other & Unspecified Sites		0.0002	0.0231	0.0004	0.0404
Total		0.0123	1.2194	0.0131	1.3051

Table 65: Number of cancer deaths by five-year age group and site (ICD 10): 2017 - 2018 Males
Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C01-C02	Tongue	0	0	0	0	0	0	0	2	2	1	0	0	0	0	0	0	5	17.2
C03-C06	Mouth	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	6.9
C07-C08	Salivary Gland	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	3.4
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C11	Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C14	Pharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C15	Oesophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C16	Stomach	0	0	0	0	0	0	0	1	1	1	0	2	0	0	0	0	5	17.2
C17	Small Intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C18	Colon	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C19-C20	Rectum	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	2	6.9
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3.4
C22	Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C25	Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C30-C31	Nose&Sinus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C32	Larynx	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	6.9
C33-C34	Lung	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3.4
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	2	6.9
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C44	Other Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C47&C49	Conn & Soft Tiss	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C50	Breast	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	3.4
C60	Penis	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	3	10.3
C61	Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C63	Oth Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C73	Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C75	Endocrine gl	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Dis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C82-C85 & C96	NHL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C91	Leuk Lymph	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	3.4
C92-C94	Leuk Myeloid	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	3	10.3
C95	Leuk. Uns	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unspecified Sites		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Total		0	1	0	1	2	1	2	3	4	4	2	3	2	1	2	1	29	100.0

Table 66: Number of cancer deaths by five-year age group and site (ICD 10): 2017 - 2018 Females
Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C01-C02	Tongue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C03-C06	Mouth	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	5	18.5
C07-C08	Salivary Gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C10	Oth. Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C11	Nasopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C14	Pharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C15	Oesophagus	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	3.7
C16	Stomach	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	2	7.4
C17	Small Intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C18	Colon	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	2	7.4
C19-C20	Rectum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C22	Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C23-C24	Gall Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C25	Pancreas	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C30-C31	Nose & Sinus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C32	Larynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C33-C34	Lung	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	3.7
C37-C38	Oth Thoracic	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C40-C41	Bone	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C43	Melanoma Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C44	Other Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C47&C49	Conn Soft Tiss	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C50	Breast	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	4	14.8
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C52	Vagina	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	3.7
C53	Cervix Uteri	0	0	0	0	0	0	0	1	1	2	1	2	0	1	0	0	8	29.6
C54	Corpus Uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C55	Oth Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C56	Ovary	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	3.7
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C64	Kidney	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C67	Urin Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C68	Urethra	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C69	Eye	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C70-C72	Brain & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C73	Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C75	Endocrine glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C81	Hodgkins Disease	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	3.7
C82-C85 & C96	NHL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C91	Leuk Lymphoid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C92-C94	Leuk Myeloid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
C95	Leuk Uns	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0
Other & Unspecified Sites		0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	3.7
Total		0	0	0	0	1	1	1	2	2	6	6	5	1	2	0	0	27	100.0

Table 67: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Males Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	5.1	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	2.4
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	4.1	0.0	0.0	0.3	0.3	0.7
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	2.5	2.7	0.0	11.2	0.0	0.0	0.0	0.0	0.8	0.9	2.9
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.0	0.3	0.5	0.0
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	0.0	0.2	0.2	0.0
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	4.8	0.0	0.0	0.0	0.3	0.4	1.3
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.9	0.0	0.2	0.2	0.0
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	0.0	1.5	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C47&C49	Conn Soft Tiss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.2	0.2	0.6
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.7	4.2	0.0	0.0	0.0	0.0	0.0	0.5	0.5	1.7
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C62	Testis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C63	Oth Male Genital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain&CN S	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C75	Endocrine glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Dis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C82-C85 & C96	NHL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	M.Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C91	Leuk Lymph	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0
C92-C94	Leuk Myel	0.0	1.9	0.0	0.0	1.5	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.5
C95	Leuk Uns	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unsp.Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total		0.0	1.9	0.0	1.5	3.0	1.6	4.7	7.2	10.2	10.6	8.5	16.8	9.7	4.1	23.9	19.0	4.6	5.1	10.2

Table 68: Average annual Age Specific, Crude (CR), Age Adjusted (AAR) and Truncated (35-64 yrs) (TR) mortality rate per 100,000 population: 2017 - 2018 – Females Visakhapatnam Tribal

ICD-10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-60	60-64	65-69	70-74	75+	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C01-C02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C03-C06	Mouth	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.2	4.7	3.2	3.5	0.0	0.0	0.7	0.9	2.5
C07-C08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C09	Tonsil	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C12-C13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.5
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.9
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C18	Colon	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5
C19-C20	Rectum	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C21	Anus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C22	Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C23-C24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C30-C31	Nose & Sinus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C33-C34	Lung	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2	0.6
C37-C38	Oth Thoracic	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C40-C41	Bone	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C43	Melanoma Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C44	Other Skin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C47&C49	Conn & Soft Tiss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	9.2	4.7	0.0	0.0	0.0	0.0	0.6	0.8	2.6
C51	Vulva	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C52	Vagina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.5
C53	Cervix Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.3	5.6	4.6	9.4	0.0	3.5	0.0	0.0	1.2	1.3	3.9
C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C55	Oth Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C56	Ovary	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C57	Placenta	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Urin Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C68	Urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C70-C72	Brain & CNS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C75	Endocrine glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkins Dis	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
C82-C85 & C96	NHL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	M. Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C91	Leuk Lymph	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C92-C94	Leuk Myel	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C95	Leuk Uns	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other & Unsp. Sites		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.7
Total		0.0	0.0	0.0	0.0	1.3	1.6	2.3	4.1	4.7	16.7	27.7	23.6	3.2	6.9	0.0	0.0	4.0	4.6	12.9

27. Paediatric cancer incidence tables as per ICC-3 standard

Table 69: Number of cases in paediatric age-group, incidence rate per million population: 2017 - 2018 (Both sex)

ICCC	Site	Agegroups						Percentage (0-14)		Percentage (0-19)		Age Specific Rate per 1000,000				AAR		Cumm Rate	
		00-04	05-09	10-14	15-19	0-14	0-19	All	Group	All	Group	00-04	05-09	10-14	15-19	0-14	0-19	0-14	0-19
I	Leukemia	13	19	11	18	43	61	47.3	100.0	43.3	100.0	21.4	31.4	14.0	22.7	22.5	22.5	334.3	447.7
	a. Lymphoid	11	13	7	8	31	39	34.1	72.1	27.7	63.9	18.1	21.5	8.9	10.1	16.5	15.1	242.7	293.1
	b. Acute myeloid	1	4	1	3	6	9	6.6	14.0	6.4	14.8	1.6	6.6	1.3	3.8	3.1	3.3	47.7	66.6
	c. CMD	1	1	2	4	4	8	4.4	9.3	5.7	13.1	1.6	1.7	2.6	5.0	1.9	2.6	29.3	54.5
	d. MDS & Other	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	e. Unspecified	0	1	1	3	2	5	2.2	4.7	3.5	8.2	0.0	1.7	1.3	3.8	0.9	1.6	14.7	33.6
II	Lymphoma&re	1	5	8	8	14	22	15.4	100.0	15.6	36.1	1.6	8.3	10.2	10.1	6.3	7.1	100.6	151.0
	a. Hodgkin	0	1	5	3	6	9	6.6	42.9	6.4	14.8	0.0	1.7	6.4	3.8	2.4	2.7	40.2	59.1
	b. NHL expt BL	1	4	3	4	8	12	8.8	57.1	8.5	19.7	1.6	6.6	3.8	5.0	3.9	4.1	60.5	85.7
	c. Burkitt (BL)	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	d. Lymphoreticular	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	e. Unspecified	0	0	0	1	0	1	0.0	0.0	0.7	1.6	0.0	0.0	0.0	1.3	0.0	0.3	0.0	6.3
III	CNS Neoplasms	3	1	5	3	9	12	9.9	100.0	8.5	19.7	4.9	1.7	6.4	3.8	4.3	4.2	64.9	83.8
	a. Ependymoma	1	0	1	0	2	2	2.2	22.2	1.4	3.3	1.6	0.0	1.3	0.0	1.0	0.8	14.6	14.6
	b. Astrocytoma	1	1	2	3	4	7	4.4	44.4	5.0	11.5	1.6	1.7	2.6	3.8	1.9	2.3	29.3	48.2
	c. CNS Embryonal	0	0	1	0	1	1	1.1	11.1	0.7	1.6	0.0	0.0	1.3	0.0	0.4	0.3	6.4	6.4
	d. Other gliomas	1	0	0	0	1	1	1.1	11.1	0.7	1.6	1.6	0.0	0.0	0.0	0.6	0.5	8.2	8.2
	e. Other specified	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	f. Unspecified CNS	0	0	1	0	1	1	1.1	11.1	0.7	1.6	0.0	0.0	1.3	0.0	0.4	0.3	6.4	6.4
IV	Neuroblastoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	a. (Ganglio) Neuroblastoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	b. Periph.nervous	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
V	Retinoblastoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
VI	Renal Tumours	5	2	0	1	7	8	7.7	100.0	5.7	13.1	8.2	3.3	0.0	1.3	4.3	3.6	57.7	64.0
	a. Nephroblastoma	4	1	0	0	5	5	5.5	71.4	3.5	8.2	6.6	1.7	0.0	0.0	3.1	2.4	41.2	41.2
	b. Renal carcinoma	0	0	0	1	0	1	0.0	0.0	0.7	1.6	0.0	0.0	0.0	1.3	0.0	0.3	0.0	6.3
	c. Unspecified	1	1	0	0	2	2	2.2	28.6	1.4	3.3	1.6	1.7	0.0	0.0	1.2	0.9	16.5	16.5
VII	Hepatic Tumours	1	1	0	1	2	3	2.2	100.0	2.1	4.9	1.6	1.7	0.0	1.3	1.2	1.2	16.5	22.8
	a. Hepatoblastoma	1	0	0	0	1	1	1.1	50.0	0.7	1.6	1.6	0.0	0.0	0.0	0.6	0.5	8.2	8.2
	b. Hepatic carcinoma	0	1	0	1	1	2	1.1	50.0	1.4	3.3	0.0	1.7	0.0	1.3	0.5	0.7	8.3	14.6
	c. Unspecified	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
VIII	Bone Tumours	2	1	5	3	8	11	8.8	100.0	7.8	18.0	3.3	1.7	6.4	3.8	3.7	3.7	56.6	75.5
	a. Osteosarcoma	0	0	2	1	2	3	2.2	25.0	2.1	4.9	0.0	0.0	2.6	1.3	0.7	0.9	12.8	19.1
	b. Chondrosarcoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	c. Ewing & Related	2	1	3	2	6	8	6.6	75.0	5.7	13.1	3.3	1.7	3.8	2.5	2.9	2.8	43.9	56.5
	d. Other specified	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	e. Unspecified	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IX	Soft Tissue Sarcoma	1	2	2	2	5	7	5.5	100.0	5.0	11.5	1.6	3.3	2.6	2.5	2.4	2.5	37.5	50.1
	a. Rhabdomyosarc.	0	0	1	1	1	2	1.1	20.0	1.4	3.3	0.0	0.0	1.3	1.3	0.4	0.6	6.4	12.7
	b. Fibrosarcoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	c. Kaposi sarcoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	d. Other specified	1	2	0	0	3	3	3.3	60.0	2.1	4.9	1.6	3.3	0.0	0.0	1.7	1.3	24.8	24.8
	e. Unspecified	0	0	1	1	1	2	1.1	20.0	1.4	3.3	0.0	0.0	1.3	1.3	0.4	0.6	6.4	12.7
X	Germ Cell Tumours	0	0	0	5	0	5	0.0	0.0	3.5	8.2	0.0	0.0	0.0	6.3	0.0	1.4	0.0	31.5
	a. CNS germ cell	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	b. Other extragonad.	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	c. Gonadal germ cell	0	0	0	4	0	4	0.0	0.0	2.8	6.6	0.0	0.0	0.0	5.0	0.0	1.1	0.0	25.2
	d. Gonad.carcinoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	e. Unsp gonadal	0	0	0	1	0	1	0.0	0.0	0.7	1.6	0.0	0.0	0.0	1.3	0.0	0.3	0.0	6.3

ICCC	Site	Agegroups						Percentage (0-14)		Percentage (0-19)		Age Specific Rate per 1000,000				AAR		Cumm Rate	
		00-04	05-09	10-14	15-19	0-14	0-19	All	Group	All	Group	00-04	05-09	10-14	15-19	0-14	0-19	0-14	0-19
XI	Carcinoma & Melanoma	0	2	1	9	3	12	3.3	100.0	8.5	19.7	0.0	3.3	1.3	11.3	1.4	3.7	22.9	79.6
	a. Adrenocortical	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	b. Thyroid	0	0	0	3	0	3	0.0	0.0	2.1	4.9	0.0	0.0	0.0	3.8	0.0	0.9	0.0	18.9
	c. Nasopharyngeal	0	1	0	1	1	2	1.1	33.3	1.4	3.3	0.0	1.7	0.0	1.3	0.5	0.7	8.3	14.6
	d. Melanoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	e. Skin carcinoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	f. Other & Unsp.	0	1	1	5	2	7	2.2	66.7	5.0	11.5	0.0	1.7	1.3	6.3	0.9	2.1	14.7	46.2
XII	Other & Unsp.	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	a. Other specified	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	b. Other unsp.	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total		26	33	32	50	91	141	100.0	100.0	100.0	231.1	42.8	54.6	40.8	63.0	46.0	49.8	691.1	1006.1

Table 70: Number of cases in paediatric age-group, incidence rate per million population: 2017 - 2018 (By gender)


ICCC-3	Description	Boys								M/F Ratio		Girls							
		Age group						AAR per million				Age group						AAR per million	
		00-04	05-09	10-14	15-19	0-14	0-19	0-14	0-19	0-14	0-19	00-04	05-09	10-14	15-19	0-14	0-19	0-14	0-19
I	Leukemia	10	12	6	13	28	41	29.1	29.9	1.9	2.1	3	7	5	5	15	20	15.4	14.8
	a. Lymphoid	8	8	4	5	20	25	21.1	19.1	1.8	1.8	3	5	3	3	11	14	11.7	10.8
	b. Acute myeloid	1	3	1	3	5	8	5.1	5.6	5.0	8.0	0	1	0	0	1	1	1.1	0.9
	c. CMD	1	1	1	3	3	6	3.0	4.0	3.0	3.0	0	0	1	1	1	2	0.8	1.2
	d. MDS & Other	0	0	0	2	0	2	0.0	1.1	0.0	0.7	0	0	0	0	0	0	0.0	0.0
	e. Unspecified	0	0	0	0	0	0	0.0	0.0	-	-	0	1	1	1	2	3	1.9	2.0
II	Lymphoma&rel	1	3	5	7	9	16	8.0	10.1	1.8	2.7	0	2	3	1	5	6	4.5	4.0
	a. Hodgkin	0	1	4	2	5	7	3.9	4.2	5.0	3.5	0	0	1	1	1	2	0.8	1.2
	b. NHL expt BL	1	2	1	4	4	8	4.0	5.4	1.0	2.0	0	2	2	0	4	4	3.7	2.9
	c. Burkitt (BL)	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	d. Lymphoreticular	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	e. Unspecified	0	0	0	1	0	1	0.0	0.6	-	-	0	0	0	0	0	0	0.0	0.0
III	CNS Neoplasms	1	0	2	0	3	3	2.7	2.1	0.5	0.3	2	1	3	3	6	9	6.0	6.4
	a. Ependymoma	0	0	1	0	1	1	0.7	0.6	1.0	1.0	1	0	0	0	1	1	1.3	1.0
	b. Astrocytoma	1	0	0	0	1	1	1.2	1.0	0.3	0.2	0	1	2	3	3	6	2.6	3.7
	c. CNS Embryonal	0	0	1	0	1	1	0.7	0.6	-	-	0	0	0	0	0	0	0.0	0.0
	d. Other gliomas	0	0	0	0	0	0	0.0	0.0	0.0	0.0	1	0	0	0	1	1	1.3	1.0
	e. Other specified	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	f. Unspecified CNS	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0	0	1	0	1	1	0.8	0.6
IV	Neuroblastoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	a. (Ganglio) Neuroblastoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	b. Periph.nervous	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
V	Retinoblastoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
VI	Renal Tumours	2	1	0	0	3	3	3.5	2.7	0.8	0.6	3	1	0	1	4	5	5.0	4.5
	a. Nephroblastoma	1	1	0	0	2	2	2.3	1.8	0.7	0.7	3	0	0	0	3	3	3.9	3.0
	b. Renal carcinoma	0	0	0	0	0	0	0.0	0.0	-	0.0	0	0	0	1	0	1	0.0	0.6
	c. Unspecified	1	0	0	0	1	1	1.2	1.0	1.0	1.0	0	1	0	0	1	1	1.1	0.9
VII	Hepatic Tumours	1	0	0	0	1	1	1.2	1.0	1.0	0.5	0	1	0	1	1	2	1.1	1.4
	a. Hepatoblastoma	1	0	0	0	1	1	1.2	1.0	-	-	0	0	0	0	0	0	0.0	0.0
	b. Hepatic carcinoma	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0	1	0	1	1	2	1.1	1.4
	7c. Unspecified	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
VIII	Bone Tumours	2	1	3	1	6	7	5.7	5.0	3.0	1.8	0	0	2	2	2	4	1.5	2.3
	a. Osteosarcoma	0	0	2	0	2	2	1.5	1.1	-	2.0	0	0	0	1	0	1	0.0	0.6
	b. Chondrosarcoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	c. Ewing & Related	2	1	1	1	4	5	4.2	3.8	2.0	1.7	0	0	2	1	2	3	1.5	1.7
	d. Other specified	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	e. Unspecified	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
IX	Soft Tissue Sarcoma	1	1	1	1	3	4	3.7	3.4	4.0	2.5	0	1	0	1	1	2	1.1	1.4
	a. Rhabdomyosar	0	0	X ^a	0	0	0	0.7	0.6	-	1.0	0	0	0	1	0	1	0.0	0.6
	b. Fibrosarcoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	c. Kaposi sarcoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	d. Other specified	1	1	0	0	2	2	2.3	1.8	2.0	2.0	0	1	0	0	1	1	1.1	0.9
	e. Unspecified	0	0	1	1	1	2	0.7	1.1	-	-	0	0	0	0	0	0	0.0	0.0
X	Germ Cell Tumours	0	0	0	1	0	1	0.0	0.6	-	0.3	0	0	0	4	0	4	0.0	2.3
	a. CNS germ cell	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	b. Oth extragonad	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	c. Gonadal germ cell	0	0	0	1	0	1	0.0	0.6	-	0.3	0	0	0	3	0	3	0.0	1.7
	d.Gonad.carcinoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	e. Unsp gonadal	0	0	0	0	0	0	0.0	0.0	-	0.0	0	0	0	1	0	1	0.0	0.6

CCC-3	Description	Boys								M/F Ratio		Girls							
		Age group							AAR per million			Age group						AAR per million	
		00-04	05-09	10-14	15-19	0-14	0-19	0-14	0-19	0-14	0-19	00-04	05-09	10-14	15-19	0-14	0-19	0-14	0-19
XI	Carcinoma & Melanoma	0	1	0	4	1	5	1.0	3.0	0.5	0.7	0	1	1	5	2	7	1.9	4.3
	a. Adrenocortical	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	b. Thyroid	0	0	0	2	0	2	0.0	1.1	-	2.0	0	0	0	1	0	1	0.0	0.6
	c. Nasopharyngeal	0	1	0	0	1	1	1.0	0.8	-	1.0	0	0	0	1	0	1	0.0	0.6
	d. Melanoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	e. Skin carcinoma	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	f. Other & Unsp.	0	0	0	2	0	2	0.0	1.1	0.0	0.4	0	1	1	3	2	5	1.9	3.2
XII	Other & Unsp.	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	a. Other specified	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	b. Other unsp	0	0	0	0	0	0	0.0	0.0	-	-	0	0	0	0	0	0	0.0	0.0
	Total	18	19	17	27	54	81	55.0	57.7	1.5	1.4	8	14	14	23	36	59	36.5	41.5

28. References

1. Legislative bodies in India web-portal
<https://legislativebodiesinindia.nic.in/states/andhra%20pradesh/andhra-w.htm>
2. Andhra Pradesh Legislature web-portal
<https://aplegislature.org/web/legislative-assembly/overview>
3. Andhra Pradesh Legislature web-portal
<https://www.aplegislature.org/documents/12524/17895/APRegACT2014.pdf/8505fe86-f67b-41a7-ac8f-571f58090586>
4. Government of Andhra Pradesh Information and Public Relations Department portal
<https://ipr.ap.nic.in/images/whitepapers/State%20Reorganization%20Act-English.pdf>
5. Government of Andhra Pradesh https://reorganisation.ap.gov.in/downloads/8_2014_LS_ENG.pdf
6. Census of India <https://www.censusindia2011.com/andhra-pradesh-population.html>
7. Andhra Pradesh State Profile Report by Ministry of Micro, Small and Medium Enterprises, Government of India.
https://dcmsme.gov.in/old/dips/state_wise_profile_16-17/AP%20State%20profile%202016.pdf
8. Government of Andhra Pradesh – District Visakhapatnam web-portal
<https://visakhapatnam.ap.gov.in/>
9. Integrated Government Online Directory <https://igod.gov.in/sg/AP/E042/organizations>
10. District Portal of Andhra Pradesh <https://andhrapradesh.s3waas.gov.in/>
11. International Classification of Diseases-Oncology Third Edition First Revision WHO IARC ICD-O-3.1: WHO, Geneva 2000
<https://www.who.int/standards/classifications/other-classifications/international-classification-of-diseases-for-oncology>
12. International Association of Cancer Registries (IACR): CanReg and Other IT Tools : (Canreg5 Open Source Software: International Agency for Research on Cancer Lyon, France.)
http://www.iacr.com.fr/index.php?option=com_content&view=article&id=9:canreg5&catid=68&Itemid=445
13. Report of National Cancer Registry Programme – Indian Council of Medical Research: 2012-2016, Bengaluru (2020). https://ncdirindia.org/All_Reports/PBCR_Annexures/Default.apx, accessed on Jul 2022.
14. International Incidence of Childhood Cancer 3 – indicators of data quality: IARC – WHO, Lyon, France <https://iicc.iarc.fr/includes/results/chapters/QualityIndicators.pdf>
15. International Classification of Childhood Cancer Volume III: International Agency for Research on Cancer (IARC), World Health Organization (WHO) <https://iicc.iarc.fr/results/> accessed on Jul 2022
16. WHO factsheet on Tobacco (<https://www.who.int/news-room/fact-sheets/detail/tobacco>)

17. IARC Monographs - Supplement 7, Overall evaluations of carcinogenicity; An updating of IARC monographs Volume 1-42: IARC monographs on the evaluation of the carcinogenic risks to humans. IARC Lyon, 1987, 357-61.
18. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.fr/today> , accessed on Jul 2022.
19. Chandigarh Population-Based Cancer Registry Report: 2017-2018 – Tata Memorial Centre, Mumbai and Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
20. SAS Nagar Population-Based Cancer Registry Report: 2017-2018 – Tata Memorial Centre, Mumbai and Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh.
21. Mansa Population-Based Cancer Registry Report: 2017-2018 – Tata Memorial Centre, Mumbai, and Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh.
22. Sangrur Population-Based Cancer Registry Report: 2017-2018 – Tata Memorial Centre, Mumbai, and Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh.
23. Varanasi Population-Based Cancer Registry Report: 2018-2019– Tata Memorial Centre, Mumbai and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi.
24. Coronavirus | First case of COVID-19 reported from Nellore in AP. The Hindu. 12 March 2020. ISSN 0971-751X. Archived from the original on 13 March 2020.
25. COVID-19 : Andhra Pradesh Department of Health, Medical, & Family Welfare. hmfw.ap.gov.in. Archived from the original on 17 April 2020. Retrieved 1 May 2020.



29. Acknowledgements

We gratefully acknowledge following dignitaries and institutions for their valuable support.

Department of Health and Family Welfare, Andhra Pradesh

Chief Minister Andhra Pradesh
State Health Minister, Andhra Pradesh
Chief Secretary, Andhra Pradesh
Special Secretary Health, Andhra Pradesh
Director of Medical Education
State Nodal Officer NCD

Anakapalle District Administration

District Collector & Magistrate
District Medical & Health Officer
District Economics and Statistical Officer
Mandal Parishad Development Officers
Block Development Officers

Tata Memorial Hospital, Mumbai

Dr. CS Pramesh, Director
Dr. Shripad Banavali, Director – Academics
Dr. Shailesh Shrikhande, Dy Director TMH
Dr. Siddhartha Laskar, Dy Director – Academics
Mr. Anil Sathe, CAO – TMC
Mr. Suryakant Mohapatra, JCFA – TMC
Mr. Vijendra Tiwari, DCA – TMC
Mr. Benny George, HRD Officer
Mr. Chandrakant Shetty, Jr AO
Mrs. Anagha Kadam, AAO
Mrs. Varsha Patil, Stenographer

Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam

Administration

Mr. P.V. Rama Krishna, Chief Administrative Officer
Mr. J. Raghava Reddy, HRD Officer
Smt. M. Avanthi, Jr Administrative Officer

Radiation Oncology

Dr. Rohit Vadgaonkar, Associate Professor
Dr. Raviteja Miriyala, Assistant Professor

Visakhapatnam District Administration

District Collector & Magistrate
Mandal Parishad Development Officers
Commissioner of Police
Municipal Commissioner
District Medical & Health Officer
District Economics and Statistical Officer
Block Development Officers

Alluri Sitaram Raju District Administration

District Collector & Magistrate
District Medical & Health Officer
District Economics and Statistical Officer
Mandal Parishad Development Officers
Block Development Officers

Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai

Dr. Sudeep Gupta, Director
Dr. Navin Khattri, Dy. Director, CRC- ACTREC
Dr. Prasanna Venkatraman, Dy Director, CRI- ACTREC
Mrs. Kusum Pednekar, Jr. PO, CCE
Mr. Suryakant Shedde, Asst Accts Officer, CCE
Mr. Prashant Kadam, Asst Admin Officer, CCE

Our Data Sources:

All- Anganwadi Centers, Visakhapatnam

All- CHC, ASR

All- Greater Visakhapatnam Municipal Corporation, Visakhapatnam

All- Panchayth Office, Visakhapatnam

All- PHC, CHC, Anakapalle

Surgical Oncology

Dr. Sasi Krishna, Assistant Professor, Head & Neck Surgical Oncology
 Dr. Rigved Nittala, Assistant Professor, Surgical Oncology
 Dr. Vamsi Pinnaka, Assistant Professor, Gynecology Surgical Oncology
 Dr. Sri Harsha Tadala, Assistant Professor, Orthopedic Surgical Oncology

Medical Oncology

Dr. Neeharika Alapati, Assistant Professor

Paediatric Oncology

Dr. Shwetha Reddy, Assistant Professor

Palliative Medicine

Dr. Vidya Viswanath, Assistant Professor

Dept of Anaesthesia & Critical Care

Dr. Aweek Jayant, Professor & Head

Pathology

Dr. Sonali Nayak, Associate Professor
 Dr. Anupoorva Dutta, Assistant Professor

Haemato-Pathology

Dr. Anumeha Chaturvedhi, Medical officer-E

Microbiology

Dr. Hima Bindhu, Medical officer-E

Biochemistry

Dr. B. Narayana Rao, Assistant Professor

Dental & Prosthetics Surgery

Dr. Pankaj Chauhan, Assistant Professor, Dental & Prosthetics Surgery & Clinical Research Secretariat

Transfusion Medicine

Dr. Charumathi Arjunan, Assistant Professor

Preventive Oncology

Dr. Dolorosa Fernandes Assistant Professor

Clinical Research Secretariat

All- Sachivalayams, Visakhapatnam

All- UPHC, PHC, CHC, Visakhapatnam

Anil Neerukonda Hospital, Visakhapatnam

Area Hospital- Aganampudi, Visakhapatnam

Area Hospital- Araku, ASR

Area Hospital- Narsipatnam, Anakapalle

Chaitanya Medical Centre, Visakhapatnam

District Hospital- Paderu, ASR

District Rural development Agency (DRDA) Office, Visakhapatnam

Dolphin Diagnostic Services, Visakhapatnam

ESI Hospital, Visakhapatnam

Gitam Institute of Medical Science and Research, Visakhapatnam

Golden Jubilee Hospital (Port Hospital), Visakhapatnam

Government ENT Hospital, Visakhapatnam

Government Victoria Hospital (Ghosha Hospital), Visakhapatnam

Govt General Hospital, Kakinada

Parshad of Respective Ward and Sarpanch of Village

King George Hospital (KGH), Visakhapatnam

NTR Hospital, Anakapalle

Steel Plant General Hospital, Visakhapatnam

Vijaya Diagnostic Centre, Visakhapatnam

Visakha Institute of Medical Sciences (VIMS), Visakhapatnam

Nursing Department

IT Department

Mr. P. Vyunta Rao, Scientific Officer 'D'
Mr. Naresh Katta, Scientific Officer 'D'

Accounts

Smt. Sunita Allampalli, Dy Accounts Officer

Purchase and Stores

Security Department



30. Annexure

Training

Dr. Dolorosa Fernandes, Assistant Professor, Department of Preventive Oncology, HBCH & RC Visakhapatnam and Ms. Sushama Saoba, Scientific Asst. 'E', Division of Medical Records & Cancer Registries, CCE, ACTREC, Mumbai attended the ChildGICR Childhood Cancer Registration online course organised by the International Agency for Research on Cancer, the St. Jude Children's Research Hospital, USA, and the Cancer Institute (W.I.A), Chennai, India as part of the programme "Targeting Childhood Cancer through the Global Initiative for Cancer Registry Development (ChildGICR)".

International Agency for Research on Cancer
World Health Organization

International Agency for Research on Cancer
St. Jude Children's Research Hospital
Cancer Institute (W.I.A), Chennai, India

**Why conduct
the ChildGICR childhood cancer registration course**

Eva Steliarova-Foucher
Scientist
Cancer Surveillance Branch
International Agency for Research on Cancer

ChildGICR CHILDHOOD CANCER REGISTRATION ONLINE COURSE
September 2022

2. Registration of cancer in childhood is often neglected in a general population-based cancer registry

International Agency for Research on Cancer
World Health Organization

International Incidence of Childhood Cancer

	CI5-IX 1998-2002	CI5-X 2003-2007	CI5-XI 2008-2012
Registries worldwide	180	290	343
Registries in India	7	13	18

Active participation during the training






Photo gallery

Training was provided to cancer registry staff to upgrade the knowledge in cancer registration by the senior faculties from Visakhapatnam as well from TMC, Mumbai.

Regular virtual training of cancer registry staff by the CCE-TMC Mumbai, team



Data collection and cancer awareness in the community

The cancer registry staff has conducted meeting with Anganwadi Sevika, ANM and ASHA worker to raise cancer awareness in the community as well as their role in cancer registration process.



Cancer cases data collection from municipal death registration office



Cancer cases data collection through community interaction and patient house visits





Meeting with the Block development officer



Cancer awareness programme



Continuing Medical Education





Participation in Screening Programme





The Registry team with Dr. Atul Budukh and Dr. Dolorosa Fernandes





Tata Memorial Centre, Mumbai, India

**Centre for Cancer Epidemiology – ACTREC,
Kharghar, Navi Mumbai, India**



Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam

“CANCER IS CURABLE, IF DETECTED EARLY”